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SUMMARY
Evidence of antigen recognition and an anti-tumour 
immune response has been sought in patients with breast 
carcinoma since a lymphocytic infiltrate was first noted 
in the primary tumours and found to correlate with an 
improved prognosis 38 4.
A variety of methods have been used to study immune 
competence but, with greater understanding of lymphocyte 
function, a clearer picture can be obtained by analysing 
the phenotypic proportions present in any lymphocyte 
p o p u l a t i o n .
The activation status of lymphocytes can also be deduced 
from their expression of activation markers and 
receptors, while the presence of surface IgG on the 
membrane of B cells is indicative of a mature humoral 
r e s p o n s e .
The aims of this study were:
1) To seek evidence of antigen recognition and an 
anti-tumour immune response in patients with breast 
c a n c e r .
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2) To assess the contribution of the axillary lymph 
nodes to any humoral or cellular immune response and the 
extent to which any response remains loco-regional at 
the time of clinical presentation.
In this study, fluorescent monoclonal antibodies were 
used to stain the phenotypic and activation markers and 
flow cytometry was used to analyse the lymphocytes 
harvested from the primary tumours of 31 patients, the 
axillary lymph nodes of 40 patients and the peripheral 
blood of 39 patient. These were analysed with regard to 
the proportions of CD4+ helper T cells, CD8+ 
suppressor/cytotoxic T cells and B cells.
We also looked at the proportion of each cell type 
carrying the activation marker HLA DR, the class II 
major histocompatibility (MHC) antigen, and the 
receptors for interleukin 2 (IL-2) and transferrin 
(Trf). In the case of the B lymphocytes, we stained 
surface membrane IgG.
These parameters were also studied on the lymph node and 
peripheral blood lymphocytes of 7 control subjects 
undergoing vascular surgery or organ donation.
The tumour cells themselves were stained for the 
expression of the class I and class II MHC antigens and 
for membrane bound IgG.
The phenotypic proportions and activation status of the
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tumour infiltrating lymphocytes (TILs) were correlated 
with the tumour cell expression of class I and class II 
MHC antigens and with the common prognostic indicators 
of tumour stage, histological tumour grade and oestrogen 
receptor status.
The composition and activation status of the lymph node 
and peripheral blood lymphocytes were correlated with 
tumour s t a g e .
PRIMARY TUMOUR
TILs were found in 85% of the primary breast tumours 
studied and, in 60%, the infiltrate was sufficient to 
allow analysis of both the phenotypic and activation 
m a r k e r s .
T cells made up the bulk of the infiltrate with few B 
cells. CD8+ suppressor/cytotoxic T cells predominated 
overall, although CD4+ helper T cells were in the 
majority in 7 tumours with a strong infiltrate. The 
size of the CD8+ T cell population increased with 
histological grade (p<0.05) and tumour cell expression 
of the class I MHC complex (p<0.01).
A large proportion of the CD8+ T cells were found to 
carry HLA DR and again this proportion increased with 
histological grade (p=0.003) and the tumour cell 
expression of both the class I and class II MHC
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complexes (p<0.001). These findings suggest that 
activated CD8+ suppressor/cytotoxic T cells are being 
attracted by surface antigen, on poorly differentiated 
tumours, when this is presented along with the class I 
MHC complex. This latter is necessary for antigen 
recognition by CD8+ T cells.
A similar pattern was seen with the CD4+ helper T cells 
but to a slightly lesser degree.
However, a higher proportion of the CD4+ T cells than 
CD8+ T cells bore the receptors for interleukin 2 
(p < 0.0001) and transferrin, suggesting there is greater 
turnover or expansion of this cell type.
There appears therefore to be some evidence, within the 
primary tumour, of the recognition of antigen and a 
cellular immune response to it.
AXILLARY LYMPH NODES
Lymph nodes from breast cancer patients were found to be 
large and engorged, with higher cell counts than nodes 
from control subjects.
The nodes from patients with breast cancer had a higher 
proportion of CD4+ helper T cells (p=0.003) with 
CD4+/CD8+ T cell ratios ranging as high as 16:1 and 
averaging 5:1 (p=0.02).
In the cancer nodes, a higher percentage of the T cells
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bore HLA DR (p<0.0001) and, in the case of the CD8+ T 
cells this correlated with tumour stage (p=0.02). This 
again reinforces the association of this marker with the 
direct interaction of CD8 + T cells with antigenic tumour 
cells, in this instance, within nodal metastases.
The IL-2 receptor was present on a greater proportion of 
the lymph node lymphocytes (LNLs) in the breast cancer 
patients (p=0.006) and, as in the TILs, this receptor 
was present on more CD4+ than CD8 + T cells.
Although the transferrin receptor was found on more 
lymphocytes in the nodes of breast cancer patients this 
was not statistically significant.
Almost double the number of B cells were found to carry 
surface IgG in the breast cancer nodes as in the control 
nodes (p = 0 .03) .
There is evidence of helper T cell expansion and a 
humoral immune response in the axillary lymph nodes of 
patients with breast cancer. The CD8+ T cells appear 
more activated in patients with nodal metastases.
PERIPHERAL BLOOD
Apart from a slightly smaller B cell population, there 
was little difference in the phenotypic proportions of 
peripheral blood from patients with breast carcinoma and 
normal subjects.
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HLA DR was found on a much greater proportion of the T 
cell population, of both phenotypes, in the peripheral 
blood of breast cancer patients compared to controls
(p<0.0001).
While more of the CD8 + T cells in the blood of cancer 
patients bore the IL-2 receptor (p<0.03), the increase 
in the expression of this marker within the CD4+ T cell 
population was even greater (p=0.006). And it was again 
found on more CD4+ T cells than CD8+ T cells.
The cancer patients also had a larger IgG bearing B cell 
population (p=0.003) than the controls.
When the different lymphocyte sources were compared, the 
axillary nodes were found to be the major site of the 
CD4+ helper T cells (p<0.03) and the B cells (p<0.001) 
while the primary tumour appeared to be the most 
relevant source of the CD8+ suppressor/cytotoxic T cells 
(p< 0.001). Although the peripheral blood lymphocytes of 
cancer patients showed some activation, when compared 
with controls, the immune response still appeared to be 
largely loco-regional at the time of presentation.
The peripheral blood was found to reflect the T cell 
subset proportions (p<0.001) and the size of the IgG 
bearing B cell population (p<0.001), within the axillary 
nodes and analysis of peripheral blood might give some 
indication of the immune status of the axillary nodes.
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HUMAN MONOCLONAL ANTIBODIES
In an attempt to characterize the IgG produced by the 
nodal B cells, in many patients with breast cancer, we 
tried to immortalize them using EBV transformation, cell 
fusion or a combination of the two.
While we did detect some immunoglobulin binding on 
sections of autologous tumour, we had no success in 
producing human monoclonal antibodies and detailed study 
of this humoral immune response was therefore not 
p o s s i b l e .
CONCLUSION
This study provides some evidence of antigen recognition 
and a loco-regional immune response, both cellular and 
humoral, in many patients with breast carcinoma. This 
is particularly evident in those patients with a 
malignancy of high histological grade and tumour cell 
expression of the class I major histocompatibility 
c o m p l e x .
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CHAPTER 1: INTRODUCTION AND AIMS
In mamillis saepe vidimus tumorem forma ac figura 
cancro animali exquisite consimilem. Nam 
quemadmodum in isto pedes ex utraqpie parte sunt 
corporis, ita in hoc morbo venae distenduntur, ac 
figuram omnio similem cancro representant.
Galen: De Art. Curat. Ad Glaucon.
Lib. 2, Cap. 10
The term "Cancer" was coined by the Roman physician 
Galen around the year 200 A.D. and was derived from his 
description of locally advanced breast carcinoma in 
which the radial congested skin veins around the tumour 
appeared like the legs of a crab. From this time until 
the second half of the nineteenth century cancer was 
considered a systemic disease caused by melancholia, an 
excess of black bile, for which there was no cure.
After this time the theory of breast cancer development 
changed and it was thought that tumours began locally, 
possibly due to obstruction or inflammation of a duct or 
gland, and then spread in an orderly fashion, via 
lymphatics, to the regional lymph nodes which acted as 
filters and from there to other organs 4 4 2 . Blood borne 
metastases were not considered to contribute greatly to
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the spread of disease. It was upon these principles 
that the rationale for radical mastectomy, as advocated 
by Halsted 175, was based (Fig. 1). This theory of 
cancer progression, and the surgical management it 
endorsed, continued until the second half of this 
century, since when it has been challenged, and once 
again breast cancer is considered to be systemic quite 
early in the disease process, though developing from a 
local tumour rather than leading to one. The surgical 
management has therefore also been challenged, both by 
those who felt the morbidity of such radical surgery was 
unacceptable and of little benefit and by those who 
believed that the destruction of the axillary lymph 
nodes might actually be detrimental if they were the 
seat of an anti-tumour immune response.
One of the major arguements against the existence of an 
anti-tumour immune response is that no definitive tumour 
antigen has ever been identified and, as oncogenic 
products are largely intracellular, there may not be any 
surface antigen to be detected by the immune system. 
Alternatively, the tumour growth and antigen 
presentation may develop so slowly as to induce 
tolerance in the host 3 51.
While tumours of viral origin are more frequent among 
patients who are immunosuppressed, due to aquired immune
24
Apical  ^
lymph node
Central 
lymph node Pectoralis
.Major
Pectoralis
Minor
Lateral Pectoral 
lymph nodes
Breast excised along with Pectoral muscles,
fascia, and all draining lymph nodes.
EigJ. The Halsted mastectomy was based on the principal that 
breast cancer spread in a progressive fashion up through 
the lymph node chains before any distant metastasis 
occured.
deficiency syndrome (AIDS) or long term
immunosuppressive therapy after organ transplant, there 
is no increase in the common malignancies such as breast 
carcinoma 1 5 3 ,  3 2 7 s
The possible existence of a host anti-tumour immune 
response is, however, supported by the long term 
survival of some patients known to have residual 
malignant disease after therapy 133 or those who develop 
recurrence, many years after the initial presentation, 
during some time of great stress, such as bereavement, 
which appears to depress the immune system 2C - 2 2 3 , 3 7 2 .
The question of whether or not patients with breast 
cancer mount an immune response to their tumour is 
important for three main reasons.
If some patients mount an effective immune response 
against their tumours this could be expected to improve 
their survival and therefore evidence of that immune 
response might be an important prognostic indicator. 
Secondly, the presence of a response and its anatomical 
site would have to be considered when planning adjuvant 
therapy which affects the immune system. If that 
response were regionally based it would be destroyed by 
loco-regional therapy such as surgery or radiotherapy 
while a centralised immune response would be depressed 
by cytotoxic chemotherapy.
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Lastly, if an effective immune response could be 
identified and the mechanisms of it understood it might 
be possible to enhance that response, where present, and 
develop methods of immunotherapy or stimulation for 
those patients not mounting a response.
AIMS OF STUDY
1) To seek evidence of antigen recognition and an 
immune response in patients with breast cancer.
This was done by studying the phenotypic subsets and 
surface activation markers of lymphocytes infiltrating 
the primary tumour of breast cancer patients and 
correlating these results with the degree of tumour 
differentiation, as represented by histological tumour 
grade and oestrogen receptor status with tumour cell 
expression of the class I and class II major 
histocompatibility molecules which are required for the 
presentation of antigenic material to the immune system 
and with the stage of tumour spread.
The phenotypic and activation markers were also studied 
on lymphocytes from the axillary lymph nodes and 
peripheral blood of patients with breast cancer, 
correlated with tumour stage and compared with lymph
26
node and peripheral blood lymphocytes from normal 
s u b j e c t s .
2) To assess the contribution of the axillary lymph 
nodes to any humoral or cellular immune response in 
patients with breast cancer and the extent to which any
response remains loco-regional at the time of clinical
p r e s e n t a t i o n .
The phenotypic subsets and surface activation markers on 
lymphocytes from the primary tumours, axillary lymph 
nodes and peripheral blood of individual patients with 
breast carcinoma were compared to assess the relative 
contribution of the axillary lymph nodes to any response 
and to consider the effect on this of the current 
management of breast cancer.
Correlation between the blood lymphocyte markers and 
those in the other tissues was sought as a guide to the
immune status in the region of the tumour.
3) To consider the possibility of developing 
immunotherapeutic approaches to the management of breast 
c a n c e r .
Based on the results of the above studies, potential 
methods of immune enhancement were considered. In
27
particular, the feasability of developing human 
monoclonal antibodies from patients with breast cancer 
were assessed as, if this were successful, it might 
allow the isolation and study of tumour antigens and 
provide useful tools for the diagnosis and therapy of 
breast cancer.
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CHAPTER 2: EVIDENCE OF ANTIGEN PRESENTATION AND AN
IMMUNE RESPONSE IN PATIENTS WITH BREAST CANCER
INTRODUCTION
The initial question to be answered was whether any 
patients with breast cancer show evidence of an immune 
response against their tumours.
As no tumour specific antigens have been identified or 
characterized, it has been suggested that there are no 
membrane tumour antigens to be recognized by the immune 
system and particular attention was therefore paid to 
evidence of tumour antigenicity or antigen presentation 
and recognition.
Lymphocytes from the axillary lymph nodes and peripheral 
blood of patients with breast cancer were compared with 
those obtained from normal subjects to demonstrate 
whether the breast cancer patients showed evidence of 
immune stimulation or suppression.
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HISTORICAL REVIEW
HISTOLOGICAL STUDIES OF TUMOUR INFILTRATING LYMPHOCYTES
The first suggestion that cancer patients might mount an 
immune response to their tumours came in the early years 
of this century when Handley 180 found that the 
spontaneous regression of malignant skin melanomata was 
associated with a round cell infiltrate and Da Fano 1b , 
from his animal studies, suggested that this 
infiltration of tumours by plasma cells and lymphocytes 
might represent an immune response as part of the host's 
tumour defences. This theory was supported by MacCarty 
& Mahle 263 who observed an improved survival among 
patients suffering from gastric cancer who had an 
inflammatory infiltrate in their tumours and 
demonstrated a similar survival advantage in both breast 
384 and colon cancer This finding appeared to be
supported by the study of medullary carcinoma which has 
a particularly good prognosis and often has a marked 
lymphocytic infiltrate ^8 4 - ’3- 48 ^ 3 44. However, as
Richardson 341 pointed out, medullary tumours have a 
better prognosis, even when the lymphocytic infiltrate 
is absent, due to their poor stroma formation and 
consequent inability to form viable metastatic deposits.
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This was confirmed in the study by Ridolfi 344 when 
patients with medullary carcinoma were found to have the 
same 1 0 year survival rate regardless of whether or not 
they had a prominent lymphocytic infiltrate although 
this infiltrate was again associated with improved 
survival in patients with non-medullary carcinoma. 
Although the positive correlation between the presence 
of an inflammatory tumour infiltrate and improved 
survival was rather weak in these original studies, 
interest in it continued and in the first half of this 
century many studies were carried out looking at the 
effect of this infiltrate on survival prognosis.
Eighteen studies looked at this phenomenon in breast 
cancer patients and thirteen of these found an improved 
survival rate among patients with an inflammatory 
infiltrate in their tumours 3 3 4 , u 7 , 3 5 , 2 7 , n > ,  3 ,
i? 7 , 9 2 , 9 4 , 48, 4 3 4 , 36, 3 4 4 ( while five groups found
no survival advantage for such patients 6 9 . :a7 . 3 2 3 ,
358, 1 3 9 . two of t h ese latter even s u g g e s t e d  that an
i n f l a m m a t o r y  i n f i l t r a t e  was a s s o c i a t e d  w ith a poor 
p r o g n o s i s  353, 139.
Taking solid tumours as a whole, the great majority of 
studies found the presence of an inflammatory infiltrate 
to be associated with a better prognosis. Controversy 
continued, however, over whether this infiltrate was 
evidence of a host anti-tumour response 3 0 4 . 123 or
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secondary to tumour necrosis which was in itself due to 
other factors 1 67, 2 0 7 , 9 9 , As a prognostic factor,
inflammatory infiltrate did not appear to be as strong 
as histological tumour grade or stage and so its 
relevance remained unclear 45 ^ 4 b - 47 ' 7 3 .
These early studies merely noted the presence or absence 
of lymphocytes within the tumour, using conventional 
haematoxylin and eosin stains, but were unable to 
differentiate the cell types involved.
ANIMAL STUDIES
In an attempt to confirm the antigenicity of tumours and 
the existence of an anti-tumour immune response, many 
workers turned to animal models. The commonest 
experimental tumours were those induced in female 
C3H/HeN mice either chemically, using methylcholanthrene 
to produce sarcomata 16 • 17 * 18 * 19 8 # or virally, using
the mouse mammary tumour virus (MMTV) 2 5 0 - 2 9 0 .
In all these animal experiments, using chemically or 
virally induced tumours, a host versus tumour immune 
response was detected. After excision of the primary 
tumour the animal was protected, to some degree, against 
the establishment of a second inoculum of tumour cells 
4 5 4 , 2 9i and. this protection was lost after splenectomy
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17 . Billingham et al 31 coined the term "adoptive 
immunity", in their study of skin homografts, to 
describe the continued function of lymphoid tissue or 
cells after transfer from an immunized animal to an 
unimmunized host. Adoptive immunity was shown to be 
conferred by transferring lymphocytes or splenocytes 
from a tumour immunized animal to a second host, prior 
to a tumour challenge, resulting in the rejection of the 
tumour 1 0 1 , 4 67, lie, i4i. i7, is. The major flaw in
these animal studies was that the tumours were either 
chemically or virally induced, which made them 
particularly antigenic 311 and when they were compared 
with truly spontaneous lesions it was notable that, in 
the latter, there was little evidence of an immune 
response 34 6, 1 3 9 . Indeed it appeared that the closer
conditions in these animal studies simulated the 
situation in humans the less evidence there was of an 
immune response to cancer 3 3 5 .
DELAYED HYPERSENSITIVITY
The limited relevance of animal experiments caused a 
return to the study of the human immune system and its 
function in patients with breast carcinoma.
The most commonly used in vivo study of the immune
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system in breast cancer patients was the test of delayed
hypersensitivity. This was performed by injecting
intradermally either dinitrochlorobenzene (D N C B ), or a 
similar chemical irritant, to test de novo sensitization 
2 7 9 , 3 0 2 , 3 4 9 , 3 q 3, 447 or an extract of autologous
tumour to test specific hypersensitivity 3b- 3 7 , 3^ , 4 ,
4 0 . Those who used the first method detected no 
difference between patients with breast cancer and 
normal controls nor was any difference seen at different 
stages of the disease apart from a reduced response in 
patients who were terminally ill. In these patients, 
Stein 393 found that tumour dissemination preceded 
impairment of the patient's immune response, suggesting 
it might be the cause rather than the result of the 
im p a irment.
Studies in which autologous tumour was inoculated, 
demonstrated a markedly greater response in tumour 
patients than in those with benign lesions. Patients 
with stage II disease also had a greater response 
compared to stage I patients 3b' 3 96, 4 0 . There was
disagreement, however, over whether or not this delayed 
hypersensitivity reaction represented an advantageous 
immune reaction associated with a good prognosis 40' 4
or was indicative of a poor prognosis 39 6 .
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FUNCTIONAL IN VITRO STUDIES
BLASTOGENESIS ASSAYS
One of the standard in vitro assays of immunocompetence 
was the blastogenesis assay. This assessed the ability 
of the patient's lymphocytes to respond to mitogen 
stimulation. The commonest mitogen used was 
phytohaemagglutanin (PHA) and the uptake of tritiated 
thymidine (3HT) by the cells was measured as an 
indicator of cell turnover in response to it. The 
majority of groups found the lymphopro 1 iferative 
response to PHA to be depressed in breast cancer 
patients, particularly with advancing disease 4 0 2 ,
3 0 2 , 3 9 3 , 4 4 7 , 2 1 2 , 2 7 2 , 2 7 although two groups found
a greater response in breast cancer patients compared 
with normal controls 1 2 8 , 2 0 1 . Fisher et al studied
lymph node lymphocytes from both patients and controls 
and found no difference in the thymidine uptake before 
stimulation with PHA, but found a wide variation between 
patients and between nodes within the same patient.
This variability may explain some of the conflicting 
results and the difficulty in interpreting them.
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CYTOTOXICITY ASSAYS
The vast majority of these were performed using the 
chromium release assay whereby tumour cells are cultured 
in medium containing c h r omium51 which is taken up by 
them and later released upon destruction or damage of 
the cells. This damage may be due either the cytotoxic 
effect of the mononuclear cells under study or to 
spontaneous cell death and therefore a control 
preparation is used to assess the background s i g n a l . 
Groups using this method to study tumour infiltrating 
lymphocytes (TILs) have again produced conflicting 
results with some showing evidence of specific 
cytotoxicity 4 2 7 , 2 4 , 386( while others found TILs to
have low levels of cytotoxicity against autologous 
tumour 4 4 4 , is. These cytotoxicity assays have several 
limitations. The indirect method of measuring cell 
death makes it a rather crude assay in which small 
variations in cytotoxicity are not detectable and the 
spontaneous cell death among the tumour cells gives a 
very high control reading. As breast cancer cells cycle 
slowly and do not grow well in tissue culture it is 
difficult to obtain large numbers of viable autologous 
tumour cells containing the chromium.
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SURFACE MARKER EXPRESSION
PHENOTYPING
With greater understanding of the immune response and 
the function of its component cells, interest has 
developed in identifying the lymphocytes that might be 
involved in any immune response being mounted by cancer 
patients, including those with breast cancer. The 
ability of T lymphocytes to rosette sheep red blood 
cells (SRBCs) and the presence of surface immunoglobulin 
on B lymphocytes was utilized in assessing the 
proportions of these cells present within the tumour, 
axillary lymph nodes and peripheral blood of breast 
cancer patients. T cells were found to be the major 
component of the tumour infiltrate l iq> 1 2 0 , 4 4 4 , of
the groups who compared the peripheral blood of normal 
controls and patients with breast cancer, two found no 
alteration in the proportion of B and T cells, as 
measured by these rosetting techniques 116• 171, while
two others found a decrease in circulating T lymphocytes 
with a concomitant increase in circulating B lymphocytes 
2 2 2 , 1 8 2 . Eremin et al 116 - 117 found a similar
alteration in the phenotypic proportions within the 
axillary lymph nodes of breast cancer patients although 
they found no alteration in the circulating blood
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lymphocytes. Other groups found no difference in the 
circulating lymphocyte proportions between patients with 
breast carcinoma and normal controls 373 > 192 .
Tsakraklides et al 430 used the rosetting method to 
compare the proportion of T and B lymphocytes in the 
lymph nodes of patients with stage I and stage II breast 
cancer and found an increase in the B cell population in 
stage II disease.
Anti-sera against T and B lymphocytes were also used to 
phenotype cells. Two studies used this method to study 
the tumour infiltrating lymphocytes (TILs) and also 
found T cells to predominate 374> J8°. At this time it 
was not possible to subdivide the T lymphocytes into the 
functional helper or suppressor/cytotoxic subsets.
Since the development of monoclonal antibodies to the 
surface markers of cell phenotype - 45, it has become 
possible to compare the type of cells making up any 
given lymphocyte population in both normal subjects and 
cancer patients.
This new technology has been applied extensively to the 
study of the TILs but little work has been done on the 
peripheral blood or lymph node lymphocytes of breast 
cancer patients. The studies of the tumour infiltrate 
have confirmed that this consists largely of T 
lymphocytes but there is controversy over the further 
classification of these into subsets. While some
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studies show a predominance of CD4+ helper T cells 4b 3 , 
164, 1 9 3 , 2 5 , 7 , 4 3 5 , 2 3 3 , i5 ; others show a
predominence of C D 8 + suppressor/cytotoxic T cells 1 5 9 ,
2 9 , 3 6 2 , 2 0 4 , 2 6 1 , 4 6 0 , 4 1 0 , 4 7 6 , 3 0 , 2 4 , 3 0 0 ,
One group compared the proportion of T and B lymphocytes 
in lymph nodes from breast cancer patients and from 
patients with non-malignant disease 5 0 . In the latter 
case, the nodes were excised because of hypertrophy or 
infection and cannot truly be considered as controls.
Two groups used flow cytometry to compare the peripheral 
blood and lymph node lymphocytes (LNLs) of patients with 
breast cancer but did not include any normal controls 
and when they found a large CD4+ helper T cell 
population in the nodes were unable to clarify whether 
this was due to the lymphocyte source or to the presence 
of malignant disease 2 89, 3 3 0 ,
Only two groups have compared the phenotypic proportions 
of normal lymph nodes with those excised from patients 
with breast cancer. Khuri et al 224 used 
immunohistochemical techniques and found an increase in 
the CD8+ T cell population in the nodes from breast 
cancer patients while Mantovani et al "7 2 , using single 
colour flow cytometry, found no alteration in the 
phenotypic proportions. These studies were small, with 
each containing fewer than ten patients.
Four studies have been carried out comparing the
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phenotypic composition of peripheral blood lymphocytes 
(PBLs) from normal controls and patients with breast 
cancer 2tb, 2bo, 3 2 5 , 2 7 2 . The last two of these
studies, utilised flow cytometry to study the phenotypic 
and activation markers. Pattanapanyasat et al found
a greater proportion of CD8+ T lymphocytes in the blood 
of breast cancer patients while the others found no 
phenotypic alterations in early disease. McCluskey et 
al 2 tb, however, did find a marked decrease in the 
proportion of circulating CD4+ helper T cells in 
patients with advanced breast cancer.
ACTIVATION MARKERS
Some groups have also studied the activation markers 
present on the surface of lymphocytes in patients with 
breast carcinoma. Studying TILs, Rowe & Beverley 3b;, 
Lwin et al and Ben-Ezra & Sheibani 25 found HLA DR
on a fairly large proportion of the lymphocytes within 
the tumours while Whiteside et al 4 -9  ^ 4 t-13 found very
few HLA DR bearing cells. Lwin et al 261 also found 
T a c , the 55Kd component of the interleukin 2 receptor 
(IL-2R) on 30% of TILs while other groups found few 
cells with this receptor 4 -g > 4 ^ 0 , 4 1 0 . 2 3 .
Only one group compared the activation marker expression
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of (LNLs) in breast cancer patients and control 
subjects. Mantovani et al 272 found more LNLs from 
patients with stage I disease to be carrying HLA DR than 
from control patients, while fewer lymphocytes from 
patients with stage II disease carried this marker.
These differences, however, did not achieve statistical 
significance. This group did not study the receptors 
for IL-2 or transferrin (Trf), nor the expression of 
surface immunoglobulin G (IgG) on lymph node B 
lymphocytes.
Pattanapanyasat et al 325 and Mantovani et al 2"- 
studied the expression of HLA DR on the peripheral blood 
lymphocytes of breast cancer patients and controls and 
found a slight increase in the number of HLA DR bearing 
cells in the breast cancer patients. Pattanapanyasat et 
al 323 also studied the receptors for 11-2 and 
transferrin but found no difference between the cancer 
patients and controls.
Most of the studies of TILs were made using 
immunohistochemical methods with a monoclonal primary 
antibody to the phenotypic surface marker and subsequent 
enzyme staining, predominantly peroxidase. The later 
studies used immunofluorescent microscopy with directly 
labelled monoclonal antibodies while the most recent 
have used two colour immunofluorescent monoclonal 
antibodies and flow cytometry.
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The use of flow cytometry to study the membrane bound 
markers, of phenotype or activation, on TILs has been 
applied to the study of other tumours such as malignant 
skin melanoma 2 0 ^. 2 3 ( eye melanoma i°8 , ovarian
carcinoma 1 e *> , hepatic tumours 457; oesophageal 
carcinoma and a selection of solid tumours 7 fc > 1 5 .
Although these last two groups did include some breast 
tumours, their numbers were fairly small and they did 
not include activation markers in their studies.
By virtue of its ability to collect data on up to 10,000 
cells, flow cytometry can make more statistically secure 
observations without introducing observer error. The 
use of propidium iodide to exclude dead cells from 
analysis, avoids non-specific cytoplasmic staining which 
can be mistaken for membrane staining in cells with a 
large nucleus and little cytoplasm; such as breast 
carcinoma cells.
A considerable advantage of flow cytometry is the 
ability to carry out accurate double staining 
experiments, allowing both the avoidance of cells 
registering in more than one phenotypic subgroup and the 
detection of surface activation markers as carried by 
different cell phenotypes.
An advantage of immunohistochemistry, which is lost in 
flow cytometry, is that the relationship of TILs to the 
overall tumour architecture can be studied.
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PRESENT STUDY
In this study we analysed the lymphocytes from the 
primary tumours of 31 patients, the axillary lymph nodes 
of 40 patients and the peripheral blood of 39 patients 
with regard to the proportions of CD4+ helper T cells, 
CD8+ suppressor/cytotoxic T cells, and B cells. We also
looked at the proportion of each cell type carrying the
activation marker HLA DR, the receptors for interleukin 
2 and transferrin and, in the case of the B lymphocytes, 
surface membrane IgG. These parameters were also 
studied on the lymph node and peripheral blood 
lymphocytes of 7 control subjects undergoing vascular 
surgery or organ donation.
The tumour cells themselves were stained for the
expression of the class I and class II major 
histocompatibility antigens and for membrane bound IgG. 
The phenotypic proportions and activation status of the 
tumour infiltrating lymphocytes were correlated with the 
tumour cell expression of class I and class II MHC 
antigens and with the common prognostic indicators of 
tumour stage, histological tumour grade and oestrogen 
receptor s t a t u s .
The composition and activation status of the lymph node 
and peripheral blood lymphocytes were correlated with 
tumour s t a g e .
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METHODS
FLOW CYTOMETER
This study of lymphocytes from the tumour, regional 
lymph nodes and peripheral blood of breast cancer 
patients was performed by flow cytometry using a FACScan 
analyser (Becton-Dickinson, Cowley, Oxford). This 
cytometer does not have a cell sorting capacity but is 
purely for the analysis of cell suspensions with regard 
to cell size, granularity and the presence of 
fluorochromes on or within the cell. It utilises a 15mW 
Argon ion gas laser because 15mW is the level at which 
the excitation of fluorochromes, conjugated to 
monoclonal antibodies, reaches a plateau and higher 
energy input brings little increase in the energy 
emission from the f luorochrome. Due to its low power, 
the laser can be air cooled and this allows its use as a 
bench top instrument by the investigator involved in the 
study rather than requiring both a purpose built room 
and a committed operator. The laser is set at a fixed 
wavelength of 488nm and therefore excites only 
fluorochromes in the red-green spectrum. While this 
limits the fluorochromes that can be used it makes the 
machine more reliable and easier to operate.
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The cytometer measures and records up to five parameters 
on each cell. The forward scatter of the laser light 
(F S C ) which, like a shadow, is related to cell size, the 
90° side scatter (SSC), which is the light reflected 
from the cell and is related to granularity and the 
binding of up to three fluorochromes. The fluorochromes 
used in this study were fluorescein isothiocyanate 
(FITC) which emits in the green waveband from 480nm to 
600nm, phycoerythrin (PE) which emits in the orange-red 
waveband from 550nm to 640nm and propidium iodide (PI) 
which emits at the strong red end of the spectrum from 
550nm to 700nm.
FLUIDICS
The function of the fluidics system is to provide a 
single file procession of cells through the viewing 
orifice of the flow cell. This is achieved by creating 
a laminar flow and driving the cells into a single 
stream (F i g . 2).
The cell suspension under study is prepared as described 
later, taking care to avoid contamination by cell debris 
which might clog the machine. The cell suspension 
(about 0.5ml) is placed in a cytometer tube (Falcon 
2052) and pushed over the sample pipette which is held
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in place by a rubber grommet to give an airtight s e a l . 
The pressure within the tube is increased slightly, by 
pumping in air, and this propels the sample up into a 
conical chamber in the flow cell assembly. Here it is 
forced into a laminar flow by a stream of isotonic 
sheath fluid driven under pressure from a tank 
maintained at 4.5PSI by an air pump. The laminar flow 
causes the cells to form a single stream as they leave 
the conical chamber and enter the flow cell where they 
are exposed to the argon-ion laser and their behaviour 
in the laser light is recorded. The flow cell of the 
FACScan analyser is a rectangular quartz cuvette with a 
large internal cross-section of 180u by 430u to avoid 
blockage by cell clumps or debris. After this the flow 
of sheath fluid carries the cell sample round to a waste 
tank. The stream of cells through the flow cell is 
controlled by the speed of the sheath fluid. A flow 
rate of 60ul/minute is used for the immunofluorescence 
of cell-bound monoclonal antibodies while DNA studies 
are carried out at the slower rate of 12ul/minute.
OPTICS
The argon ion laser beam is first passed through a 
prismatic refracting beam expander and then through a
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lens, to produce a converging elliptical beam, 20u 
vertically by 60u horizontally. This is focused on the 
stream of cells in the flow chamber by a steering plate 
and the behaviour of the cells within the laser light is 
recorded (Fig. 3).
The forward passage of the beam is scattered by each 
cell and this increases with size in a similar way to 
the shadow of an object in normal, radiant light. This 
forward scatter (FSC) is recorded on a silicon 
photodiode lying in the path of the laser on the 
opposite side of the flow chamber.
The reflection of the laser light from the cell 
increases with granularity and this reflected light is 
collected, along with the fluorescence, through a 
condenser lens set at 90' to the laser beam. This is a 
bi-convex lens which converts the scattered light and 
fluorescence into parallel light.
The reflected light or side scatter (SSC) and the green 
fluorescence (FL1) are separated from the red 
fluorescence by a 22.5" dichroic mirror with a 560nm 
edge which reflects longer wavelengths and transmits 
shorter wavelengths. The red fluorescence is reflected 
by this mirror while the green fluorescence and side 
scattered light pass through it to be separated from 
each other by a Brewster window. This is a quartz plate 
set at an angle between 5 3 G and 57' which reflects the
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side scattered light because it is polarized, while 
allowing the green fluorescence to pass through without 
loss .
The green fluorescence then continues through a band 
pass filter with a wavelength of 530nm and width 30nm. 
The red fluorescence, after being reflected by the first 
dichroic mirror, is separated into strong-red (FL3) and 
orange-red (FL2) wavebands by a second dichroic mirror, 
this time set at 45 ; with a 640nm edge. The strong-red 
fluorescence passes through this and through a long pass 
filter of wavelength 640nm while the orange-red 
fluorescence is reflected and passes through a band pass 
filter with a wavelength of 585nm and width 42nm.
DETECTION AND DISPLAY
The side scatter (SSC) and fluorescent emissions of the 
three f 1uorochromes are each detected by separate 
photoelectric multipliers.
The photons enter the photoelectric cell and each photon 
excites one electron which is reflected backwards and 
forwards off alternate parallel cathode plates. These 
carry an electric charge to accelerate the electrons and 
so each electron that strikes the cathode causes the 
emission of several more, thus leading to a great
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amplification of the original signal.
It can be seen from the emission wavebands of each 
fluorochrome that there is considerable spectral overlap 
between them (Fig. 4). This is of particular 
importance between FITC (FL1) and PE (FL2) as these are 
the fluorochromes conjugated to the cell surface marker 
antibodies and are therefore among the parameters being 
measured. This overlap of the FITC signal into the PE 
channel and vice versa is therefore compensated 
electronically, as is that between PE and PI.
The final signal for each parameter is in the form of an 
analog electronic pulse which is converted to digital 
data by an analog/digital converter to allow storage and 
processing by the computer system. The data management 
system is based on the HP310 computer (Hewlett-Packard) 
and this is connected to the cytometer by a parallel 
interface (GP10). The software program utilised in this 
study was FACScan Research which allows the collection 
and storage of raw data from all five parameters in list 
mode and display and analysis on a screen with 1024 
channel resolution.
The limit of sensitivity is 1000 FITC equivalent 
molecules per cell and, as the amount of fluorescence 
borne on the surface of the cells varies widely, the 
resultant range is displayed on a four decade log scale 
to allow easier measurement and analysis.
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Fig. 4 Showing the overlap of the emission spectra of the 
f luorochromes used in th is study. This is corrected 
fo r  by an electronic compensation.
The preparation of cells for the flow cytometer and 
analysis of the data obtained are outlined later.
SURFACE MARKERS 
PHENOTYPIC MARKERS
The lymphocytes were identified phenotypically using 
combined "Simultest" preparations of two antibodies, one 
conjugated with PE, the other with FITC (Becton 
Dickinson, Oxford). This allowed the identification of 
two phenotypes at the same time with those outwith these 
subsets remaining unstained at the origin (Fig. 5).
The lymphocytes were phenotyped as B or T lymphocytes 
using PE conjugated Leu 12 antibody to the CD19 antigen 
on the surface of B cells and FITC conjugated Leu 4 to 
the CD3 antigen on T cells. The T cells were further 
phenotyped into their subsets using Leu 2a, conjugated 
with PE, to the CD8 antigen to identify the 
suppressor/cytotoxic T cells. It is not yet possible to 
separate this subgroup further into suppressor cells and 
cytotoxic cells.
The Leu 3a antibody, conjugated with FITC, was used to 
identify the CD4 antigen on the helper T cells. As yet 
there there does not appear to be a clear delineation,
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as is seen in the murine system, between CD4 T cells 
which provide help for B cells and those which stimulate 
T cells. The use of these reagents allowed the 
phenotypic proportions of B and T cells and the T cell 
subsets to be measured.
When studying the activation marker expression within 
each cell population the same antibodies to the cell 
phenotypic markers were used but, in this case, they 
were all conjugated with PE while the antibodies to the 
activation markers were conjugated with FITC. Thus, 
cells of the phenotype under study would be stained 
orange-red and any of those bearing the activation 
marker of interest would also be stained green by the 
FITC conjugated antibody. On a coloured screen this 
mixing of green and red results in yellow (Fig. 6).
ACTIVATION MARKERS
Cl ass I major histo compatibi1it y c o mp 1 e x 
To avoid confusion with tumour antigen we will refer 
to the major histocompatibility (M H C ) "complex'1 rather 
than MHC "antigen".
The class I MHC complex is made up of two polypeptide 
chains. One of these traverses the cell membrane, is 
glycosylated with a molecular weight of 45,000 and has
51
three domains, alpha 1, alpha 2 and alpha 3. The other, 
the beta - 2 microglobulin, is not transmembranous, is 
non-glycosylated and has a moleclular weight of 1 2 ,0 0 0 . 
The alpha 3 domain and beta-2 microglobulin form the 
base of the complex near to the cell membrane while the 
antigen presenting groove is constructed from the alpha 
1 and alpha 2 domains on the heavy chain (Fig. 7). The 
walls of the groove are formed from the side chains of 
the alpha helices while the base is made up of the side 
chains of the central beta strands on these alpha 
domains 3 3 ( Fig. 8 ).
C D 8 + suppressor/cytotoxic T cells can only recognize 
and bind antigen in combination with this complex. This 
combined recognition prevents the antigen receptors on 
C D 8 + T cells from being blocked by free circulating 
antigen, such as virus, and ensures the killing of 
infected cells ^ , its, i&4 (Fig. 9).
While benign breast lesions and medullary tumours appear 
to have fairly uniform cell expression of the class I 
MHC molecule ‘ 4 t 3 ( some groups have demonstrated a 
lack of class I MHC complexes on the cells of many 
breast tumours 1 4 3 : 3 , and as the immune system,
and in particular the C D 8 + cells, can only recognize 
antigen in the presence of this complex, its lack might 
prevent the recognition of tumour antigen. We therefore 
studied the expression of this marker on the tumour
52
Al loantigenic 
s ites on oc ^  
domains
a2
a3
Plasma membrane
Cytoplasm
Fig. 7 A schematic drawing of the structure of the 
Class I major h is tocompat ib i l i ty  antigen 
showing the threeoc domains and the 
p2 microglobulin.
q . 8  The antigen presentation groove, w i th in  which 
antigen is held, is approximately 10X by 25&. 
The wal ls  ere the side chains of the <x helices 
while  the f loor  formed by the side chains of 
the p sheet between the two <x domains.
CD8+ cyto toxic
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Class I MHC w i th  
Vira l antigen
? Class I MHC w i th  
k Tumour antigen
Somatic cel 
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Eig_9 CD8+ cytotoxic  T cells recognize foreign antigen 
presented by the Class I MHC structure on somatic 
cells. It may be that they can recognize tumour 
antigen in a s im i la r  fashion on tumour cells which 
are expressing Class I.
cells and correlated it with the degree and type of 
immune reaction found within the tumours. This marker 
was detected using the W6-32 antibody which was used 
with a second goat anti-mouse antibody conjugated to 
FITC .
HLA DR
HLA DR is the predominant antigen of the class II MHC 
complex. The structure of this complex is less well 
known but does appear to be similar to that of the class 
I complex except that the four domains are arranged on 
two polypeptide chains of similar size, both of which 
are transmembranous in position b0 (Fig. 10).
Antigen is recognized by CD4+ helper T cells when it is 
presented in conjunction with this MHC complex in a 
similar fashion to the recognition of antigen, in 
conjunction with the class I MHC complex, by 
suppressor/cytotoxic T cells (Fig. 11). The antigen 
presenting cells include £ cells and macrophages and 
this complex is usually found on these cells 1 7 a . The 
antigen presenting capability of B cells has been shown 
to relate directly to the degree of HLA-DR expression on 
their surface 4” 3 .
HLA-DR has also been demonstrated as a T cell activation 
marker which is absent on resting T cells 338 but is 
present on T cells stimulated by antigen, in mixed
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C w  C
F i g . 10  in the case of the Class II MHC structure, the 
ot and (3 domains are s im i la r  in size and are 
both transmembranous.
CD4+ HelperT cell
Ag. presenting cell
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T cell dependent help 
(lymphokines) \
? Tumour Ag. 
presented 
by CD8+ 
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CD8+ T cell
Macrophage
F jq . 1 1 CD4+ helperT cells ere st imula ted by antigen
presented along w i th  the Class II MHC structure 
and they, in turn, s t imula te macrophages and 
B cells by secreting lymphokines. Act ivated CD8 + 
suppressor/cytotoxic T cells express the Class II 
s tructure and may present antigenic mater ial 
f rom cells they have destroyed.
lymphocyte cultures 3 2 6 - 98, or mitogen 2 3 4 . Although
its exact function on T cells is unknown, there is some 
evidence to suggest it is involved in antigen 
presentation as is the case with B cells 338, 326.
Some role in cell communication is also suggested by the 
number of CD4+ helper T cells which bear this marker and 
the finding that blocking the class II complex with a 
specific antibody prevents activated cells from 
responding to interleukin 1 3 22.
In this study, therefore, it was used as a marker of T 
cell activation along with antigen recognition and 
p r e s e n t a t i o n .
This complex has also been identified on certain 
epithelial cells and the murine equivalent has been 
found on the mammary glands of mice < 3 2 . Studies of 
renal graft rejection have shown a strong correlation 
between rejection of the graft and the expression of 
this complex on both the tubular epithelium of the graft 
and the circulating T cells 2 - 2 < :84. We therefore also
studied the expression of this complex on the tumour 
cells and correlated this with parameters of the 
intratumoral immune response.
The class II MHC complex was stained with a FITC 
conjugated antibody to HLA DR from Becton Dickinson.
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Interleukin 2 receptor
The receptor for the lymphokine interleukin 2 is 
composed of two glycoprotein chains, an intermediate 
affinity alpha chain with a molecular weight of 75,000 
which transduces the signal into the cell 4 3 3 ,  4 1 3 4 ;
and a beta chain of low affinity with a molecular weight 
of 55,000 4 3t. When combined, the affinity increases a 
thousand fold because of kinetic cooperation between the 
two chains. The 55,000 beta chain binds interleukin 2 
briefly and then dissociates, which brings the IL-2 into 
the plane of the membrane and allows the 75,000 alpha 
chain to bind it (Fig. 12).
This chain binds and dissociates from IL-2 very slowly 
and these cooperative kinetics create a very efficient 
receptor J . On antigen stimulated T cells the 
expression of the low affinity beta chains is 5 to 10 
fold greater than that of the intermediate affinity 
chain. IL-2 binding to high affinity receptors 
decreases their expression by 50%, but increases the 
expression of the beta chain 10 to 20 fold '■>b 1 , 
producing an excess of beta chains and allowing the 
number of high affinity receptors to be controlled by 
the number of alpha chains. This increase in beta 
chains makes their presence a good guide to the increase 
in IL-2 receptors after activation, antigen stimulation 
or in the presence of IL-2.
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ELg_12 a schematic representation of the high a f f in i t y  
ln ter leukin-2 Receptor showing the kinetic  
cooperation between the two chains. The p chain 
binds the ln ter leukin-2 only br ie f ly  before 
releasing i t  w i th in  the plane of the membrane 
thus making i t  possible fo r  the p chain to bind 
i t  and transduce the signal into the cell
Expression of the interleukin 2 receptor increases after 
stimulation, by mitogen or antigen, and IL-2 then 
mediates the movement of the cell from G l a to Gib ready 
to enter the S phase of the cell cycle 28 . The 
expression of this marker precedes that of the Trf 
receptor in actively dividing cells.
The anti Tac antibody detects CD-25, an antigenic 
determinant on the beta chain of the IL-2 receptor and 
this was therefore used as an activation marker on T 
lymphocytes. Tac was also used as an activation marker 
on B cells where it is expressed at about one third of 
the level of T cell expression 28^ .
Tac was stained with a FITC conjugated antibody to CD25 
from Becton Dickinson.
Transferrin receptor
This receptor consists of a transmembranous glycoprotein 
with a molecular weight of about 95,000, made up of 2 
identical subunits bound by di-sulphide bonds.
Iron in its ferric form binds to transferrin (Trf) which 
then binds to the Trf receptor. Ferric-transferrin is 
then endocytosed on the receptor to an acidic, 
n o n - 1y s o s o m a 1 compartment where the iron is released 
from the protein and transported across the cell 
membrane into the cytoplasm. The Trf protein 
(a p o - t r ansferrin) remains on the receptor and is
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recycled to the cell surface and released leaving the 
receptor free again 417 (Fig. 13).
This receptor is poorly expressed on resting and well 
differentiated cells but strongly in tissues with a high 
proportion of dividing cells 4^9 , 4 -^ or on mitogen
stimulated lymphocytes 3 o y . m b  , n ? .  The changes in
the Trf receptor occur prior to DNA synthesis 8 : > 58
with the peak just prior to cell division 7 -. This 
increase in Trf receptors prior to cell division is due 
to the increased need for intracellular iron, required 
by the enzyme ribonucleotide reductase which is involved 
in RNA transcription.
These receptors appear on cells passing from late G1 
phase through S phase to cell division after cell 
stimulation, the appearance of IL-2 receptors 3 o i , and 
stimulation by IL-2 1 9 .
We studied this marker on the lymphocytes of patients 
with breast cancer and normal subjects to see if there 
was increased turnover of these cells in the cancer 
p a t i e n t s . This marker was stained using a FITC 
conjugated anti-CD71 monoclonal antibody from Becton 
Di c k i n s o n .
Membrane immunoglobul i n G
Immunoglobulin M (IgM) appears in the initial stages of 
a primary humoral immune response but is poly-valent and
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F i g . 15  Ferric iron, bound to Transferr in , is carried into
the cell by endocytosis of the Transferr in  Receptor. 
A f te r  t ran fer  of the iron accross the true cell 
membrane, the Receptor end Transferr in  are 
re-cycled to the surface.
of fairly low affinity. After isotype switching and 
affinity maturation IgG is produced. This bi-valent 
immunoglobulin is of much higher affinity and it is this 
immunoglobulin class which appears during the mature 
secondary immune response (Fig. 14). Production of
IgG may also continue in the presence of chronic antigen 
although in some cases, when patients develop 
h y p e r i m m u n i t y , the isotype switching continues until IgE 
is produced. We therefore used the expression of 
surface membrane IgG as an indicator of a mature humoral 
immune response. This was stained with a Dako rabbit 
F ( a b ) ? anti-human IgG, conjugated with FITC.
Artifactual detection of monocytes binding IgG to their 
Fc receptors 4b4 was avoided by the double staining of B 
lymphocytes with the PE conjugated anti-CD19 antibody.
PATIENTS_ AND SAMPLES
Samples of primary tumour, axillary lymph nodes and 
peripheral blood, or all three, were obtained from 46 
patients undergoing definitive surgery for breast 
carcinoma and seven control patients, five of whom were 
undergoing aortic bifurcation graft surgery while two 
were cadaveric organ donors. Two of the control 
subjects were female and five were male, with an average
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E i g J j l  While IgM is the immunoglobulin produced short ly af ter  
in i t ia l  antigen exposure, IgG secretion fo l lows w ith in  
a few days and i t  is this la t te r  which is the major 
immunoglobulin secreted during a secondary immune 
response.
age of 48 years, while all of the breast cancer patients 
were female and the average age was 61 years.
None of the patients with breast cancer had received 
preoperative cytotoxic, endocrine or radiotherapy and 
there was no evidence, in either group, of concomitant 
disease or therapy which might cause immune stimulation 
or depression.
The samples were collected aseptically in the operating 
theatre and later processed in a laminar flow hood. 
Providing this would not compromise the amount of tissue 
available for routine investigations, a central slice, 
representative of the tumour as a whole, was taken. The 
remainder was sent to the Western Infirmary department 
of pathology for routine histology and grading 47, and 
to the biochemistry department for oestrogen receptor 
assay by the ligand binding method 2 -s < . The lymph nodes 
collected were bisected and while one half was processed 
for this study, the other was also sent for routine 
histological staging. 10ml of peripheral venous blood 
was taken during the operative procedure and collected 
in potassium ethylene diamine tetra-acetic acid (EDTA) 
t u b e s .
59
CELL HARVESTING
BREAST TUMOUR SAMPLES
Tumour samples were collected from 31 patients. 29 of 
these subsequently proved to have invasive ductal breast 
carcinoma while two had lobular breast carcinoma. The 
tumour samples were washed in a petri dish containing 
RPMI 1640 medium and, after trimming away any fat, the 
sample was transferred to another petri dish and 
mechanically disaggregated using a scalpel and needle to 
tease apart the tumour tissue and release the cells into 
the medium. The spilled cells were pipetted off, 
washed, resuspended in freezing medium consisting of 10% 
d i m e t h y 1sulphoxide (DMSO) and 90% foetal calf serum 
(F C S ) and stored in liquid nitrogen.
No attempt was made to separate the tumour infiltrating 
lymphocytes (TILs) from the tumour cells as many would 
be lost and this might distort the proportions of 
various mononuclear cells present within the infiltrate. 
Surface marker analysis was performed only on cells 
spilled mechanically from the tumours because a lengthy 
incubation in collagenase might allow changes to occur 
in the membrane markers 4 -9 ' '7  ^ and preparation was
carried out shortly after receipt of the samples to 
minimise turnover of the membrane receptors.
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A similar method was applied to 6 normal breast tissue 
samples obtained at the time of reduction mammoplasty 
but few cells were harvested and very few lymphocytes 
seen. It was not practicable to analyse so few cells by 
flow cytometry and reasonable cell numbers could only be 
achieved after at least two weeks in culture. This was 
not comparable with fresh samples and therefore, no 
control lymphocytes were available from normal breast 
tissue for comparison with the TILs. Benign lesions 
could not be used as controls in this study because all 
of the lesion must be submitted for frozen section 
histology to exclude malignant disease and, while this 
would have allowed study of these lesions using 
immunohistochemical techniques, it meant there was no 
fresh tissue available for flow cytometric analysis.
This is an advantage which remains with
immunohistochemical analysis which can be performed on 
sections cut from the original frozen block.
LYMPH NODE LYMPHOCYTES
Lymph node samples were obtained from 40 patients 
undergoing definitive surgery for breast cancer which 
included excision sampling of the ipsilateral axillary 
lymph nodes. Iliac lymph nodes were collected from 7
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normal controls consisting of 2 cadaveric kidney donors 
and 5 patients undergoing aortic bifurcation vascular 
surgery. The cells were released from the nodes by 
teasing them apart with a scalpel and needle. The 
lymphocytes were isolated from the lymph node suspension 
by layering this over an equal volume of Ficoll Hypaque 
(Pharmacia) and centrifuging at 500 G for 20 minutes.
The lymphocytes were removed from the interface by 
careful pipetting, minimising the contamination by 
Ficoll or RPMI medium 57. The lymphocytes, thus 
obtained, were then washed, resuspended in freezing 
medium and stored in liquid nitrogen until they could be 
analysed on the flow cytometer.
All samples were processed as quickly as possible to 
avoid turnover or any major alteration in the membrane 
r e c e p t o r s .
PERIPHERAL BLOOD
10ml of peripheral venous blood was obtained from 39 
patients with breast carcinoma and 7 control patients, 
during surgery, and collected in potassium EDTA tubes. 
The blood was diluted with 10ml of RPMI medium and this 
cell suspension was gently layered over 10ml of Ficoll 
Hypaque (Pharmacia) and the lymphocytes obtained by
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density gradient separation. These lymphocytes were 
also washed and resuspended in freezing medium to be 
stored in liquid nitrogen for later analysis on the flow 
c y t o m e t e r .
FLOW CYTOMETRY 
STAINING OF CELLS
The basic method of cell staining and preparation was 
the same regardless of whether the lymphocyte sample was 
from the primary tumour, lymph nodes or peripheral 
b 1o o d .
The cell samples were quickly thawed, in a water bath at 
37 C, to avoid damage by ice crystal formation within 
the cells. The cells were washed twice in filtered 
phosphate buffered saline (PBS) and resuspended at a 
cell density of approximately 2 X 10" cells/ml. 50ul of 
this cell suspension was placed into each of fourteen 
flow cytometry test tubes (Falcon 2052) and monoclonal 
antibodies, to the phenotypic and activation membrane 
markers on the cells, were then added (Table 1). Apart 
from the W6 32 antibody to the class I MHC antigen, 
these antibodies were directly conjugated with 
fluoroisothiocyanate (FITC) or phycoerythrin (PE) which
63
T A B L E  1. Monoclonal antibodies used in this study.
Antibody
IgG l-F IT C  + IgG2a-PE 
Leucoeate
(Anti-CD  45 + Anti-CD 14 )
Simultest (Phenotype analysis) 
Anti-Leu 2a PE 
Anti-Leu 3a FITC
Anti-Leu 4 FITC 
Anti-Leu 12 PE
Predominant Reactivity.
Irrelevant antibody as control.
Analysis o f leucocyte subpopulations 
(lymphocytes, monocytes, neutrophils).
Suppressor/cytotoxic T lymphocytes. 
Helper T lymphocytes.
T lymphocytes.
B lymphocytes.
Activation analysis
Anti-Leu 2a PE Suppressor/cytotoxic T lymphocytes.
Anti-Leu 3a PE Helper T lymphocytes.
Anti-Leu 12 PE B lymphocytes.
A n ti-H LA  DR FITC 
Anti -CD-25 FITC 
Anti-Transferrin receptor FITC 
Anti-Human IgG FITC
H LA  DR, the Class II MHC antigen. 
Interleukin 2 receptor, (Tac). 
Transferrin receptor.
Membrane bound IgG on B lymphocytes.
Tumour cell analysis 
W 6 32 antibody with goat 
anti-mouse 2Y antibody 
A n ti-H LA  DR FITC
Anti-Human IgG FITC
Tumour cell expression o f the Class I major 
histocompatibility antigen.
Tumour expression o f the Class II MHC 
antigen.
IgG bound to the membrane o f the tumour 
cells.
emit green and orange-red fluorescence respectively and 
were supplied by Becton Dickinson, Cowley, Oxford.
After addition of the antibodies, the tubes were 
agitated on a vortex and incubated for twenty minutes. 
This was carried out in the dark to prevent bleaching 
of the PE. To avoid capping and internalisation of the 
antibody/antigen complexes, 0.02% w/v sodium azide was 
added and the tubes were kept on ice. After 
incubation with the fluorescent antibodies, the cells 
were washed and resuspended in filtered PBS. Propidium 
iodide was added to each tube to a final concentration 
of 2 u g / m l , to allow the identification and exclusion of 
dead cells from the analysis. The cell samples were 
then run through the flow cytometer and data on 5000 
live cells collected.
LIVE COLLECTION GATES
The size and granularity of cells affect the forward and 
side scatter of laser light from them and these 
properties can be used to differentiate between 
lymphocytes, monocytes and neutrophils. In this study a 
gate was drawn around the lymphocyte populatiion to 
exclude the other cell types and collect data only on 
lymphocytes (Fig. 15).
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Fig. 15 The forward scatter  (FSC) and side scat te r  (SSC)
of laser l ight from lymphocytes, 1s used to Ident ify 
them and a co llect ion gate, based on these properties, 
excludes other cell types from analysis.
A further gate was set to exclude dead or damaged cells 
which have strong red fluorescence (FL3) due to the 
uptake of propidium iodide, through breached membranes, 
into their nuclei. Using this gate data was collected 
only on live cells (Fig. 16).
These gates were not applied when the degree of 
lymphocytic infiltra-te within the tumours was being 
studied as they would have altered the cell proportions 
considerably. Leucogate, a combined antibody 
preparation which differentially stains lymphocytes, 
monocytes and neutrophils, was used to measure the 
degree of lymphocytic infiltrate within the tumours and 
also to assess the effectiveness of the lymphocyte gate 
(Fig. 17).
When the MHC antigens were being studied on the tumour 
cells the lymphocyte gate was reversed to collect tumour 
cell data and exclude the lymphocytes (Fig. 18). This 
gate was also checked using the Leucogate preparation.
ANALYSIS
An irrelevant antibody control (goat anti-mouse IgG FITC 
and goat anti-mouse IgG PE) was used to set the analysis 
gates to exclude non-specific binding (Fig. 19).
The relative proportions of the phenotypic subsets were
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Fia 17 The effectiveness of the lymphocyte gate 
is checked using Leucogate an antibody 
combination which d i f fe ren t ia l ly  stains 
lymphocytes, monocytes and neutrophils. 
In the tumour samples this preparation is 
used to assess the degree of lymphocytic 
in f i l t ra t ion .
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F i g . 19  To avoid non-specif ic binding giving false
posit ive results, the quadrant analysis markers 
ere set on the control sample to place 99.5% of 
the cells in the th ird quadrant at the origin.
analysed using four quadrant analysis (Fig. 20) while 
activation markers were measured by isolating the 
phenotype under study, using a PE conjugated antibody, 
and performing histogram analysis to identify the 
percentage of these cells carrying the FITC conjugated 
activation marker (Fig. 21). In both cases, the 
analysis gate for positive cells was based on the goat 
anti-mouse control for non-specific binding. Several 
patterns emerged, with some samples producing one 
histogram curve representative of a varied distribution 
of the activation marker (Fig. 21) while for other 
markers cells fell clearly into negative or positive 
populations (Fig. 22). In the case of HLA DR 
expression on B cells, while all B cells carried this 
marker, there appeared to be a cell population with a 
tenfold greater expression and this is what was measured 
( F i g . 23).
STATISTICAL_ANALYSIS
Due to the small number of subjects in the control 
group, the Student's t test was used to compare the 
peripheral blood and lymph node lymphocytes of these 
with those from the patients with breast cancer. This 
test was also used to compare the different lymphocyte
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Eig_ 25 Analysis of the HLA DR expression on B cells 
suggested the presence of two populations 
w i th  one expressing higher levels of this 
marker. It was this population which was 
studied.
sources within the breast cancer patients. When the 
expression of surface markers was correlated with the 
expression of the MHC complexes or the known prognostic 
indicators of tumour stage, histological grade and 
oestrogen receptor status, the Spearman Rank correlation 
test was applied. This was also applied when 
correlation was sought between the surface marker 
expression on the PBLs and those from the regional 
nodes or primary tumour.
The data tables given in this study include the 
descriptive statistics of the mean and the standard 
error of the mean for the populations under comparison. 
Where comparison is by the Student's t test, the t value 
and significance (p value) are given. For the Spearman 
rank correlation, the r coefficient and significance are 
given and, where a significant correlation is found, the 
equation for the gradient of the line is also given. 
Statistical significance was taken at the 95% confidence 
1 eve 1.
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RESULTS
TUMOUR INFILTRATING LYMPHOCYTES
PHENOTYPIC MARKERS
Four of the tumours contained too few lymphocytes to 
allow the infiltrate even to be phenotyped leaving 
twenty seven with a scanty to strong infiltrate.
The lymphocytic infiltrate ranged from less than 1% of 
the cells harvested to 83%, with a mean of 10.5%. 
Phenotypic analysis was performed using both the 
lymphocyte and live cell gates and phenotypic 
proportions are expressed as a percentage of the total 
lymphocyte population present within the tumour (Table 
2). This analysis showed the tumour infiltrate to 
consist largely of T cells with only one tumour 
containing a significant number of B cells. This was 
also the tumour with the strongest lymphocytic 
infiltrate but no trend was seen among the other 
t u m o u r s .
When the T cells were further subdivided, the CD8 + 
suppressor/cytotoxic T cells were found to predominate 
with the CD4+/CD8+ ratio ranging from 0.2 to 2.1 and 
having an average of 0.8.
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PARAMETER
DESCRIPTIVE
STATISTICS
CORRELATION OF TIL SURFACE MARKERS WITH FEATURES 
OF PRIMARY TUMOUR, (n = 2 7 )
STAGE GRADE E.R. CLASS I CLASS 11
%TILs 10.5  ± 2 . 9 8 r = -  0 . 0 9 4
p = 0 . 6 1 6
r = 0 . 1 02  
p=0 .5 92
r = -  0 . 2 9 4  
p = 0 . 1 15
r * -  0 .0 6  
p = 0 .7 4 8
r = 0.01 2
p = 0.947
%T cells 67.1 ± 2 . 7 3 r = -  0.1 55  
p = 0 . 4 4 0
r = 0 . 2 2 4  
p=0.271
r = - 0 . 1  0
p = 0 .6 2 6
r 0 . 4 1 6  
p = 0 . 0 3 1 ( c )
r = 0.085 
p = 0.673
%B cells 1 1.5 ±  1.57 r = -  0.01 9 
p = 0 . 9 2 3
r = 0 . 0 5 1
p = 0 .8 0 6
r = - 0.21 4  
p = 0 .29 3
r = 0 . 2 7 0  
p = 0.1 73
r = - 0.1 1 3 
p = 0.574
%CD4 cells 3 0 .3  ± 2 . 3 3 r = -  0.21 0 
p = 0 .2 9 2
r=  0.101  
p = 0 . 6 2 4
r = - 0 . 2 0 2  
p = 0 .3 2 2
r = 0 . 3 9 6  
p = 0.041 (d)
r = 0.1 30 
p = 0.5 1 9
%CD8 cells 41.1 ± 2 . 9 1 r = -  0 . 2 3 5  
p = 0 .23 8
r = 0 . 3 9 0  
p = 0 . 0 4 3 ( a )
r = - 0 . 0 6 3
p = 0 .75 9
r = 0 . 4 7 9  
p = 0 . 0 1 2 ( e )
r = 0.1 83 
p = 0.360
CD4/CD8
ratio
0 .8 6  ± 0 . 1 3 r = 0 . 1 25  
p = 0 .5 3 6
r = -  0 .4 9 9  
p = 0 . 0 1 ( b )
r = - 0.1 25  
p = 0 . 5 4 2
r = -  0 .221  
p = 0 . 2 6 9
r = -  0.061 
p = 0.762
Table 2 Correlation of the phenotypic proportions of the TILs with  
features of the primary lesion and stage of disease. There 
is some correlation of the CD8+ T cell population w i th  
tumour grade and both T cell subsets correlate w i th  the 
expression of the Class I MHC antigen on the tumour cells
CORRELATION GRADIENTS
(a) y=-2.0909+7.5 1 66x R“2=0.191
(b) y= 1.905 1 -0.4833X R‘2=0.246
(c) y=5.2731+0.3615x R~2 = 0.198
(d) y=7.4941 +0.4969X R*2 = 0.089
(e) y=4.2 1 54+0.6389X R~2=0.217
Only in seven tumours with a moderate or strong 
infiltrate were the helper T cells present in greater 
numbers (Fig. 24).
Although it did not achieve statistical significance, 
both phenotypes within the T cell infiltrate tended to 
diminish in patients with advancing disease stage.
With regard to oestrogen receptor (ER) status there was 
an inverse relationship, with oestrogen receptor 
negative tumours containing an average lymphocytic 
infiltrate which accounted for 15% of the cells while 
tumours which were oestrogen receptor positive contained 
6% lymphocytes. This trend was seen in all T cell 
subsets but again did not achieve statistical 
s igni f i c a n c e .
When the infiltrating phenotypes were correlated with 
tumour grade there was found to be a positive 
correlation with the degree of infiltration by CD8 + 
suppressor/cytotoxic T cells (p<0.05) (Fig. 25). This 
alteration in the phenotypic constitution of the 
infiltrate, caused the CD4+/CD8+ ratio to decrease with 
increasing tumour grade (p<0.01) (Fig. 26).
No correlation was found between the proportion of 
tumour cells bearing the class II complex and the degree 
or phenotypic composition of the lymphocytic infiltrate 
but some correlation was found between the tumour cell 
expression of the class I MHC complex and the presence
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of a lymphocytic infiltrate (p=0.05).
When this tumour marker was correlated with the T cell
subset proportions it was found that, while it did 
correlate with the number of CD4+ helper T cells 
infiltrating the tumour (p<0.05) (Fig. 27), there was a 
stronger correlation with the size of the CD8+ 
suppressor/cytotoxic T cell population (p<0.01)
(Fig. 28).
ACTIVATION MARKERS 
HLA DR
This marker was found to be was present on 49% of the
CD4 + helper T cells and 57% of the CD8 +
suppressor/cytotoxic T cells infiltrating the tumours.
No relationship was found with tumour stage or ER status 
but a strong correlation was found with tumour grade 
(Table 3). This relationship between grade and the 
number of cells expressing HLA DR was seen in both 
subsets although it was stronger among CD8+ 
suppressor/cytotoxic T cells (p=0.003) (Fig. 29a) than 
among the CD4+ helper T cells (p=0.03) (Fig. 29b).
This marker was also found to correlate strongly with 
the tumour expression of both the class I and class II 
MHC complexes. The number of CD4 + cells bearing HLA DR
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PARAMETER
DESCRIPTIVE
STATISTICS
CORRELATION OF TIL SURFACE MARKERS WITH FEATURES 
OF PRIMARY TUMOUR, (n = 2 2 )
STAGE GRADE E.R. CLASS 1 CLASSII
%C D 8 + D R+ 5 6 .9  ± 3 . 5 9 r — 0.1 13
p = 0 . 6 1 8
r - 0 . 6 1  1 
p = 0 . 0 0 3 ( a )
r = -  0 . 0 6 4  
p = 0 .7 8 2
r - 0 . 6 9 3  
p < 0 .0 0 0 1 ( c )
r = 0 .8 2 3  
p<0.0001 ( f )
%CD8 + Tac + 13.7  ±  1 .36 r =0.1 5 4  
p = 0 .4 9 5
r = -  0 . 0 4 7  
p = 0 .8 3 8
r = 0 . 2 2 6  
p = 0 . 3 2 4
r = -  0 . 2 0 7  
p = 0 . 3 5 6
r = 0 . 0 3 4
p = 0 .88  1
%CD8 + Tr fR 38.1 ± 2 . 1 5 r=0 .1  50  
p = 0 .5 5 3
r = 0 . 1 3 4
p = 0 .6 0 8
r= 0 .0 4 1
p = 0 .87 7
r = 0.1 78  
p = 0 . 4 7 9
r = 0 . 2 9 4  
p = 0 .2 3 6
%CD4+ DR + 4 8 .6  ±  3 .8 0 r = -  0 . 2 4 4  
p = 0 .2 7 5
r = 0 .4 7 2  
p = 0.0 31 ( b)
r = -  0 . 0 0 9  
p = 0 . 9 6 9
r = 0 . 5 4 8  
p = 0 . 0 0 8 ( d )
r = 0.51 8 
p = 0 . 0 1 4 ( g )
%CD4+Tac + 2 7 .6  ±  1.31 r = - 0.031  
p = 0 . 8 8 9
r = 0 . 0 9 1 
p = 0 . 6 9 4
r = -  0.1 7 4  
p = 0 . 4 5 2
r = 0.41 5 
p = 0 . 0 4 9 ( e )
r = 0 . 4 8 7  
p = 0 . 0 2 2 ( h )
% CD4+ Tr fR 4 8 .6  ± 4 . 2 3 r = 0 .2 0 2
r = -  0 . 0 9 8 r = 0 . 0 7 2 r = 0 . 0 6 4 r = 0 . 2 1 8
p = 0 .4 2 3 p = 0 .7 0 9 p = 0 . 7 8 4 p = 0 . 8 0 1 p = 0 .3 8 5
Table 3 Correlation of the act ivation marker expression on the 
TILs and the features of the primary lesion. There is 
strong correlation between the T cell subset expression 
of HLA DR end both tumour grade and the tumour cell 
expression of the Class I and II MHC antigens.
CORRELATION GRADIENTS
(a) y=28.6 1 7+ 14.409x R‘2=0.364
(b) y=22,830+13.106x R‘2=0.251
(c) y=-23.845+0.637x R‘2=0.4I3
(d) y=- 1 1.734+0.497x R‘2-0.28 1
(e) y=25.485+0.1657x R‘2=0.203
(f) y=-27.924+0.735x R‘2=0.523
(g) y=-3 .1072+0.3 5 lx  R‘2=0.133
(h) y-25.00+0.1 827x R‘2=0.259
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correlated with the proportion of tumour cells bearing 
the class I (p<0.01) (Fig. 30a) and class II antigens 
(p<0.02) (Fig. 30b). The correlation of HLA DR 
expression on CD8 + T cells with the presence of tumour 
histocompatibility antigens was even stronger with 
p<0.0001 for both class I and class II complexes (Figs. 
31a & 3 1 b ) .
HLA DR tended to be carried by a greater proportion of 
suppressor/cytotoxic CD8 + T cells in tumours with a 
strong CD8+ T cell component to their infiltrate 
(p<0.01) (Fig. 32) and was present on up to 90% of the 
tumour infiltrating CD8 + T cells in some patients.
Inter 1eukin 2 receptor
The Tac antigen was present on 14% of the CD8 + 
cytotoxic T cells in the infiltrate but was 
consistently found on a higher proportion of the CD4 + 
helper T cells (mean 28%) (p<0.0001) (Fig. 33).
There was no relationship detected between this marker 
and tumour stage, grade or ER status but its presence on 
the CD4+ helper T cells correlated with the proportion 
of tumour cells bearing the class I (p<0.05) and class 
II (p < 0.03) MHC complexes (Figs. 34a & 34b).
This marker was also present on a greater proportion of 
CD4 + helper T cells as the number of these cells within 
the tumour increased (p<0.05) (Fig. 35).
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T ransferrin receptor
The transferrin receptor was present on the surface of 
39% of the CD8 + suppressor/cytotoxic T cells and 48% of 
the CD4+ helper T cells within the tumour. This marker 
did not relate to the histological grade, stage of 
disease or ER status, nor to the proportion of tumour 
cells bearing the class I or class II MHC complexes.
Immu n o g lobu lin G
This was found on an average of 28% of the tumour cells, 
with a range from 3% to 81%. The presence of IgG on the 
tumour cells was not related to tumour stage, grade or 
ER expression, nor to the proportion of tumour cells 
bearing the class II MHC complex but did correlate with 
the number of tumour cells carrying the class I antigen 
(p< 0.03) (Fig. 36).
LYMPH NODE LYMPHOCYTES 
PHENOTYPIC MARKERS
The axillary lymph nodes from the breast cancer patients 
were found to be large and engorged with an average cell 
yield of 4X10"1 from each half while normal nodes were 
small and pale with cell counts of less than lxl O 7 .
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Class I MHC expression
From the results given in Table 4 it can be seen that, 
when lymph node lymphocytes (LNLs) from breast cancer 
patients were compared with those from normal controls, 
there was some alteration in the phenotypic proportions. 
In this study no significant differences were found in 
the proportion of T or B lymphocytes between the lymph 
nodes of patients with breast cancer and those from 
normal controls.
However, when the T cell population was further 
subdivided, there was found to be a great increase in 
the CD4 + helper T cell population in the nodes of cancer 
patients, with a mean of 49% as opposed to 33% in the 
normal controls (p=0.003) (Fig. 37) and a slight 
decrease in the proportion of CD8+ suppressor/cytotoxic 
T cells with a mean of 12% in the patients and 17% in 
the controls (p=0.01).
While the CD4+/CD8+ ratios for the normal nodes were 
within a tight range with a mean of 2, those of the 
patients' nodes ranged widely from 1.22 to 16.25 and had 
an average of 4.86 (p=0.02) (Fig. 38). This broad 
range of CD4+/CD8+ ratios in the patient group appeared 
to be a function of the variation in the size of the 
CD4+ helper T cell population from 22% to 69% with less 
variation in the size of the CD8+ suppressor/cytotoxic 
p o p u 1 at i o n .
There appeared to be no relationship between the
73
PARAMETER PATIENT LYMPH NODE n = 40
CONTROL LYMPH 
NODE n = 7
STUDENT'S 
/ TEST
% T cel ls 59.2 + 2.06 50.7 ± 5.20 t = 1.584
p = 0.120
% B cells 35.0 + 2.01 39.6 ± 5.65 t = -0.866 
p = 0.391
% CD4+ T cells 49.0 + 1.95 33.1 ± 4.05 t = 3.200 
p = 0.003
% CD8 + T cells 12.2 + 0.65 16.9 ± 1.98 t = -2.671 
p = 0.01
CD4+/CD8+ 4.9 + 0.49 2.0 ± 0.15 t = 2.394
ratio p = 0.021
Table 4 Comparing the phenotypic proport ions of lymph nodes 
from patients w i th  breast cancer and normal subjects
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phenotypic proportions and the stage of the disease.
ACTIVATION MARKERS 
HLA DR
As can be seen in Table 5, this surface marker was found 
to be on many more LNLs from the lymph nodes of patients 
with breast cancer than from the control nodes. This 
increase was largely among the T lymphocytes with 49% of 
the CD8 + T cells from patients and only 18% of those 
from control nodes bearing this marker (p<0.0001) while 
38% of the CD4+ T cells from the patients bore this 
antigen compared with 12% from the nodes of normal 
controls (p<0.0001) (Fig. 39). This marker tended to 
be present on more CD8 + than CD4+ T cells (p<0.001). 
Virtually all B lymphocytes carry the HLA DR antigen and 
there appeared to be no difference in the number of B 
cells with high HLA DR expression between the two 
g r o u p s .
The expression of HLA DR on the CD8+ T cell population 
correlated with tumour stage, increasing in patients 
with nodal metastases (p=0.02) (Table 6; Fig. 40).
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PARAMETER PATIENT LYMPH NODE n = 40
CONTROL LYMPH 
NODE n = 7
STUDENT’S 
/  TEST
CD8+ T cells 
bearing HLA DR
CD8+ T cells  
bearing Tac
CD8+ T cells  
bearing TrfR
CD4+ T cells 
bearing HLA DR
CD4+ T cells 
bearing Tac
CD4+ T cells 
bearing TrfR
B cells w i th  
high HLA DR
B cells bearing 
T ac
B cells bearinq 
TrfR
B cells bearing 
surface igG
48.6 ± 2.09
16.0 ± 1.07
33.7 ± 2.0
37.5 ± 1.59
22.5 ± 1.07
29.1 ± 2.16
26.7 ± 2.09
6.6 ± 1.58
43.6 ± 1.86
30.6 ± 2.51
18.3 ± 2.25
8.1 ± 1.75
31.3 + 13.59
12.1 ± 2.6
14.4 ± 2.82
22.0 1 6.76
9.1 ± 5.04
15.3 + 4.09
33.3 + 6.18
17.1 ± 2 . 5 1
t = 5.910 
p < 0.000 I
t = 2.921 
p = 0.005
t = 0.332 
p = 0.742
t = 6.367
p < 0.0001
t = 2.883
p = 0.006
t = 0.989 
p = 0.328
t = 1.383 
p = 0.173
t = 0.330 
p = 0.743
t = 1.670 
p = 0.102
t = 2.195 
p = 0.033
Table 5 Comparison of the act ivat ion marker expression on 
lymphocytes from the lymph nodes of patients w i th  
breast cancer and normal subjects.
PARAMETER 
LNLs(n = 40)
CORRELATION WITH TUMOUR STAGE 
(Spearman Rank correlat ion)
CORRELATION
GRADIENT
% T cel ls r  = -0.204 p = 0.363 NS
% B cells r  = 0.215 p = 0.336 NS
% CD4+ T cells r  = -0.072 p = 0.751 NS
% CD8 + T cells r  = -0.274 p = 0.217 NS
CD4+/CD8+ r  = 0.085 p = 0.706 NS
y=38.426+6.7794xSCD8+ HLA DR+ r  = 0.486 p = 0.022 R'2 = 0.210
%CD8+ T ac + r = 0.108 p = 0.634 NS
8 CD8+ T rfR + r  = 0.245 p = 0.272 NS
SCD4+ HLA DR+ r  = 0.168 p = 0.456 NS
&CD4+ T ac+ r  = 0.257 p = 0.247 NS
%CD4+ T rfR+ r = 0.325 p = 0.140 NS
high HLA DR r = 0.148 p = 0.512 NS
%d  Tac + r = -0.330 p = 0.144 NS
%B TrfR + r  = 0.071 p = 0.754 NS
^B 1 gG + r  = -0.096 p = 0.672 NS
Table 6 Correlation of the surface markers borne by lymph node 
lymphocytes end tumour stage. The expression of HLA DR 
on the lymph node CD8+ T cells increases w i th  the 
development of nodal metastases.
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Interleukin 2 receptor
This marker was also found on many more T lymphocytes 
from the lymph nodes of breast cancer patients than from 
normal subjects, while there was no difference in the 
number of B lymphocytes carrying this marker in the two 
g r o u p s .
When the T cell subsets were studied, it was seen that 
this marker increased from being carried on 8% of CD8+ T 
cells in the control subjects to 16% of CD8 + T cells in 
the patient group (p=0.005) and from 14% of control CD4+ 
T cells to 23% of CD4 + T cells in the nodes of breast 
cancer patients (p=0.006) (Fig. 41). It was again 
noted that more CD4+ than CD8+ T cells carried this 
m a r k e r .
The presence of this receptor on the lymph node T cells 
of breast cancer patients did not appear to be affected 
by spread of the tumour to the regional nodes.
Transferr i n__rec eptor
As can be seen in Table 5, more lymphocytes, of all 
phenotypes, bore this marker in the nodes of patients 
with breast cancer than in the normal controls but this 
did not achieve statistical significance. There was no 
relationship with tumour stage.
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Fig. 41
■  CD8+ Tac+ 
□  CD4+Tac+
Cancer Nodes Normal Nodes
Lymph Nodes
Immunoglobulin G
A marked increase in the number of B lymphocytes
carrying surface IgG was found in the breast cancer
patients compared with the controls. The number of IgG 
committed B cells in the lymph nodes of normal subjects 
varied within a fairly narrow range from 8% to 24% with 
a mean of 17% while in the cancer patients the mean was 
higher at 31% with a much wider range from 3% to 70%
(p = 0 .03) (Fig. 42). The number of B lymphocytes
present in the lymph nodes correlated with the number 
bearing surface IgG (p=0.04) (Fig. 43). No correlation 
was found between the number of IgG committed B 
lymphocytes and tumour stage.
PERIPHERAL BLOOD 
PHENOTYPIC MARKERS
Similar lymphocyte yields were obtained from the blood 
samples of breast cancer and normal patients.
T lymphocytes were found to be the major cell type 
making up 59% of the cells in the controls and 64% of 
the cells in patients. B lymphocytes accounted for 19% 
of the circulating lymphocytes in control subjects and 
12% in breast cancer patients and this difference was
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statistically s i g n ificant (p=0.006) (Fig. 44).
Further s u b d i v i s i o n  of the T lymphocytes into CD4+ 
helper T cells and CD8+ suppr e s s o r / c y t o t o x i c  T cells 
revealed that, on average, 40% of the T cells in normal 
subjects were of the CD4+ phenotype while 24% were of 
the CD8+ phe n o t y p e  w i t h  a helper/ c y t o t o x i c  ratio of 1.7 
(Table 7). The number of CD4+ and CD8+ cells in the 
control samples also fell w i t h i n  limited ranges of 30% 
to 54% and 16% to 30% r e s p e c t i v e l y  with a ratio ranging 
from 1.07 to 2.44. There was much greater v a r i a t i o n  
among the cancer patients wit h  the p ercentage of CD4+ 
helper T cells r a n ging from 8% to 70% and the CD8 + 
suppressor/cytotoxic cells r a nging from 6% to 47%. This 
gives a CD4 + / C D 8 +  ratio w h ich itself ranges from 0.53 to 
5.00 (Fig. 45) a l t h o u g h  the m ean size of each subset 
and the average ratio were similar to those of the 
contro1s .
ACTIVATION MARKERS  
HLA DR
This activation m a r k e r  was found on many more T cells in 
the breast cancer patients, being present on 36% of CD8 + 
suppressor/cytotoxic T cells as compared to only 14% of 
normal CD8+ cells (p<0.0001) (Fig. 46a) while for the
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PARAMETER PATIENT BLOOD n = 39
CONTROL BLOOD 
n = 7
STUDENT'S 
t TEST
% T cel ls 64.4 ± 2.33 58.9 ± 4.88 t = 0.943 
p = 0.35 1
% B cells 12.2 ± 0.87 19.4 ± 3.48 t = -2.91 1
p = 0.006
% CD4+ T cells 39.9 t 1.99 40.3 1 3.16 t = -0.079 
p = 0.937
% CD8+ T cells 26.2 ± 1.52 26.2 ± 1.52 t  = 0.544 
p = 0.589
CD4+/CD8+
ratio
1.7 ± 0.14 1.7 ± 0.18 t = 0.016 
p = 0.988
Table 7 Comparison of the phenotypic proport ions in peripheral 
blood f rom breast cancer pat ients  and normal subjects.
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CD4+ helper T cells the proportions were 19% and 8% 
respectively (p<0.0001) (Table 8; Fig. 46b).
HLA DR was found, as expected, on v i r tually all B 
lymphocytes. No r e l a t i o n s h i p  between the e x p r e s s i o n  of 
this marker and disease stage was identified (Table 9).
Interleukin 2 r e c eptor
This surface a n t i g e n  was also present on greater numbers 
of T lymphocytes in the patient samples. 15% of the 
patients' CD8+ T cells bore the Tac a n t igen while 9% of 
the control CD8+ T cells did so (p<0.03) (Fig. 47a) and 
while 31% of the patients' CD4+ T cells were positive 
only 20% of the control CD4+ cells were so (p=0.006)
(Fig. 47b).
The number of B lymphocytes bearing this m a r k e r  was 
similar in each g r oup with 21% of patients' and 18% of 
the control B cells positive for Tac. In all samples, 
from both normal subjects and breast cancer patients, 
the Tac antigen was found on more CD4+ T cells than CD8+ 
T cells (p<0.0001) (Fig. 48). This marker also did not 
appear to be af f e c t e d  by tumour stage.
Transferrin receptor
This marker was carried by slightly more cells, of all 
phenotypes, in the peripheral blood samples of patients 
with breast carcinoma than in those from normal subjects
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PARAMETER
PATIENT BLOOD 
n = 39
CONTROL BLOOD 
n = 7
STUDENT’S 
t TEST
CD8+ T cells  
bearing HLA DR
CD8+ T cells  
bearing Tac
CD8+ T cells  
bearing TrfR
CD4+ T cells  
bearing HLA DR
CD4+ T cells  
bearing Tac
CD4+ T cells  
bearing TrfR
B cells w i th  
high HLA DR
B cells bearing 
Tac
B cells bearinq 
TrfR
B cells bearing 
surface IgG
35.6 ± 1.70
15.1 ± 1.05
37.9 ± 1.97
19.1 ± 1.07
30.5 ± 1.47
35.0 ± 2.08
9.6 1  1.33
21.7 1  1.8
49.1 ± 2.04
17.7 ± 1.43
13.9 ± 1.78
8.9 1  2.28
23.3 ± 10.35
8. ± 0.80
20.1 ± 1.58
25.3 ± 10.59
25.3 ± 7.26
18.1 1  4.65
54.3 ± 10.33
6.9 ± 1.61
t = 5.276
p < 0.0001
t  = 2.348 
p = 0.023
t  = 1.926
p = 0.061
t  = 4.31 1
p < 0.0001
t = 2.920
p = 0.006
t = 1.215 
p = 0.23
t = -3 .644  
p = 0.001
t  = 0.756 
p = 0.454
t  = -1 .478 
p = 0.147
t = 3.172 
p = 0.003
Table 8 Comparing the expression of ac t iva t ion  markers on the 
peripheral blood lymphocytes of pa t ien ts  w i th  breast 
cancer and normal subjects.
PARAMETER 
PBLs (n = 39)
CORRELATION WITH TUMOUR STAGE 
(Spearman Rank corre la t ion)
CORRELATION
GRADIENT
% T cel ls r  = 0.312 p = 0.157 NS
% B cells r  = -0 .073 p = 0.746 NS
% CD4+ T cells r  = 0.239 p = 0.284 NS
% CD8+ T cells r  = 0.160 p = 0.478 NS
CD4+/CD8+ r  = 0.219 p = 0.327 NS
SCD8+ HLA DR+ r  = 0.033 p = 0.884 NS
&CD8+ Tec+ r  = -0 .146 p = 0.515 NS
SCD8+ TrfR+ r  = -0 .126 p = 0.576 NS
SCD4+ HLA DR+ r  r  0.1 19 p = 0.606 NS
%CD4+ T ac + r  = -0 .013 p = 0.953 NS
SCD4+ TrfR + r  = 0.146 p = 0.515 NS
SB high HLA DR r  = -0.001 p = 0.996 NS
SB Tac+ r  = 0.329 p = 0.146 NS
SB TrfR+ r  = 0.086 p = 0.702 NS
&B lgG+ r  = -0 .020 p = 0.930 NS
Table 9 Correla t ion of the surface markers borne by peripheral
blood lymphocytes w i th  disease stage. There is no change 
in the ac t iva t ion  status of the peripheral blood 
lymphocytes w i th  advancing tumour spread.
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but this was not s t a t i stically significant.
Immunoglobulin G
There were greater numbers of IgG committed B 
lymphocytes circ u l a t i n g  in the blood of breast cancer 
patients than in normal controls. In the breast cancer 
patients an average of 18% of B cells bore surface IgG 
as compared to only 7% in the control g r oup (p=0.003) 
(Fig. 49).
79
IgG
 
be
ar
in
g 
B 
ce
lls
Fig. 49
40
30
BB
QB
BB
BB
BBBB
0.5 1.5 2.5Patient samples Control samples
Peripheral Blood
DISCUSSION
TUMOUR INFILTRATING LYMPHOCYTES 
PHENOTYPIC MARKERS
From these results it can be seen that about 85% of the 
tumours studied had enough infiltrating lymphocytes to 
allow cell phenotyping to be carried out with 60% having 
sufficient to also allow the activation markers to be 
studied. This is similar to the findings of other 
groups 2 1  * 137, in this study, the maximum infiltrate 
accounted for slightly more than 80% of the cells 
harvested from the tumour and the highest ratio of 
lymphocytes to tumour cells was therefore 4 :1 . This 
calls into question the use, in cytotoxicity assays, of 
effector/target ratios as high as 50:1 .
Like other groups, we found the infiltrate to consist 
largely of T lymphocytes. We found CD8 + 
suppressor/cytotoxic T cells to predominate in most 
tumours which is in agreement with the previous work by 
Giorno 159, Bhan & DesMarais 29 , Rowe & Beverly 3 *>2 , 
Hurlimann & Saraga 204, Lwin et al 261, Whiteside et al 
459, Tanaka et al 4ioj Bilik et al 30 and Naukkarinen & 
Syrjanen 3 o o j although at odds with the findings of
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other groups such as Whitwell et al 4t>3 ( Gotti inger et 
al lb4, Horny & Horst 19 3 , Ben-Ezra & Sheibani 2 5 , 
Underwood et al 4 3 5 , Zuk & Walker von K l e i s t  et al
233, An et al 7 and Balch et al 1 5 , who found a 
predominance of CD4+ helper T cells. The widely 
conflicting phenotypic p roportions found w i thin breast 
tumours by d i f ferent groups may reflect the dif f e r e n t  
methods used. Most groups have used tissue sections 
stained with monoclonal antibodies to the p henotypic 
markers which were c o n j ugated to either an enzyme or a 
fluorochrome. It is therefore possible that sample 
variability may have played a part in giving such a 
variety of results. This is p a r t i c u l a r l y  important in 
view of tumour h e t e r o g e n e i t y  is?, 1 1 2 , the effect of 
which is reduced by p r o c e s s i n g  larger amounts of tumour. 
It was however notable that while the CD8+ 
suppressor/cytotoxic T cells p r e d o m i n a t e d  in most 
tumours, CD4+ helper T cells were seen in large numbers 
in tumours with a strong infiltrate. This p a t t e r n  has 
been noted pre v i o u s l y  in other studies 1 9 3 - 3 0 0 and it
may therefore be that patient selection is a c t u a l l y  
responsible for the c onflicting results. If only those 
tumours with a sizable infiltrate are studied, more are 
seen with a large CD4+ T cell infiltrate whereas if 
tumours are selected at rand o m  and even those w i t h  very 
few lymphocytes are c h a r a c t e r i z e d  the picture alters in
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favour of CD8+ T cell infiltration.
Like others 193' 475, we did not find a strong 
relationship between the degree of lymphocytic 
infiltrate and tumour stage. Although one group found 
an increased infiltrate in tumours which had 
metastasized to the axilla 233, our results do not 
confirm this.
There appeared to be a slight inverse correlation with 
the presence of the oestrogen receptor (ER) on the 
tumour cells, the ER negative tumours having greater 
lymphocytic infiltration, but this did not achieve 
statistical significance. Underwood et al 435 also did 
not find a statistically significant correlation between 
lack of ER and lymphocytic infiltration but this trend 
can be seen in their results and several other groups 
have found a similar inverse correlation which did 
achieve significance 2 0 4 ,  1 0 2 ,  1,  3 0 0 .  The failure of
the present study to demonstrate statistical 
significance may reflect the need for larger patient 
numbers.
This trend would also be in keeping with the finding 
that the degree of infiltration by CD8+ 
suppressor/cytotoxic T cells correlates strongly with 
histological tumour grade, suggesting that a lymphocytic 
reaction is more likely in tumours which are poorly 
differentiated. This finding suggests that the immune
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system is able to detect tumour antigen on these 
undifferentiated and markedly abnormal cells and this is 
clearly of importance in the search to identify tumour 
antigen. Several other groups have also found some 
correlation between lymphocytic infiltration and tumour 
grade 475, 40, 30, 300, although they did not study the
effect of tumour grade on T cell subset proportions. 
While no correlation with the presence of the class II 
antigen was seen, there was a fairly strong correlation 
between the degree of lymphocytic infiltrate and the 
expression of the class I antigen on the tumour cells. 
Again this relationship was most strongly seen with the 
infiltration of CD8 + T cells. As the CD8+ 
suppressor/cytotoxic T cells are known to recognize 
target antigens only in association with the class I MHC 
complex its, 104, 268, ie4; it is likely that antigen
can only be detected and a response mounted when the 
class I complex is present. While Bhan & DesMarais 29, 
Whitwell et al 4 6 3 ; zuk & Walker 47 b and Moller et al 
282 found no correlation between lymphocytic infiltrate 
and class I expression, our findings are in keeping with 
those of Rowe & Beverley 362, Hurlimann & Saraga 204,
Bel Giglio et al 100 and Nakazawa et al 299, who found a 
strong correlation in breast tumours and with others, 
who found a similar correlation in other malignancies 
3b4' 255. The reason for these conflicting results may
83
be due to the hetero g e n e o u s  e xpression of these antigens 
on the tumour cells and the consequent sample variation. 
Two groups also found a c o r r elation b e t ween the degree 
of infiltrate and the expr e s s i o n  of the class II MHC 
antigen 4 1 B ' 164 and this has been noted in other 
tumours 122 but while we also found a trend in this 
direction, it did not achieve statistical significance. 
Tumour cell e x p r e s s i o n  of the class II MHC a n t i g e n  was 
found to correlate with the acti v a t i o n  status of cells 
within the tumour infiltrate rather than with its 
phenotypic composition.
ACTIVATION MARKERS 
HLA DR
HLA DR is a m a r k e r  of both T cell act i v a t i o n  and a n t i g e n  
presentation 333 and is found on greatly increased 
numbers of peripheral blood CD8+ T cells and renal 
tubule cells of patients und e r g o i n g  host r e j e c t i o n  of a 
transplanted k i d n e y  121 * 1 B 4 .
A similar d i s t r i b u t i o n  is seen in the breast cancer 
patients with i n  this study where there is a c o r r e l a t i o n  
between the H LA DR exp r e s s i o n  on the tumour cells and 
the infiltrating lymphocytes.
The association with an t i g e n  p r e s e n t a t i o n  is also
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supported by our finding that this marker is present on 
greater numbers of tumour infiltrating lymphocytes, 
particularly CD8+ T cells, with increasing histological 
grade and increasing tumour cell expression of the class 
I MHC complex suggesting that the immune system is able 
to detect antigen on the surface of cells from poorly 
differentiated tumours when presented alongside the 
class I MHC complex. This marker tends to be expressed 
on more CD8+ than CD4+ T cells 340 and is present on a 
greater number of CD8+ T cells as the proportion of 
these cells within the infiltrate increases. It is 
possible that, after recognition of the tumour antigen 
combined with the class I MHC complex and destruction of 
the tumour cell, the CD8+ cytotoxic cells present part 
of the antigenic structure of the "foreign” cell within 
the groove of their HLA DR complex to signal to other 
cells of the immune system.
While several groups have found HLA DR to be carried by 
an increased number of T cells infiltrating breast 
tumours 2bi, 25 and other malignancies iss, ist, 407,
307 there is a great variation in results, with those 
methods which involve long preparation times, or fixing 
of the cells, showing fewer positive cells. This is 
most notable in the study by Whiteside et a. 1 4 6 0 where 
collagenase digestion, followed by a long incubation 
period, was used to release the lymphocytes from the
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tumour prior to staining. This group found very few 
lymphocytes bearing any activation markers and it is 
likely that these were lost during the enzymatic 
digestion and incubation period.
As tumour cells also carry this surface antigen, 
staining with phenotypic antibodies is vital to ensure 
accurate assessment of the number of lymphocytes and 
tumour cells bearing this marker. This requires the use 
of dual immunofluorescent staining and fluorescent 
microscopy or flow cytometry. The relationship of the 
TIL expression of this activation marker to other 
features of the tumour, such as histological grade, has 
not previously been reported.
Interleukin 2 receptor
No great difference was found, in the number of 
lymphocytes bearing the IL-2 receptor, between tumours 
of differing grade or stage but it was most striking 
that consistently more of the CD4+ helper T cells than 
CD8+ suppressor/cytotoxic T cells bore this marker.
Some groups have found very few infiltrating lymphocytes 
bearing this marker in breast 4 6 0 , 25 or other tumours
307> 407 tut this may be due to the cell preparation as 
these groups used long incubation periods during cell 
harvesting or staining. They also did not use sodium 
azide to avoid capping of the antibody/antigen complexes
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formed by the immunof l u o r e s c e n t  a n t ibody and the marker 
it stains. Studies per f o r m e d  using fresh cells i b s ,
1 8 6 , loe found a high p r o p o r t i o n  of IL-2 receptor 
bearing T cells while Lwin et al 2 b l , using 
i m m u n o h i s t o c h e m i s t r y , found great v a r i a t i o n  b e t ween 
tumours. None of these groups looked at the 
distribution of cells be a r i n g  this receptor w i t h i n  the T 
cell subsets.
In this study we found the presence of the IL-2 receptor 
on the CD4+ T cells to correlate with both the extent of 
infiltration by these cells and the tumour cell 
expression of the class I and class II MHC antigens.
This receptor only increases on cells after they have 
been stimulated by a n t i g e n  and so its presence again 
suggests that these lymphocytes are reco g n i z i n g  some 
tumour a n t igen a l o n gside the class I MHC complex.
This receptor is a marker of cell d i v ision and this 
finding indicates increased t u r nover and possibly 
expansion of the CD4+ helper T cell subset. The CD8+ T 
cells show little evidence of d i v i s i o n  and this may be 
due to their terminal d i f f e r e n t i a t i o n  into functional 
cytotoxic cells with no further need of replication.
The most notable finding was the consistent presence of 
this receptor on almost twice as many CD4+ h e lper T 
cells as CD8+ s u p p r e s s o r / c y t o t o x i c  T cells. This may be 
due to greater a c t i v a t i o n  of the CD4+ T cells or may
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represent a functional difference between the two T cell 
subsets with regard to stimulation by IL-2 .
This is of importance as, in TIL therapy, the TILs are 
harvested and cultured in IL-2 before being returned to 
the patient. The rationale for this therapy is that the 
cytotoxic cells, which have already been primed by 
tumour antigen, will greatly increase in numbers in the 
IL-2 culture and, upon return to the patient, will 
destroy metastatic deposits of tumour 354. Two groups, 
who phenotyped the TILs from malignant melanoma before 
IL-2 expansion, also found the IL-2 receptor to be 
present on more of the CD4+ T cells than the CD8+ T 
cells 2 58, if. Although some groups, who phenotyped the 
cells after IL-2 culture, found CD8+ T cells to 
predominate 24^, 427y others found the greatest
expansion to be in the CD4+ helper T cell population, 
with the CD8+ suppressor/cytotoxic T cells dying away 
after two or three weeks. Thus, the cells being 
returned to the patient, as TIL therapy, were 
predominantly of the helper T cell phenotype 2 2  > 294,
185, 2 4 2 ,  2 7 7 ,  356 , 2 3 ,  386 . a.s TIL therapy has
produced some striking responses, particularly in 
malignant melanoma 354, 357( it is possible that these 
have actually been mediated by the CD4+ helper T cells 
rather than the remaining CD8 + T cells. How these 
responses have been mediated must be clarified to allow
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further d e v e l o p m e n t  of this therapeutic approach.
Transferrin receptor
Increased t r a n s f e r r i n  recep t o r  levels on the membrane of 
a cell suggest it is pre p a r i n g  for d i v ision at which 
time the iron r e q u i r e m e n t  increases because of the 
production of r i b o n u c l e o t i d e  reductase. This mark e r  was 
found on a g r e a t e r  number of CD4+ helper T cells than 
CD8+ s u p p r e s s or/cytotoxic T cells again suggesting there 
is more cell d i v i s i o n  in this subset. No r e l a t i o n s h i p  
was found b e t w e e n  this marker and the prognostic factors 
or tumour cell e x p r e s s i o n  of the class I or class II MHC 
a ntigens.
Immunolqlobulin G
A great v a r i a t i o n  was seen in the number of tumour cells 
with IgG bound to their surface membrane. The 
distribution of this i m m u n oglobulin w i t h i n  the tumours 
could not be further clarified by flow cytometry but 
several studies, u s ing immunohistochemical techniques, 
have also found IgG to be the major i m m u n o globulin and 
have found the g r e a t e s t  c o n c e n t r a t i o n  to be in the 
tumour stroma 1 o 6 , 2 o e .
The presence of tumour bound IgG did not relate to 
tumour stage, grade or ER status but showed some 
correlation with e x p r e s s i o n  of the class I MHC complex
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on the tumour cells. Although we found no relationship 
between the presence of the ER and IgG on the tumour 
cells, an inverse correlation has been noted by others 
262, 46 5 and the lack of significance in our results may 
simply reflect the small number of tumours in which this 
parameter was studied. Roberts et al 348 noted a 
correlation between the amount of IgG in the tumour and 
the degree of lymphocytic infiltrate and whilst this 
trend was also seen in our results, it again did not 
achieve statistical significance. The effect of this 
membrane bound immunoglobulin on the tumour cells is not 
clear and while it is indicative of a humoral 
anti-tumour immune response there is evidence to suggest 
that in some patients this response is flawed. These 
antibodies may act as a shield, by blocking the 
antigenic sites, while not themselves activating a 
complement cascade or chemotaxis to bring about 
destruction of the antigenic tumour cell i83, 262, io7 ,
LYMPH NODE LYMPHOCYTES
It is clear from these results that there are major 
alterations of both the phenotypic proportions and the 
expression of surface activation markers in the axillary 
lymph nodes of patients with breast cancer.
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PHENOTYPIC MARKERS
The grossly e n g orged a ppearance of some of the axillary 
lymph nodes from the breast cancer patients has been 
previously n o ted 34 > 35 ^ 94 > lie and contrasts sharply
with the small pale control nodes and these a ppearances  
are reflected in the higher cell counts obtained from 
the former.
No difference was found in the prop o r t i o n  of T cells or 
B cells in the lymph nodes of breast cancer patients and 
normal controls. This is contrary to the findings of 
Eremin et al 118 who found an increase in the B cell 
population and a corre s p o n d i n g  decrease in the T cell 
population in cancer patients but is in keeping with the 
findings of H e i d e n r e i c h  et al i 8 2 / Gupta et al 171 and 
Bonilla et al 50 who also found no difference b e tween 
the two groups. Tsak r a k l i d e s  et al 4 so, Erem i n  et al 
118 and M o r t o n  et al 289 found an increase in the B 
lymphocyte p o p u l a t i o n  in patients with stage II breast 
cancer and while we also detec t e d  a slight trend in this 
direction it did not achieve statistical significance.
In this study we found an overall increase in the 
CD4+/CD8+ ratio in the lymph nodes of cancer patients, 
due largely to a m a r k e d  increase in the number of CD4+ 
helper T cells. There is also a m uch wider range of 
ratios among the cancer patients while normal ratios
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range around 2:1, which is in keeping with other 
studies of normal nodes 1 9 5 . There are two other 
studies comparing the T cell subsets in breast cancer 
patients with those in normal controls 2 2 4 , 2 1 2  ; with
the former u s ing immunohistochemical techniques while 
the latter used single colour flow cytometry. Both 
studies were small, havi n g  8 patients each and Khuri et 
al 224 included only 3 control subjects. While 
Mantovani et al 272 found no difference in the overall 
phenotypic prop o r t i o n s  of nodes from breast cancer 
patients and control subjects, Khuri et al 224 suggested 
there was an increase in the CD8+ T cell p o p u l a t i o n  in 
the cancer patients. An o t h e r  group, who compared the 
phenotypic prop o r t i o n s  of PBLs and LNLs in patients with 
breast cancer found a large pro p o r t i o n  of CD4+ T cells 
in the nodes but, lacking any controls were unable to 
clarify w h e t h e r  this was due to the presence of 
malignant disease or mere l y  to the lymphocyte source 
28 *. From our results it can be seen that this large 
CD4+ popu l a t i o n  occurs only in the cancer patients and 
is therefore likely to be part of an immune r e a c t i o n  to 
the tumour.
We, like M o r t o n  et al 2 8 9 , found some decrease in the 
size of this p o p u l a t i o n  with adv a n c i n g  disease but it 
was not s t a t i s t i c a l l y  significant while Mantovani et al 
Ll2 found an increase in the CD4+ pop u l a t i o n  in nodes
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containing m e t a static deposits. Farzad et al 1 2 4 , 
working with skin melanoma, and Cozzolino et al 8 3 , 
working with tumours of the larynx and bladder, also 
noted a decrease in the CD4+ T cell p o p u l a t i o n  in 
patients wit h  stage II disease.
From the wide v a r i a t i o n  in this popu l a t i o n  it can be 
seen that some patients have a smaller CD4+ T cell 
population t han normal subjects along with a lower 
CD4+/CD8+ ratio. As this ratio is c onsidered a useful 
guide to immune competence in patients with 
immunosuppressive conditions such as AIDS 2 3 t , it may 
also be a useful indicator of i m m unosuppression or 
stimulation of the immune system, by the tumour, in 
patients with breast cancer.
ACTIVATION MARKERS 
HLA DR
In this study we found this marker to be present in 
similar q u a n tities on B lymphocytes from the two groups 
but on almost treble the number of T cells, of both 
phenotypes, from the a x i llary nodes of breast cancer 
patients compa r e d  with normal controls. Only one other 
study has b een p e r f o r m e d  c o m paring the expr e s s i o n  of 
"this marker in the nodes of normal subjects and breast
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cancer patients 272 and, as this was carried out using 
single colour flow cytometry, the phenotypic 
distribution of the HLA DR was not demonstrated. 
Mantovani et al 272 found no significant difference, in 
the expression of this marker, b e t ween the LNLs of the 
two groups but the source of the control nodes is not 
stated and, as they were found to have a fairly high 
proportion of H LA DR b e a ring lymphocytes, it is possible 
that they were excised because of a benign disease 
process w h ich m i ght n evertheless have caused some degree 
of immune stimulation.
This marker of a c t i v a t i o n  and antigen p r e s e n t a t i o n  was 
expressed on a g r e ater p r o p o r t i o n  of the CD8+ T cell 
population in patients with stage II disease. As these 
patients had nodal metastases, the CD8+ T cells with i n 
the nodes were a g a i n  in direct contact with tumour cells 
and tumour antigen, which may have lead to their 
stimulation. M o r t o n  et al 289 also found an increase in 
the number of cells bearing this marker in stage II 
disease but Mantovani et al 2 7 2 , comparing invaded and 
uninvaded nodes, found the e x p r ession of HLA DR to be 
higher in the u n i n v a d e d  nodes. Two groups, w o r king with 
other tumours, found no r e l a t i o n s h i p  between HLA DR 
expression and tumo u r  stage i 2*, 8 3 .
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Interleukin 2 receptor
While this m a r k e r  was u n a l t e r e d  in the B cell pop u l a t i o n
it was present on many more T cells in the lymph nodes
of patients w i t h  breast cancer. A g ain this increase was 
seen in both subsets with the greatest number of 
positive cells in the CD4+ subgroup. Tac, which is the
55Kd component of the interleukin 2 (IL-2) receptor, is
present at very low levels on resting T cells but 
greatly increases on those which have been stimulated 
through the T cell a n t i g e n  receptor complex 4 46, 367,
After stim u l a t i o n  by an t i g e n  or mitogen, the number of 
surface r e c eptors increase in the presence of IL-2. The 
presence of this re c e p t o r  on greater numbers of both T 
cell subsets in the lymph nodes of breast cancer 
patients suggests that they have been stimulated by 
antigen and are being m a i n t a i n e d  by the presence of 
IL-2. There are no other studies in this field w h ich 
compare the e x p r e s s i o n  of the Tac marker on lymphocytes 
from the lymph nodes of breast cancer patients with 
those from normal subjects but it was studied by 
Cozzolino et al 83 who work e d  with laryngeal and bladder 
carcinoma and F a r z a d  et al 124 who w o rked with skin 
melanoma. While Farzad et al 124 found this re c e p t o r  on 
almost no cells in the regional lymph nodes of patients 
with skin melanoma, Cozzolino et al 83 found it on up to 
30% of LNLs w ith a m e a n  of 21% in nodes with m etastatic
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tumour and 12% in nodes u n i n v o l v e d  with tumour. The 
difference in the findings of Farzad et al 124 and both 
Cozzolino et al 83 and ourselves may be due to the long 
incubation p e riod used whe n  staining the cells with 
monoclonal antibodies. They were mai n t a i n e d  overnight 
at 4°C w i t hout the presence of sodium azide, and this 
may have a l l owed the a n t i b o d y / a n t i g e n  complexes to "cap" 
and become i nternalised thus greatly reducing the 
surface an t i b o d y  rem a i n i n g  to be detected by flow 
c y t o m e t r y .
Unlike Coz z o l i n o  et al 8 3 , we found no correlation 
between the size of the IL-2 receptor bearing pop u l a t i o n  
and tumour s t a g e .
Transferrin rec e p t o r
Although we found a slight increase in the number of 
cells bearing this re c e p t o r  in the nodes of the cancer 
patients it was not s t a t i stically significant and showed 
no r elationship to tumour stage. This m a rker has not 
been studied on lymph node lymphocytes by other groups. 
Although the e x p r e s s i o n  of this receptor u s u ally  
increases after IL-2 s t i m u lation and just prior to cell 
division, there is some evidence to suggest that a 
second pathway exists t h r ough w h ich IL-2 s t i m u lation 
leads d i r ectly to cell d i v i s i o n  without a m a jor increase 
in the number of t r a n s f e r r i n  receptors 4 3 2 .
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Immunoglobulin G
More IgG co m m i t t e d  B lymphocytes were det e c t e d  in the 
axillary lymph nodes of the breast cancer patients than 
in the normal nodes. A broad range of IgG commitment 
was found in the cancer patients while in the controls 
the level fell w i t h i n  a m uch tighter band suggesting 
that there may be a normal level of IgG bearing B cells 
and that some breast cancer patients fall below this 
while others show evidence of raised IgG production. 
Artifactual causes for this apparent increase were 
avoided by the use of double staining with the CD19 
marker an t i b o d y  so that only cells of the B lymphocyte 
phenotype were studied. Other disease conditions which 
might cause such a response had been excluded at the 
time of p a tient selection.
Richters & K a s p e r s k y  34 3 were the first to study the 
surface immunoglobulins on B lymphocytes from the 
axillary lymph nodes of patients with breast cancer and 
they found IgG to be carried by 22% of B cells wit h  a 
range from 2% to 50%. They did not include any normal 
controls but E r e m i n  et al 118 compared the surface 
immunoglobulins borne on lymphocytes from the axillary 
lymph nodes of patients with those from control 
subjects. They also found the normal level of IgG 
bearing B cells in lymph nodes to be about 17% while in 
breast cancer patients it was about 28%. This presence
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of large numbers of B cells bearing IgG suggests a 
mature s e c o ndary humoral immune response 3 5 1 . E r e m i n  et 
al 1 18, like us, found no alte r a t i o n  with tumo u r  stage 
but one other group, using histochemical analysis of 
immunoglobulin distribution, found more IgG bearing B 
cells in the nodes of patients with stage II disease and 
therefore identified this as a bad prognostic indicator 
4 3 9 ,
PERIPHERAL B L OOD 
PHENOTYPIC MARKERS
In contrast to other studies comparing the peripheral 
blood of breast cancer patients and controls, we found a 
slight fall in the p r o p o r t i o n  of B lymphocytes.
Previous studies have found either no d i f f erence 1 1 6 >
2 0 5 ,  3 0 9 , 2 fc 0 , 3 2 5  or a fall in the p r o p o r t i o n  of T
lymphocytes 4 58, 2 2 2 , 102 with the last group suggesting
a compensatory rise in the B cell population. One group 
359 suggested a rise in the peripheral T cell p o p u l a t i o n  
was associated wit h  a poor prognosis.
The apparent fall in the number of B cells de t e c t e d  in 
this study could reflect the m a t u r i t y  of these cells as 
the B cell ph e n o t y p e  mark e r  is lost when they become
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terminally d i f f e r e n t i a t e d  plasma cells.
The T cell p o p u l a t i o n  was further d i vided into the 
helper and sup p r e s s o r / c y t o t o x i c  subsets and while the 
average p r o p o rtions and ratio were almost identical and 
fell w i t h i n  a c c e p t e d  normal ranges 4 5 2 ,  i t i ,  3 7 5 ,  2 69 ,
the v a r i a t i o n  in phenotypic subgroup proportions was far 
greater in the cancer patients. This suggests that 
while the control samples may represent "normal" 
phenotypic proportions, the cancer patients appear to be 
scattered to the extremes which may be due to 
suppression or stim u l a t i o n  of the immune system. 
Mantovani et al 272 also found no difference in the 
phenotypic p r o p o r t i o n s  b e tween breast cancer patients 
and controls but great v a r i a t i o n  in the C D 4 + /CD8+ ratios 
was noted by a n o ther group who used flow cytometry 37 8. 
This variation, combined with patient selection may 
explain the d i f f e r e n c e s  be t w e e n  our findings and those 
of Pattan a p a n y a s a t  et al 225 who found the cancer 
patients to have a larger CD8 + T cell p o p u l a t i o n  and 
Valavaara et al 440 who, studying the response to 
anti-oestrogen therapy, found them to have a smaller 
CD4+ T cell p o p u l a t i o n  prior to treatment.
A broad range of CD4+/CD8+ ratios was not noted by 
groups using fluorescent m i c r o s c o p y  to study patients 
undergoing p o s t o p e r a t i v e  r a d i o t h e r a p y  or c hemotherapy 
who also found initial CD 4 + / C D 8 +  ratios to be w i t h i n  the
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normal range 3 3 0 ,  3 3 1 ,  4 2 5 ,  3 3 2 ,  3 0 5 .  The ratios later
fell, due to a selective loss of the CD4+ h e lper T cells 
as the course of adjuvant therapy progressed. The use 
of m i c r oscopy is limited in this area by the d i f f i c u l t y  
of counting suff i c i e n t l y  large numbers of cells to give 
statistical a c c u r a c y  and the group who used flow 
cytometry only counted 1000 cells for each sample.
Apart from the technical differences, in all these 
studies the initial samples were taken after surgery 
which may itself cause some disturbance of the immune 
system 7 7 .
High CD4+/CD8+ ratios have been suggested as a sign of 
immunocompetence in patients with immunosuppressive 
disorders 230 and low ratios are certainly found in 
patients with i m m u n o s u p p r e s s i o n  secondary to 
chemotherapy 3 3 : ,  3 3 1 ,  376, The CD4+/CD8+ T cell ratio
of the peripheral blood lymphocytes may therefore act as 
a useful guide to the immune status of patients with 
breast cancer or to immu n o s u p p r e s s i o n  in patients 
undergoing adj u v a n t  therapy.
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ACTIVATION MARKERS
HLA DR
This marker of a c t i v a t i o n  and antigen p r e s e n t a t i o n  in T 
lymphocytes, was present on greater numbers of both 
helper and su p p r e s s o r / c y t o t o x i c  T cells in the 
peripheral blood of breast cancer patients. We found 
this marker to be present on greater numbers of T cells 
than P a t t a n a p a n y a s a t  et a 1 325 but our figures are 
similar to those of Mantovani et al 272 who, using this 
as their only a c t i v a t i o n  marker, found it to be present 
on about treble the number of PBLs in the cancer 
patients. As this group used only single colour flow 
cytometry they could not determine the cellular 
distribution of this marker. L a k hdar et al 2 4 , in 
their study of patients with nasopharyngeal carcinoma, 
also found about 35% of the c i r c ulating T cells to be 
carrying this marker. It was found on a similar 
proportion of T cells by van Es et al 121 in patients 
with an allogenic kidney graft, suggesting its 
relationship wit h  the chronic presence of antigenic 
mat e r i a l .
Interleukin 2 receptor
Little difference was seen in the numbers of B cells 
bearing this receptor in the two groups but there was a
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significant increase in the number of T cells positive 
for this r e c e p t o r  and p a r t i c u l a r l y  striking was the 
finding that this r e c eptor was again c o nsistently 
present on more CD4+ helper T cells than CD8+ 
suppressor/cytotoxic T cells, in both normal subjects 
and patients w ith breast cancer. While P a t t a n a p a n y a s a t  
et al 325 found no d i f f erence b e t ween the control and 
cancer patients with regard to this receptor, La k h d a r  et 
al 2 *7, in their study of patients with nasopharyngeal 
carcinoma, found a similar increase in the number of T 
cells b e a ring the IL-2 receptor. These groups did not 
study the d i s t r i b u t i o n  of this receptor w i t h i n  the T 
cell subsets .
The e x p r e s s i o n  of this re c e p t o r  on more of the CD4+ 
helper T cells may reflect a greater s t i m u lation of 
these cells by an t i g e n  or may represent a constitutional 
difference b e t w e e n  them and the CD8+
suppressor/cytotoxic T cells. As this p a t tern is also 
found among the normal subjects, the latter w o uld appear 
more likely.
Transferrin receptor
As was the case wit h  the lymph node lymphocytes, no 
significant d i f f e r e n c e  was found in the number of cells 
bearing this r e c e p t o r  b e t w e e n  the breast cancer patients 
and the normal controls. This is in k e e ping wit h  the
102
findings of P a t t a n a p a n y a s a t  et al 325
Immunoglobulin G
More IgG b e a r i n g  B cells were found to be c i r c u lating in 
the breast cancer patients as opposed to the normal 
controls sug g e s t i n g  that there may be some degree of 
secondary or chronic humoral response in many of the 
patients. Several a pproaches have been taken to 
studying the humoral immune response with i n  peripheral 
blood. Most groups have studied the serum 
immunoglobulins either d i r ectly 3 4 9 ,  4 4 1 ,  3 2 0  or by
assaying the serum of patients against breast cancer 
cell lines i 1 3 - 2 -c or mouse mammary tumour virus (MMTV)
336' 42 6. While studies u s ing direct assay p r o duced no 
clear evidence of a humoral immune response in breast 
cancer patients, those looking at the binding of patient 
sera on tumo u r  sections, cell lines or against MMTV 
suggested there was c i r c ulating a n t i -tumour 
immunoglobulin. Most of these studies found no 
relationship b e t w e e n  the presence of serum 
immunoglobulin and prognosis but one group, who studied 
both the serum levels of IgG and the p r o p o r t i o n  of IgG 
bearing B cells, found this to correlate with a poor 
outcome 4 7 4 . This would be in keeping with the theory 
of antigenic sites being shielded by antibodies which 
themselves fail to t r igger an immune re a c t i o n  lfi3< 1 0 7 .
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CONCLUSIONS
PRIMARY T UMOUR
85% of the b r e a s t  tumours, in this study, show some 
evidence of a cellular immune response c onsisting of T 
lymphocytes and in 60% this is sufficient to allow 
detailed analysis. CD8 + suppresso r / c y t o t o x i c  T cells 
predominate and increase with histological grade and the 
expression of the class I MHC complex on the tumour 
cells. This suggests that the first r e a c t i o n  may be of 
the CD8 + cytotoxic T cells to tumour a n t i g e n  p r e s ented 
along with the class I MHC complex.
The expr e s s i o n  of HLA DR on the CD8 + T cells also 
increases wit h  tumour grade and e x p r ession of the 
class I MHC complex. It is possible that a n t i g e n  is 
further p r e s e n t e d  by the CD8+ T cells to the CD4+ helper 
T cells w h i c h  are only found in significant numbers in 
those tumours w ith a heavy CD8 + T cell infiltrate.
The HLA DR e x p r e s s i o n  on the CD4+ T cells also increases 
in poorly d i f f e r e n t i a t e d  tumours again r e i n f o r c i n g  its 
association wit h  tumo u r  antigenicity.
The receptors for t r a n s f e r r i n  and interleukin 2 are 
present on a h i g h e r  p r o p o r t i o n  of the CD4+ T cells 
suggesting that while the CD8+ T cells are p r o bably
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fairly static and d i f f e r e n t i a t e d  there is greater cell 
division and e x p ansion among the CD4+ T cell population. 
The finding that, in all samples, the IL-2 receptor was 
found on more CD4+ T cells than CD8 + T cells suggests 
that there may also be a functional difference between 
these two cell types with r e gard to stimulation by IL-2. 
There appears therefore to be evidence, w i thin the 
primary lesions themselves, of a cellular immune 
response to t u mour a n t i g e n  in poorly d i f f e r e n t i a t e d  
tumours w h ich have high levels of the class I MHC 
c o m p l e x .
AXILLARY L Y M P H  NODES
When axillary lymph nodes from breast cancer patients 
are compared w i t h  iliac nodes from control subjects, 
those from the cancer patients are seen to be much 
larger and rather engorged in contrast to the small pale 
control nodes.
The increase, in many patients, in the number of B 
lymphocytes be a r i n g  surface IgG is in keeping with a 
well d e v e l o p e d  secondary humoral immune response and as 
these patients had no c oncomitant disease it is likely 
that this re s p o n s e  is to the carcinoma.
There is also a much gr e a t e r  CD4+ T cell p o p u l a t i o n  in
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the cancer nodes and this leads to an increase in the 
CD4+/CD8 + ratio.
More of the CD4+ and CD8+ T cells from the axillary 
nodes of breast cancer patients express HLA DR than 
from the control nodes and, in the case of the CD8+ T 
cells, this increases with tumour stage. The increase 
in HLA DR e x p r e s s i o n  on the nodal CD8+ T cells in 
patients with stage II disease is in keeping with the 
role of this mark e r  in a n t i g e n  r e c o g n i t i o n  as, in this 
circumstance, the CD8+ T cells are again in direct 
contact with tumour cells and tumour antigen.
The presence of the IL-2 r e c eptor on many more T cells, 
of both phenotypes, suggests antigenic s t i m ulation and 
the presence of secreted IL-2 w i t h i n  the lymph node 
environment of many patients with breast cancer. More 
CD4+ T cells tha n  CD8 + T cells were noted to bear this 
m a r k e r .
From this study therefore, there is evidence of antigen 
recognition, stimulation and an immune response, both 
cellular and humoral, in the regional lymph nodes of 
patients with breast carcinoma.
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PERIPHERAL BLOOD
From the results of this study it would appear that, 
while there are no major a lterations in the overall 
phenotypic proportions, there is a small but significant 
decrease in the B cell p o p u l a t i o n  and a g r e ater range of 
T cell subset p r o p ortions among the breast cancer 
patients whe n  c o m pared with the controls.
There is a m a r k e d  increase in the number of T cells, of 
both phenotypes, b e aring HLA DR and the IL-2 r e c eptor  
both of w h ich are a s s o c i a t e d  with antigenic s t i m ulation 
and cell activation.
Again more CD4+ T cells t han CD8+ T cells were found to 
carry the IL-2 rec e p t o r  and, as this was also the case 
in the control samples, it is likely that this 
represents a constitutional d i f f erence b e t ween the two 
cell types with r e gard to their response to IL-2.
There are more c i r c u l a t i n g  B cells bearing surface IgG 
in the peripheral blood of the breast cancer patients 
than in that of the control subjects and this suggests a 
mature humoral immune response.
These findings suggest that there is some immune 
activition of the peripheral blood lymphocytes in 
patients with breast cancer.
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CHAPTER 3: THE C O N T R I B U T I O N  OF THE A X I LLARY L Y M P H  NODES
TO THE IMMUNE R E S P O N S E  IN PATIENTS WITH BREAST C A NCER
INTRODUCTION
For the m a j o r i t y  of patients, the treatment of breast 
cancer involves surgical e x c ision of the primary lesion 
by lumpectomy or mastectomy, along wit h  e x p l o r a t i o n  and 
excision sampling of the ipsilateral axillary nodes.
In many cases, p a r t i c u l a r l y  if the breast has been 
conserved or the disease is stage II, the patient will 
also receive loco-regional radiotherapy.
From the results given in the p r e c eding chapter it would 
appear that some patients with breast carcinoma are 
detecting a n t i g e n  on the surface of the tumour cells, 
along with the class I MHC complex, and m o u n t i n g  an 
immune re s p o n s e  to it. It is therefore important to 
clarify the tissue sites involved in this response and, 
from this, how they might be a f f ected by the treatment 
modalities co m m o n l y  used. Various approaches have been 
used to assess the importance of the regional nodes in 
any immune r e s ponse but their exact role and 
contribution is still not clear 3 2 3 .
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HISTORICAL REVIEW
HISTOLOGICAL STUDIES
The p o s s i b i l i t y  that the axillary lymph nodes might be 
more than just filters was first raised by H a lsted 
himself in 1898 3 7 b when he noticed that cell 
proliferation in the axillary lymph nodes of breast 
cancer patients was asso c i a t e d  with a good prognosis.
In 1906, Sc h i n d l e r  371 found that lymph node metastases 
were less c o mmon in the presence of sinus cell 
hyperplasia but it was B l ack et al in 1953 3 4 , who 
suggested that this r e p r e s e n t e d  a h o s t -tumour immune 
response. Black's observations were confirmed by 
others 2 b > 21 > 448 , 2 7 3 ,  e ,  3 8 3 ,  4 3 1 , al t hough the 
interpretation o c c a s i o n a l l y  d i f fered 27 . Berg et
a! 26' 27 and F i s h e r  et al 1 3 1 4 0  both found sinus 
hyperplasia to be ass o c i a t e d  with nodal status but not 
with survival and Steele et al 392 found the macr o p h a g e s  
within the lymph node sinuses to be r e l a tively  
inactivated. Several other morphological patterns were 
identified on histological examination, r a nging from 
paracortical e x p a n s i o n  and germinal centre pred o m i n a n c e  
to unstimulated or even lymphocyte de p l e t e d  nodes 4 3 1 . 
Paracortical expansion, r e p r e s e n t i n g  an increase in the 
T cell area w i t h i n  the nodes ap p e a r e d  to be a s s o c i a t e d
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with a good prognosis 34 5, 4 0 3 ( while lymphocyte
depletion was found in those patients who a l r eady showed 
signs of w i d e l y  d i s s e m i n a t e d  disease.
Some groups found germinal center predominance, which 
suggests a p r o l i f e r a t i o n  of B cells, to be a s s o ciated 
with an intermediate or even good prognosis 4 3 1 ,  i 4 7 #
while others found this p a t tern correlated with a bad 
prognosis 2 0 3 ,  n e ,  n o .  jn his initial work with 
breast carcinoma, T s a k r aklides et al 431 found this 
pattern to be a s s o c i a t e d  with an intermediate prognosis 
while in his later study of ovarian cancer it correlated 
with a poor outlook 4 3 0 .  it has been suggested that 
this pattern r e p r esents a humoral response of antibodies 
which coat the tumo u r  but do not initiate any further 
response of the immune system and mas k  the antigenic 
sites from further immuno d e t e c t i o n  i b 3 , 1 0 7 .
CLINICAL STUDIES
It was the po s s i b l e  c o n t r i b u t i o n  of the a x i llary lymph 
nodes to the host defence against breast cancer that led 
to the v i g orous debate over the surgical m a n a g e m e n t  of 
breast cancer, with t r a d i t i o n a l i s t s  b e l ieving fervently 
in the e f f icacy of radical surgery 173 while others 
proposed more c o n s e rvative surgery with p r e s e r v a t i o n  of
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the axillary nodes. Much of the drive for change came 
from George Crile, a C l e v e l a n d  surgeon who was convinced 
of the value of the regional lymph nodes in the defence 
against breast cancer and who, in his own surgical 
practice, p e r f o r m e d  only simple mastectomies and 
preserved the a x i l l a r y  nodes. Presenting his own 
figures, he d e m o n s t r a t e d  a s ignificantly increased 5 
year survival in patients with clinical stage I disease 
87 •- 8 8 ' 87 . This was supported by M o n t gomery et al 283 
who per f o r m e d  only biopsy e x c ision on 31 patients with 
invasive brea s t  cancer and reported 100% survival at 
five years. In contrast to this, Urban 4 3 b ,  4 3 7
proposed that, far from reducing the surgical excision, 
it should be exten d e d  to include the internal mammary  
nodes of patients with tumours of the medial aspect of 
the breast. In a series of patients t r e ated u s ing his 
surgical approach, a Eu r o p e a n  group showed a survival 
advantage for the subset of patients u n d e r g o i n g  this 
extended surgery who had internal mammary lymph node 
metastases 2 4 8 .
Destruction of the axillary lymph nodes by r a d i o t h e r a p y 
was also shown to be harmful by several groups, who 
found it to be a s s o c i a t e d  with both an increased relapse 
rate 74 and p o orer survival rate 3 9 a, 3 0 4 , 368^ but it
must be borne in mind that r a d i a t i o n  affects tissues 
other than the regional nodes and that v a r i ations in
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total r a d i a t i o n  dose may affect outcome regardless of 
how the axi l l a r y  nodes themselves are t r eated 1 4 .
In an a t t empt to clarify the situation, over the 
surgical m a n a g e m e n t  of breast cancer, the National 
Surgical Ad j u v a n t  Breast P r oject was set up 131 which 
was a m u l t i c e n t r e  trial comparing simple mastectomy, 
simple m a s t e c t o m y  plus radi o t h e r a p y  and radical 
mastectomy in the t r e a tment of clinical stage I disease. 
After 10 years of follow up there was no significant 
difference in survival or w i d e s p r e a d  metastatic disease 
between the three groups but there was a higher 
incidence of loco-regional r ecurrence in the simple 
mastectomy group. However, 40% of the patients who 
underwent radical m a s t e c t o m y  and were c linically thought 
to have stage I disease, where found to have nodal 
metastases. As this was a rand o m i s e d  trial it is 
reasonable to assume that a similar prop o r t i o n  of 
patients in the simple m a s t e c t o m y  group had also, in 
fact, stage II disease. Only 15% of these patients went 
on to present, w i t h i n  the 10 years of follow up, with 
axillary m e t a s t a s e s  while the other 25% r e m ained well 
and a pparently disease free. It was also noted that 
while 88% of patients in the radical m a s t e c t o m y  group 
with loco-regional r ecurrences went on to de v e l o p  
systemic d i s ease only 58% of similar patients in the 
simple m a s t e c t o m y  group went on to develop distant
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metastases. This could be due to the fact that local 
recurrence in the radical m a s t e c t o m y  group repr e s e n t e d  
truly r e c u r r e n t  disease which, being r e l ated to the 
aggressiveness of the tumour, was a s s o ciated with 
disseminated disease while local recurrence in the 
simple m a s t e c t o m y  group often merely r e p r e sented 
residual disease. From these findings it would appear 
that many patients can bear occult residual tumour which 
appears to cause little in the way of symptoms or 
occasionally presents many years later w hen the patient 
has been s u b j ected to severe stress such as illness or 
bereavement 2 c * 2 2 3 - 3 7 2 .
The question, of course, is why this happens, w h e ther it 
is due to features of the host defences or the tumour 
aggressiveness or a comb i n a t i o n  of both. In this large 
study of 1,665 w o m e n  no significant survival d ifference 
was seen b e t w e e n  the three clinically stage I groups 
regardless of management. However, as almost half of 
each group had in fact stage II disease, it is not 
possible to exclude a survival advantage or d i s a d vantage 
for either true stage by the use of any of these three 
treatment modalities.
The best p r o g nostic indicator remains lymph node stage 
46' 135 and as there is, as yet, no other sati s f a c t o r y  
way of staging patients 9 5 ' 2 > 41 3 3 3 , 151 it is not
possible to study the impact of leaving the axilla
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intact in true stage I patients.
ANIMAL STUDIES
To try and g a i n  more i nformation about the role of the 
regional lymph nodes in cancer patients, several studies 
using animal t u mour models were carried out.
Mitchison 2 8 0 , isi showed that the regional lymph nodes 
in a tumour b e a ring animal could transfer adoptive 
immunity to a g r e ater degree than remote lymph nodes, 
splenocytes or peripheral blood lymphocytes.
Considering the c o n t r i b u t i o n  of the regional lymph nodes 
to the defence of the tumour host, Crile 8 b found a 
greater number of mice with wide s p r e a d  m etastases among 
those who u n d e r w e n t  radical amp u t a t i o n  of their tumours 
including ex c i s i o n  or irradiation of the regional lymph 
nodes. This effect was lost if the a m p u t a t i o n  was 
delayed until a late period in the growth of the tumour 
suggesting that the nodes might be of greatest 
importance in the initiation and early phase of an 
immune response. This finding was confirmed by other 
studies 1 1 1 , 3 2 8,
Studying the contribution of the nodes to tumour 
resistance, one group found that excision of the 
regional lymph nodes prior to inoculation with tumour
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resulted in twice as many tumour takes in the group with 
no regional lymph nodes as in those with their regional 
nodes intact 1 2 c . Ex c i s i o n  of the nodes up to 4 weeks 
after tumour inoculation also resulted in increased 
tumour takes from a second tumour challenge, with 
tumours d e v e l o p i n g  in 81% of control mice, 54% of those 
who had their regional lymph nodes excised and only 38% 
of those who had their regional lymph nodes left intact 
127. Clearly some centralised immune response had 
developed w i t h i n  the first four weeks but this 
experiment suggested that a significant c o n t r i b u t i o n  was 
still being made by the regional lymph nodes.
This was s u p p orted by a further study w h ich d e m o n s t r a t e d  
an effect of the regional lymph nodes on tumo u r  growth
up to two months after excision of the primary lesion
1 -7
Five groups, in studies involving m e t h y l c h o l a n t h r e n e  
induced sarcomas, found evidence more suggestive of a 
centralised immune response. Andreini et al 1 2 , 
measuring the w e i g h t  of various lymphoid tissues in 
tumour b e a ring animals, found the greatest increase to 
be in the spleen.
Gardner & R o s e n  150 found no effect of radical tumour 
and lymph node ex c i s i o n  on a second tumour challenge. 
Similarly, H a m m o n d  & Rolley 179 found little effect if 
the regional lymph nodes were r e t ained or excised with
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the primary tumour. A l t hough Bard ^  showed that 
regional lymph node lymphocytes could indeed be used to 
transfer immunity from tumour bearing animals to 
syngeneic hosts as effi c i e n t l y  as splenocytes, he also 
found that while removal of the spleen s i g n i ficantly 
reduced the animal's r esistance to a second tumour 
inoculum, e x c i s i o n  of the regional lymph nodes had 
little effect. Hum p h r e y  et al 199 found that adding 
splenocytes from an immunized animal reduced successful 
tumour takes to 59% while 85% of the tumour inocula grew 
if combined w i t h  lymphocytes from the regional lymph 
nodes .
From these e x p e r iments it was concluded that regional 
lymph nodes were not necessary for an animal to mount an 
immune r e s ponse a g ainst a tumour as splenocytes were 
just as effective, if not more so, in t r a n s f e r r i n g  
immunity to other animals and the spleen ap p e a r e d  to be 
more important as a seat of immune memory for m o u n t i n g  a 
secondary immune response to any subsequent tumour 
cha l l e n g e .
However, all of these studies were performed using 
chemically induced tumours w h ich are k n own to be 
strongly a n t i genic 311 and Fisher & Fisher 127 found 
that c h e m ically induced tumours grew signi f i c a n t l y  less 
often in p r e v i o u s l y  immunized mice, w h e t h e r  the regional 
lymph nodes had bee n  r e m oved or not, whereas the lymph
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nodes ap p e a r e d  to have a greater impact on the growth of 
spontaneous tumours. This suggested a dif f e r e n t  p a t tern  
of immune response in spontaneous and c h e m ically induced 
tumours and studies of tumour models, which more closely 
resembled the poorly antigenic human tumours, re v e a l e d  a 
weak immune r e s ponse but with the regional lymph nodes 
making a g r e ater c o n t r i b u t i o n  3 3 5 .
Unfortunately, because of these variations, the 
relevance of animal studies to patients is limited and 
many of the conf l i c t i n g  results are probably due to the 
use of d i f f e r e n t  animal and tumour models.
FUNCTIONAL IN VI TRO STUDIES
These e xperiments were per f o r m e d  using cells har v e s t e d  
from patients with breast cancer. Most groups compared 
lymph node lymphocytes with those from peripheral blood 
although some groups w o rked only with blood because of 
the ease of h a r v e s t i n g  samples. The experiments fell 
into three m a i n  categories: blast o g e n e s i s  assays, 
cytotoxicity assays and observations of in vitro 
behaviour such as cell m i g r a t i o n  or clumping.
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BLASTOGENESIS ASSAYS
Using similar methods to those outlined in chapter 2, 
most groups found lymph node lymphocytes to have a 
higher t h y midine uptake after mi t o g e n  stim u l a t i o n  than 
blood lymphocytes 1 0 3 , 1 : 8 , although Fisher et al 128 
found the re v e r s e  w h e n  they u sed c oncentrated PHA.
Reiss et al 239 found a higher cell turnover of lymph 
node lymphocytes from patients with small tumours and of 
peripheral b l ood lymphocytes from patients with large 
tumours. In a later study Fisher et al 130 found a 
greater cell turnover, after PHA stimulation, in 
lymphocytes from low axill a r y  nodes than from high 
axillary nodes. The results of these experiments were 
variable but t e n d e d  to suggest a greater 
lympho-pro1iferative response, to mitogenic stimulation, 
by lymph node lymphocytes than peripheral blood 
lymphocytes.
CYTOTOXICITY ASSAYS
These were again performed using the chromium release 
assay outlined in chapter 2.
Initially, the lymphocytes studied using this method 
were harvested either from the peripheral blood or
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regional lymph nodes but later studies also looked at 
the cytotoxic effect of tumour infiltrating lymphocytes 
(TILs). As it is d i f f icult to get fresh tumour cells to 
grow well in culture and take up the chromium, few 
studies have been carried out with autologous tumour 
cells as the target, alt h o u g h  this is clearly the most 
r e l e v a n t .
Using this approach, H i ckok et al found the lymph
node lymphocytes (LNLs) to have a much greater cytotoxic 
effect on aut o l o g o u s  tumour cells than peripheral blood 
lymphocytes. This r e a c t i v i t y  could be tran s f e r r e d  to 
peripheral blood lymphocytes by m a c r ophages from 
hyperplastic nodes but not by those from small quiescent
nodes. S k o r n i c k  et al 386 found LNLs and TILs to have a
similar degree of cytot o x i c i t y  against autologous tumour 
and found this to be g r e ater than that of the P B L s . 
Belldegrun et al 24 found cytotoxicity, against 
autologous tumour, in the maj o r i t y  of TIL p r e p arations 
tested. Two other groups, who also studied TILs, found 
them to have only negligible cytotoxic a c t ivity against 
autologous t u mour cells 4 4 4 , 1 3 .
Of those who did not use autologous tumour as the 
target, one group, who also studied the histological
features of the nodes, found that a high level of
cytotoxicity was a s s o c i a t e d  with paracortical exp a n s i o n  
and sinus h i s t i o c y t o s i s  which r e p r esent an increase in
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the T cell p o p u l a t i o n  7 1 . Germinal centre hyperplasia, 
however, was a s s o c i a t e d  with low levels of c y t o toxicity 
possibly due to antigenic sites being blocked by 
ineffective antibodies 3 8 3 . Several groups tested the 
cytotoxicity of peripheral blood, lymph node and tumour 
infiltrating lymphocytes on a cell line, K562, which is 
particularly sensitive to natural killer (NK) cells and 
is used as a m e t h o d  of detecting their presence and 
function. PBLs appear to have a greater cytotoxicity  
against this cell line than lymphocytes from other 
sources, in patients with breast cancer u ’ - so and 
other m a l i g n a n c i e s  4 4 3 , 4 4 5 , 296, suggesting that this
might be the m a j o r  site of NK cells. C u n n i n g h a m - R u n d l e s  
et al 91 found that some patients had a very high NK 
cell function among their LNLs and B l a n c h a r d  et al 42 
found NK a c t i v i t y  could be induced in lymphocytes 
obtained from a mal i g n a n t  pleural effusion by culture in 
IL-2. The rel e v a n c e  of the K562 c ytotoxicity assay and 
the function of natural killer cells are still not 
c l e a r .
In view of the severe limitations of the chromium 
release assay, a more precise meth o d  of studying 
cytotoxic f u n c t i o n  is required. Flow cytometry may be 
helpful in this area as d a m aged cells could be 
identified u s i n g  p r o p i d i u m  iodide (PI) to stain the 
nuclei, a v o i d i n g  the need for chromium uptake and so
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allowing the greater use of autologous tumour cells.
CELL MIG R A T I O N
The m i g r a t i o n  of lymphocytes towards tumour cells, to 
encircle them and form clumps, has been noted by several 
observers 3 4 2 , 1 0 3 , 1 1 5 , 2 2 8 , 1 3 2  a n d found to be
greater among lymph node lymphocytes than among 
peripheral blood lymphocytes 1 0 3 , 1 1 5  or tumour
infiltrating lymphocytes 3 4 2 . This method is very 
subjective and therefore results are d i f f icult to 
compare or interpret.
The above in vitro studies are very indirect and take no 
account of the functional subgroups with i n  each 
lymphocyte population.
SURFACE MARKERS  
CELL P H E N O T Y P I N G
With gr e a t e r  u n d e r s t a n d i n g  of the function of cells 
within the immune system, analysis of the phenotypic 
composition and activation, of a lymphocyte p o p u l a t i o n
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allows a clearer i n terpretation of its immune status. 
Using ros e t t i n g  techniques, three groups compared 
lymphocytes from the a x i llary lymph nodes and peripheral 
blood in the same patients l i t ,  1 0 2 ,  i ? i ,  and found a 
greater B cell p o p u l a t i o n  in the nodes while Vose &
Moore 444 found the T and B cell populations in the 
tumour and the peripheral blood to be similar.
The d e v e l o p m e n t  of monoclonal antibodies to the 
phenotypic markers on the cell surface membrane has 
greatly improved the a c c uracy of phen o t y p i n g  and the use 
of flow cyt o m e t r y  allows dual i m m u nofluorescent staining 
of both the phenotypic and a c t i v a t i o n  markers on the 
same cell.
Three groups have used flow cytometry to compare 
lymphocytes from dif f e r e n t  sources w i t h i n  the same 
patient w ith breast c a r c inoma 2 ^ 5 ,  2 8 9 , 2 7 2 , .
The first of these studied only the phenotypic markers 
on peripheral blood and lymph node lymphocytes and found 
proportionally fewer T cells and fewer CD8 + T cells in 
the nodes, along w ith an increased CD4+/CD8+ ratio.
This is equ i v a l e n t  to an increase in the p r o p o r t i o n  of B 
cells and CD4+ T cells in the nodes. M o r t o n  et al 289 
also found an increased p r o p o r t i o n  of B lymphocytes and 
CD4+ helper T cells in the lymph nodes with CD4+ T cells 
predominating in stage I patients while B cells 
predominated in the nodes of patients with stage II
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disease. They found HLA DR to be present on a higher 
proportion of T cells in the lymph nodes suggesting cell 
activation and antigenic stimulation and again this was 
greater in patients with stage II disease. As this 
study included no control subjects, they were unable to 
clarify wh e t h e r  these d i f f erences were due to lymphocyte 
source or the presence of mal i g n a n t  disease. They did 
not include analysis of the TILs or other a c t i v a t i o n  
markers such as the receptors for interleukin 2 (IL-2) 
and t r a n s f e r r i n  (Trf) nor did they seek evidence of a 
humoral immune response in the form of IgG production. 
Mantovani et al 2 7 2 # using only single colour flow 
cytometry, c o m pared the peripheral blood with invaded 
and u n i n vaded axi l l a r y  lymph nodes. They found a 
greater B cell p o p u l a t i o n  in the lymph nodes regardless 
of metastatic involvement but found the CD4+ T cell 
population to be lowest in the u n i n v a d e d  nodes while 
these were the nodes with the greatest HLA DR 
e x p r e s s i o n .
No studies have yet compared the lymphocytes 
infiltrating the tumour with those from the axillary 
lymph nodes and peripheral blood, w i thin the same 
patients, wit h  r e gard to phenotypic comp o s i t i o n  and cell 
a c t i v a t i o n .
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PRESENT STUDY
In this study, the phenotypic proportions and act i v a t i o n  
status of lymphocytes from the primary tumour, axillary 
lymph nodes and peripheral blood were ch a r a c t e r i z e d  in 
22 patients with breast carcinoma, from w hom all three 
samples were available. The aims of this c o m p arison 
were to assess the loco-regional immune response at the 
time of presentation, to consider how it might be 
affected by conventional breast cancer therapy and to 
judge if the peripheral blood might be of use as a guide 
to the loco-regional immune status.
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METHODS
Samples of p r i m a r y  tumour, axillary lymph nodes and 
peripheral blood were collected from 25 patients 
undergoing surgery for breast carcinoma w h ich involved 
axillary node dissection. The cells were har v e s t e d  from 
these samples as de s c r i b e d  pre v i o u s l y  and frozen in 
liquid n i t r o g e n  until they could be stained with 
monoclonal anti b o d i e s  and an a l y s e d  by flow cytometry.
No TILs were o b t ained from 3 of the tumours and so they 
were excluded and the analysis p e r f ormed on the 
remaining 22 patients.
As described in chapter 2, the cell suspensions were 
stained using the fluorescent antibodies listed in Table 
1 which a l l o w e d  the cells to be phe n o t y p e d  as B 
lymphocytes, CD4+ helper T cells or CD8+ 
suppressor/cytotoxic T cells. These cells were also 
stained for H LA DR, the receptors for IL-2 and 
transferrin and, in the case of the B cells, surface 
IgG. As few B lymphocytes were found infiltrating the 
tumours the a c t i v a t i o n  markers of these were not 
studied.
The phenotypes are expressed as a percentage of the 
total lymphocyte population while activation markers are 
given as a percentage of each phenotype bearing the 
marker.
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In this study the p henotypic proportions and a c t i vation 
status of lymphocytes from the three tissue sources were 
compared to det e r m i n e  the major site of each phenotypic 
population and p a r t i c u l a r l y  the extent of the 
loco-regional response. The degree to which peripheral 
blood might be used as a guide to the status in the 
other tissues was as s e s s e d  by c orrelating the phenotypic 
proportions and a c t i v a t i o n  mark e r  expression of the PBLs 
with those lymphocytes h a r v e s t e d  from the regional lymph 
nodes and pr i m a r y  tumour.
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RESULTS
PHENOTYPIC MARKERS
Lymph nodes y i e lded greater numbers of lymphocytes than 
the other sources with an average of 4 X 1 0 7 cells from
each half lymph node compared with 1.5 X 1 0 7 cells from
lOmls of peripheral blood. As the TILs were not 
separated from the tumour cells it was not possible to
get fresh cell counts but it was clear from later
analysis that, in most tumours, the lymphocyte yield was 
less than that from peripheral blood.
The major source of B lymphocytes was found to be the 
axillary lymph nodes where they accounted for 35% of the 
lymphocytes while the blood contained 13% and the tumour 
12% ( p < 0 .001) (Table 10) (Fig. 50). There was no 
correlation b e t w e e n  the size of the B cell p o p u l a t i o n  at 
these d i f f e r e n t  sites.
The axillary lymph nodes were also the major site of the 
CD4+ helper T cells which made up 49% of the L N L s , 39%
of the PBLs and 30% of the TILs (p<0.03) (Fig. 51).
11% of LNLs and 25% of blood lymphocytes were CD8+
suppressor/cytotoxic T cells while these cells made up a
much larger p r o p o r t i o n  of the TILs (41%) (p<0.001) (Fig.
52). A l t h o u g h  these cells are clearly therefore the
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PARAMETER
TILs 
(n = 20)
LNLs 
(n = 20)
PBLs 
(n = 20)
STUDENT'S 
t TEST
a. t=0.556 p=0.58 1
% T cel ls 63.8 ±4 .38 58.9 ±3 .12 60.6 ±  3.69 b. t= -0 .399  p=0.694
c. t=0.923 p=0.362
a. t= -0 .848  p=0.40 1
% B cells 10.9 ± 1.76 34.8 ± 3.05 1 2.7 ± 1.29 b. t=-7 .39 p<0.0001
c. t= -6 .599  p<0.0001
a. t= -2 .237  p=0.03
SCD4+ 29.3 ±2.91 48.4 ± 3.07 38 .9±  3.13 b. t= 3 .1 66 p=0.005
T cells c. t= -4 .509  p<0.0001
a. t=4.820 p<0.0001
SCD8+ 43.1 ±3 .39 1 1.4 ± 0.88 24.8 ± 1.90 b. t = - 7 . 1 16 p<0.0001
T cells c. t=9.446 p<0.0001
a. t = - 3 . 4 1 7 p=0.001
CD4/CD8 0.83 ±0 .15 5.5 ±0 .83 1.8 ± 0 .2 3 b. t= 5 .1 75 p<0.0001
RATIO c. t=-5 .2  1 3 p<0.0001
Table 10 Comparing the phenotypic proport ions among lymphocytes 
f rom  the pr imary  tumour, regional lymph nodes and 
peripheral blood of pat ients  w i th  breast cancer.
(a.) is  the comparison of TILs and PBLs; (b.) the comparison 
of LNLs and PBLs and (c.) that  of TILs and LNLs.
ce
lls
Fig. 50
m
p<0.001
Tumour peripheral blood Lymph nodes
Lymphocyte source
Fi
g.
 
51
 
Fi
g.
 
52
S||®0 1  + 8 0 0 %
Ly
m
ph
oc
yt
e 
so
ur
ce
 
Ly
m
ph
oc
yt
e 
so
ur
ce
largest component of the tumour infiltrate in many 
patients, the small quantity of infiltrate makes it 
difficult to harvest large numbers of CD8+ cells from 
this source.
Although the peripheral blood contained fewer CD4+ T 
cells it r e f l e c t e d  the lymph node population with a 
strong positive c o r r e lation (p<0.001) (Table 11) (Fig. 
53) while an inverse c o r r elation was found, with regard 
to the CD8 + T cell population, between the peripheral 
blood and the regional lymph nodes (p<0.03) (Fig. 54). 
There was no c o r r e l a t i o n  b e t ween tumour and blood for 
either T cell population.
Due to the above variations in the T cell subset 
proportions, the CD4+/CD8+ ratio was also found to vary 
markedly b e t w e e n  the tissue sources, unlike the findings 
in normal subjects where there was little d i f f erence in 
the ratio b e t w e e n  lymph node and peripheral blood 
lymphocytes (see chapter 2). The average subset ratio 
in the peripheral blood of breast cancer patients was 
1.8 while that in the nodes was 5.5, r e f l ecting the 
greater CD4+ p o p u l a t i o n  in the latter. The average 
ratio in the tumour samples was 0.8, due to the larger 
CD8+ T cell p o p u l a t i o n  at this site (Fig. 55). As the 
subset prop o r t i o n s  c orrelated between lymph node and 
blood so did the ratio (pCO.OOl) (Fig. 56) although, as 
can be seen from the significance values, it is the CD4+
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PARAMETER
CORRELATION OF 
PBLs and LNLs 
(n = 39)
CORRELATION 
PBLs and TILs 
(n = 20)
CORRELATION
GRADIENT
% T cel ls r  = 0.148 
p = 0.368
r = 0.222 
p = 0.347
% B cells r  = 0.285 
p = 0.89
r  = -0.001 
p = 0.997
% TD4+ T r p l l s r  = 0.525 r  = -0.030 y= 14.1 88+0.5247xrO UL/ fcT 1 UC I 1 O
p = 0 .001* p = 0.901 RA2 = 0.276
% CD8 + T ce l ls r  = 0.356 
p = 0 .027*
r  = 0.160 
p = 0.501
y= 16.044+0.8389x 
R‘2 = 0.127
CD4+/CD8+
ratio
r  = 0.640 r  = 0.262 y=0.836+0 .1833x
p < 0 .0001* p = 0.265 RA2 = 0.410
Table 1 1 Corre la t ing the phenotypic proport ions found in
peripheral blood w i th  those in the pr imary  tumour 
and regional lymph nodes. The peripheral blood shows 
strong corre la t ion  w i th  the T cell  subsets in the nodes 
but not those in f i l t r a t i n g  the tumour.
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population which appears to affect the ratio most 
s t r o n g l y .
ACTIVATION MARKERS 
HLA DR
The class II MHC antigen, was present on about half of 
the CD8 + T cells in both the tumour (53%) and the lymph 
nodes (50%) but on fewer of the circulating b l ood CD8+ T 
lymphocytes (37%) (p<0.001) (Fig. 57a).
The greatest p r o p o r t i o n  of CD4+ T cells b e a ring HLA DR 
was found to be w i t h i n  the tumour (46%) while 37% of the 
CD4+ cells in the lymph node and 20% of those in the 
blood also bore this a c t i v a t i o n  marker (Table 12). The 
difference b e t w e e n  tumour and lymph node was not 
significant but that b e tween blood and the other sources 
was greater (p<0.001) (Fig. 57b).
There was no c o r r e l a t i o n  b e t ween the e x p r ession of HLA 
DR on the CD8 + or CD4+ T cells in the blood wit h  those 
from the regional nodes or w i t h i n  the tumour (Table 13).
Interleukin 2 receptor
The IL-2 receptor, was found on an average of 15% of all 
CD8+ T cells reg a r d l e s s  of the tissue studied but as no 
significant c o r r e l a t i o n  was seen between the cells in
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PARAMETER
TILs 
(n = 17)
LNLs 
(n = 17)
PBLs 
(n = 17)
STUDENT'S 
t TEST
a. t=2.597 p=0.02
50 .112.42 37.0 1 2.23 b. t=4.327 p<0.0001
c. t=0.090 p=0.929
a. t= -0 .97  1
r^^rK)oiiCL
15.71 1.47 16.1 1 1.33 b. t = - 0 . 1 94
COCOoiiCL
c. t= -0 .984 p=0.341
a. t=0.72 1 p=0.482
32 .512 .34 38.0 1 2.49 b. t= -2 .933
COoooiiCL
c. t= 2 .1 93 p=0.044
a. t=7.738 p<0.0001
37.51 1.98 19.9 1 1.60 b. t=4.349 p=0.001
c. t= 1.677 p=0.1 14
a. t=-3 .589 p=0.003
22.81 1.45 33.1 1 2.02 b. t = - 5 . 1 92 p<0.0001
c. t=2.563 p=0.023
a. t=2.466 p=0.027
28.712.83 34.3 1 2.77 b. t= -3 .060
COoooiiCL
c. t= 3 .166 p=0.007
30 .913.23 10.3 1 2.10 b. t=9.027 p<0.0001
16.21 1.17 2 2 .91 2 .4 9 b. t= -3 .286 r^
ooo’nCL
42 .512.58 49.1 12 .74 b.
CDCNin p=0.023
33.314 .19 19.412.02 b. t=3.753 p=0.001
%CD8+ 
HLA DR+
%CD8+ 
Tac +
%CD8+
TrfR+
%CD4+ 
HLA DR+
&CD4+
Tec+
%CD4+
TrfR+
%B high 
HLA DR
8B Tac+ 
TrfR+ 
lgG+
5 2 .5 1 4 .47
14.31 1.69
39 .81 2 .3 7
45.514.31
27 .21  1.54
4 7 .01 5 .0 2
Table 1 2 Comparing the ac t iva t ion  status of lymphocytes f rom the 
pr imary  tumour, regional lymph nodes and peripheral 
blood of pat ients  w i th  breast cancer.
(a.) is the comparison of TILs w i th  PBLs; (b.) tha t  of LNLs 
w i th  PBLs and (c.) that  of TILs w i th  LNLs.
PARAMETER
CORRELATION OF 
PBLs and LNLs 
(n = 39)
CORRELATION 
PBLs and TILs 
(n = 17)
CORRELATION
GRADIENT
CD8+ T ce l ls r  = 0.233 r  = -0.313
bearing HLA DR p = 0.1 17 p = 0.238
CD8+ T ce l ls r  = 0.219 r  = 0.172
bearing Tac p = 0.126 p = 0.524
CD8+ T ce l ls r = 0.587 r  = -0.399 y= 18.934+0.5623x
bearing Tr fR p < 0 .0001* p = 0.126 RA2 = 0.345
CD4+ T ce l ls r  = 0.309 r  = -0.152
bearing HLA DR p = 0.064 p = 0.589
CD4+ T ce lls r  = 0.244 r  = 0.373
bearing Tac p = 0.107 p = 0.171
CD4+ T ce lls r  = 713 r  = -0 .0 1 9 y= 1 5.1 10+0.6763X
bearing TrfR p < 0 .0001* p = 0.947 RA2 = 0.509
B cells w i th r  = 0.700 y=-1.439+0.4122x
high HLA DR p < 0 .0001* RA2 = 0.490
B cells bearing r = 0.560 y=6.484+0.984x
Tac p < 0 .0001* RA2 = 0.314
B cells bearing r = 0.500 y=25.782 + 0.5332x
TrfR p = 0 .001* RA2 = 0.250
B cells bearing r  = 0.670 y=6.663+0.3625x
surface IgG p < 0 .0001* RA2 =0.449
Table 1 3 Corre la t ion of the ac t iva t ion  marker expression on blood 
lymphocytes w i th  that  on lymphocytes f rom the regional 
nodes and pr imary  tumour. There is strong corre la t ion  of 
T r fR expression and al l the B cell  markers but not the 
T cell  ac t iva t ion  markers.
the tumour, node and blood, individual patients appeared 
to have this re c e p t o r  on different proportions of CD8 + 
cells in the d i f ferent tissues.
This re c e p t o r  was found on a greater p r o p o r t i o n  of the 
CD4+ T cells in the tumour (27%) than in the lymph nodes 
(23%) but the g r e atest e x p r ession of this marker was on 
the circ u l a t i n g  CD4+ T cells (33%) (p<0.001).
It was a g a i n  noted that this receptor was carried by 
almost twice the number of CD4+ as CD8+ T cells 
regardless of the lymphocyte source (p<0.001) (Fig.
58) .
Transferrin re c e p t o r
As seen in the previous chapter, there was no 
significant dif f e r e n c e  between the number of 
lymphocytes, of all phenotypes, bearing the t r a n s f e r r i n  
receptor in the nodes and blood of breast cancer 
patients and of normal controls.
There were, however, more cells carrying this receptor 
among the CD4+ T cells infiltrating the tumour (47%) 
than from lymph node (29%) or blood (34%) (p<0.05) (Fig.
59) .
The p r o p o r t i o n  of lymph node T cells, of either 
phenotype, b e a r i n g  this r e c eptor was clearly r e f l e c t e d  
in the peripheral blood (p<0.001) (Figs. 60a & 60b).
No significant d ifference was found in the a c t i v a t i o n
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marker e x p r e s s i o n  of the lymph node or peripheral blood 
B cells from patients with breast cancer or from normal 
controls but a strong c o r r elation was noted b e t w e e n  the 
two sources w i t h i n  individual patients (p<0.001) (Figs. 
61a, 61b & 6 1 c ) .
Immunoglobulin G
This was found on the membrane of 33% of the lymph node 
B lymphocytes as compared with 19% of the peripheral 
blood B lymphocytes (PC0.001) (Fig. 62). A broad range 
was seen in both sources, with the IgG p o p u l a t i o n  in the 
nodes va r y i n g  from as little as 3% to as much as 70%, 
and the r e l a t i o n s h i p  between the two sources showing a 
strong c o r r e l a t i o n  (p<0.001) (Fig. 63).
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DISCUSSION
PHENOTYPIC MARKERS
From these results it can be seen that there is great 
variation in the phenotypic proportions b e t w e e n  the 
three sources. The axillary lymph nodes appear to be 
the major site of the B lymphocyte p o p u l a t i o n  w h ich is 
in a g r e ement with previous studies which have compared 
axillary lymph node and peripheral blood lymphocytes, 
either by u s ing surface i m m u n oglobulin and ros e t t i n g  
techniques 1 8 2 ,  1 1 8  or monoclonal antibodies and flow
cytometry 2 8 9 > 295 to identify the B cells.
As with m any previous studies (see chapter 2) we found 
few B lymphocytes w i t h i n  the primary tumours.
Studying the T cell subsets, we found that the regional 
lymph nodes were also the mai n  site of the CD4+ T cells, 
with a smaller p r o p o r t i o n  of CD8+ T cells than 
peripheral blood. This is similar to the findings of 
Morton et al 2 8 9 , Na k a j i m a  et al 295 and Mantovani et al 
272 who c o m pared the PBLs and LNLs using flow cytometry. 
While this last group found a smaller CD8+ T cell 
population w i t h i n  the regional nodes, they found no 
increase in the CD4+ T cell p o p u l a t i o n  and indeed a fall 
in this cell type in the u n i n v a d e d  nodes.
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Although other groups have found no r e l a t i o n s h i p  between 
the phenotypic p roportions of the PBLs and LNLs 3ie,
4 56 t we did find c o r r e l a t i o n  b e t ween the size of the 
CD4+ T cell p o p u l a t i o n  in the axillary nodes and 
peripheral blood and, because of this, the C D 4 + /CD8+ 
ratio also cor r e l a t e d  strongly. The size of the CD4+ T 
cell p o p u l a t i o n  and the C D 4 + /CD8+ ratio of the PBLs 
might t h e r efore give some indication of those patients 
with an increased p r o p o r t i o n  of CD4+ helper T cells in 
their axi l l a r y  nodes.
Controversy exists over the T cell subset proportions 
among the tumour infiltrating lymphocytes (see chapter 
2) but in this study the CD8 + T cells were found to 
predominate. The cell yield from the tumours is not as 
high as that obtained from lymph node or blood and this 
may not the r e f o r e  be the g r e atest q u a n titative source of 
these cells.
ACTIVATION MARKERS 
HLA DR
In chapter 2 it was shown that this a c t i v a t i o n  marker 
was present on more than twice as many T lymphocytes in 
the patients w ith breast cancer as in the controls. In 
this study, c o m p aring the d i f f e r e n t  lymphocyte sources,
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this marker is seen to be on a large p r o p o r t i o n  of the 
CD8+ T cells infiltrating the tumour and present in the 
axillary nodes. In the TILs this pro p o r t i o n  increases 
to include almost all of the CD8+ T cells in poorly 
differentiated tumours which express the class I MHC 
complex and contain a strong lymphocytic infiltrate. In 
the nodes the exp r e s s i o n  of HLA DR on the CD8+ T cells 
is related to tumour stage and thus to the direct 
contact of these cells with metastatic tumour deposits. 
Both of these findings reinforce the a s s o c i a t i o n  of this 
activation m a r k e r  with a n t igen presentation.
As in the study by M o rton et al 2 8 9 , we found many more 
lymphocytes, of all phenotypes, carrying HLA DR in the 
axillary lymph nodes than in the peripheral blood and 
this presence of so many HLA DR bearing lymphocytes in 
the regional lymph nodes suggests that the a c t i v a t i o n  
and a n t igen p r e s e n t a t i o n  seen w i t h i n  the tumour also 
involves the a x i llary lymph nodes particularly, though 
not exclusively, if the tumour has spread to these 
nodes .
Interleukin 2 receptor
The IL-2 r e c e p t o r  was found on v i r t u a l l y  the same 
proportion of CD8+ cells from each source but was on 
more CD4+ T cells in the peripheral blood w ith much 
greater v a r i a t i o n  b e t ween the dif f e r e n t  sites. Neither
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Morton et al 289 nor Mantovani et al 272 included this 
receptor in their studies.
As this r e c e p t o r  is present on almost twice as many CD4+ 
T cells as CD8 + T cells, regardless of the source, it 
may be that either the CD4+ T cells are more a c t i vated 
than the CD8 + T cells or that there is some functional 
difference b e t w e e n  the two with regard to b i nding and 
stimulation by I L - 2 . This lymphokine is being 
considered as a possible therapeutic agent and this 
difference therefore requires further investigation.
Transferrin r e c eptor
The Trf r e c e p t o r  was found to be present on slightly 
more lymphocytes in the nodes and blood of breast cancer 
patients than of normal controls but this was not 
statistically significant. The highest level of 
expression of this receptor was among the tumour 
infiltrating CD4+ T cells suggesting there was greater 
expansion among this population. While there was no 
great dif f e r e n c e  between cancer patients and control 
subjects, a v ery strong c o r r e lation was seen b e t w e e n  the 
transferrin re c e p t o r  expression on lymphocytes, of each 
phenotype, from the axillary nodes and peripheral blood 
of individual patients suggesting that the v a r i a t i o n  
between patients may be due to constitutional 
differences rath e r  than the presence of m a l i gnant
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disease. This marker has not been included in any other 
studies comparing lymphocyte sources w i thin patients 
with breast cancer.
Immunoglogulin G
It can be seen from the results presented in chapter 2 
that breast cancer patients have more mature IgG bearing 
B lymphocytes and, in this study, the axillary lymph 
nodes were found to be the major source of these 
lymphocytes. The pro p o r t i o n  of peripheral blood B cells 
bearing surface IgG was found to correlate strongly with 
that in the nodes and might therefore act as a useful 
guide to the presence of a regional humoral immune 
r e s p o n s e .
It is notable from these findings that all the 
parameters on B cells correlate strongly between lymph 
node and blood. This finding suggests that these cells 
circulate more freely between the tissues than the T 
cell populations.
CLINICAL IMPLICATIONS
At the present time, the conventional treatment for 
breast car c i n o m a  involves surgical excision of the
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primary tumour along with the axillary lymph nodes and 
this is often followed by adjuvant therapy which 
includes loco-regional radiotherapy to the breast, 
axilla or both. Clearly, any regional immune response 
is likely to be destroyed by this management and indeed 
studies of the circulating lymphocytes after 
radiotherapy show a loss of the CD4+ helper T cells 330, 
331 - 4 2 5 ,  2 1 5 ,  3 7 8 , 3 0 5 ; which persists for many years
after the initial disturbance 33 c, 310, 30 5 # and. a loss
of responsiveness to mitogens 397, 424, 451, t3; which
was found, by one group 451 to be prognostic of long 
term outcome. Radiotherapy has also been shown to 
reduce both the B cell population 449 and immunoglobulin 
secretion which are based in the axillary nodes 397,
4 5 0 ,
If cytotoxic chemotherapy is also used then the patients 
suffer from generalised immunosuppression which again 
decreases the immunoglobulin secretion of B cells 472 
and affects the CD4+ helper T cells which do not recover 
easily 2 t b ,  3 3 2 ,  4 4 ,  3 7 a ,  2 2 7 ,  However, recent
concensus analysis, of many systemic adjuvant therapy 
trials, does suggest an improvement in survival for 
premenopausal women with stage II breast cancer treated 
with chemotherapy and for postmenopausal women treated 
with Tamoxifen 110. Accurate staging of the disease is 
therefore required for the logical planning of adjuvant
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therapy.
Clinical staging is not very accurate, as has been borne 
out by several studies 93 > 133, although the findings of
the NSABP trial would also suggest that it is 
unimportant whether microscopically involved nodes are 
removed prophylactically or only upon clinical 
presentation. Indeed 60% of these patients will not 
progress to develop clinical disease in the axilla 133. 
fhis does not help in planning the management of 
individual patients and various approaches have 
therefore been tried to improve staging while avoiding 
an axillary clearance.
Scintigraphy, using injections of colloid or monoclonal 
antibodies, has been tried by several groups 2, 41, 333,
151 , but while some groups remain hopeful about the 
eventual application of this technique 221, 211 t the
results are difficult to interpret and subsequent 
axillary dissection has shown this method to be 
unre1iable 4 2 2 .
Other groups considered the possibility of sampling a 
few lymph nodes lying low in the axilla 134, 144, 23c,
391 or even just at the pectoral margin, within the 
mastectomy specimen 144' 391, While some felt this 
reduced dissection was sufficient i44> 391; others
maintained that a greater clearance was necessary 134 or 
that at least a minimum of 4 axillary lymph nodes should
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be ret r i e v e d  to achieve reliable staging 23 o ,
As this often requires considerable d i s s e c t i o n  of the 
lower axil l a  and it has been suggested that this is the 
site of the most a c t ivated nodes i 3 o < it is likely that 
even limited e x c ision sampling of the a x i llary lymph 
nodes will result in damage to any r e g i onally based 
immune response.
A recent article has suggested that a thorough 
dissection of the axilla is m a n d atory to allow accurate  
staging of breast carcinoma and the selection of the 
appropriate adjuvant therapy 2 2 8 . It is also implied 
that ax i l l a r y  clearance itself makes a major t herapeutic 
contribution to the outcome but while the former 
argument may be valid there is little evidence to 
support the latter.
The major i n d i cation for axillary lymph node excision 
sampling is to stage the disease as this remains the 
most important single prognostic indicator 48 and 
criterion for adjuvant therapy.
Although lymph node stage remains the most important 
prognostic indicator 4 8 , it is by no means accurate with 
30% of patients with stage I breast cancer still dying 
from their m a l i g n a n t  disease.
As features of the tumour itself, such as o e s t rogen 
receptor status, c-erbB-2 (neu) onco p r o t e i n  e x p r e s s i o n  
and the levels of u r o k i n a s e - t y p e  p l a s m i n o g e n  act i v a t o r
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(u-PA), are identified as useful prognostic indicators 
the role of lymph node staging may diminish, a l l owing 
the axilla to be considered from a therapeutic rather 
than d i a g nostic point of view.
In this study, the peripheral blood was found to give 
some i n d i cation of a lterations in the phenotypic 
proportions and a c t i v a t i o n  marker expression of 
lymphocytes w i t h i n  the axillary lymph nodes of breast 
cancer patients. This was p a rticularly so with regard 
to the re l a t i v e  proportions of CD4+ helper T cells and 
CD8+ s u p p r e s s o r / c y t o t o x i c  T cells and the humoral 
response of the B cells. Including this analysis in the 
preoperative a s s e s s m e n t  might allow the selection of 
patients, d e emed to be mount i n g  a response, to be 
considered for c o n s e r v a t i o n  of the axillary lymph nodes 
and the use of n o n - i m m u n o s u p p r e s s i v e  adjuvant therapy 
rather tha n  the more d estructive modalities such as 
radiotherapy or chemotherapy.
Several studies suggest that while the progesterone 
receptor blocking agent, megesterol acetate, does appear 
to cause some immunosuppression 36 9 , 3 2 4  the oestrogen
blocking agents do not 2 1 4 ,  3 2 4 ,  4 4 0  anci one group even
found them to cause some stimulation of the immune 
system 3 o 1 .
Enhancement of any immune response may also be possible 
using biological response modifiers. Although there are
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other biologically active substances which can be 
considered for anti-tumour therapy 145, such as alpha 
interferon 212, ‘i, 293, 303( an^ tumour necrosis
factor 22b, 43, 379( IL-2 has shown the greatest
promise in the treatment of solid tumours 314, 313.
IL-2 , which was originally called T cell growth factor, 
was first isolated from the supernatant of PHA 
stimulated lymphocyte cultures 285 .
Since recombinant IL-2 first became available 422 its 
clinical potential has been studied extensively by 
Rosenberg and his group who first demonstrated that 
peripheral blood lymphocytes, from all patients, could 
be stimulated in vitro to produce lymphokine activated 
killer (LAK) cells 1 7 which were cytotoxic to fresh 
tumour cells. The anti-tumour potential of IL-2 has 
been demonstrated as a single agent 2 56, 257, n ; in
combination with LAK cells 292, 337^ or m0re recently in
combination with IL-2 stimulated tumour infiltrating 
lymphocytes (TILs) 427, 35 &.
These various forms of IL-2 therapy have been tried in 
the treatment of many tumours 314 including malignant 
melanoma 335, renal cell carcinoma 333; bladder 
carcinoma 334, lymphoma 455 and tumours of the head and 
neck 4(34 but this approach has, as yet, been tried in 
only a few patients with breast cancer who have been 
included in mixed trials 61 ^ 2 2 5 ,  32, 2 1 9 ,  2 2 9 ,  363.
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The initial response rates have not always been 
maintained as more centres have tried to use this 
therapy 4 5 5 ,  1 4 2 ,  i o 9 ( £>u t there are still reports of
lasting remissions.
The present use of IL-2 is as a growth factor, a l l owing 
the exp a n s i o n  of TILs which are harvested from the 
patient's tumour, cultured in IL-2 and then re t u r n e d  to 
the patient as a systemic therapy for metastatic disease 
. 5 4 ,  38 9 , 2 2 0 .  It is thought that IL-2 works by
expanding and a c t i v a t i n g  the cytotoxic T cells from the 
tumour which, u p o n  return to the patient, destroy the 
metastases by direct cell killing. However, where the 
phenotype of the TILs has been studied, it has 
frequently b e e n  found that while those h a r v e s t e d  from 
the patient are pr e d o m i n a n t l y  CD8+ cytotoxic T cells, 
those being infused back into the patient are m o stly 
CD4+ h e lper T cells. Thus the greatest expansion 
appears to be in the CD4+ helper T cell subset wit h  a 
concomitant decline in the pro p o r t i o n  of CD8+ cytotoxic 
T cells causing the h e l p e r /cytotoxic ratio to reverse 
after two or three weeks in IL-2 stimulated culture 2 2 ' 
i b s ,  2 9 4 ,  2 4 2 ,  27 b , 38 b .  From our results it would
appear that more CD4+ helper T cells than CD8+ 
suppressor/cytotoxic T cells carry the re c e p t o r  for this 
lymphokine and this may be the reas o n  for their 
preferential expansion. There are also some studies, in
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animals and humans, which suggest that CD4+ T cells 
cells play a g r eater role in the rej e c t i o n  of 
allografted kidneys than the C D 8 + T cells 7 8 > 49 - i t 6 .
It is possible, therfore, that the responses to TIL 
therapy may have been media t e d  by the CD4+ helper T 
cells rath e r  t h a n  the C D 8 + s u p p ressor/cytotoxic T cells. 
If this is the case, culturing and expanding the large 
CD4+ T cell p o p u l a t i o n  from the regional nodes may be 
more effective. The huge cost of culturing individual 
cell therapies for patients makes the study of this 
approach very dif f i c u l t  but the regional i nstillation of 
IL-2 could be considered. Some m e c h a n i s m  such as 
microsphere de l i v e r y  could be used, to reduce spillage 
into the systemic c i r c ulation and avoid some of the 
extreme side effects e xperienced when intravenous 
a d ministration has been used 2 5 7 . Other biological 
response modifiers, such as alpha and gamma interferon, 
should also be considered i 4 3 > 2 4 6 . These have been
found to induce the e x p r ession of class I and class II 
MHC complexes on tumour cell lines 2 1 1 ,  5 5 ,  210 a n d
might the r e f o r e  improve a n t i g e n  recognition, by the 
immune system, of those tumours with poor e x p r e s s i o n  of 
these complexes.
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CONCLUSIONS
From these results it would appear that the lymphocytes 
involved in the host anti - t u m o u r  immune response, in 
patients wit h  breast carcinoma, are sited w i t h i n  the 
primary t u mour or a x i llary nodes.
The a x i llary nodes are the mai n  site of the IgG bearing  
B lymphocytes in patients who appear to be m o u n t i n g  a 
humoral immune response to their tumours. The 
antibodies secreted by these cells require to be 
immortalized and studied to assess their specificity and 
fu n c t i o n .
These nodes are also the major site of the CD4+ T cell 
population in patie n t s  with a high CD4+/CD8+ ratio 
although those in the tumour appear to be more actively  
dividing. These cells require to be analysed with 
regard to lymphokine secretion to assess their 
functional contribution, as helper T cells, to the 
anti-tumour immune response.
The CD8+ T cells make up the greater p r o p o r t i o n  of cells 
infiltrating the tumours a l t hough the regional nodes are 
the greater q u a n t i t a t i v e  source. The strong c o r r e l a t i o n  
between the p r o p o r t i o n  of CD8 + TILs bearing HL A  DR and 
both tumour grade and class I MHC antigen e x p r e s s i o n  
suggests that the primary lesion is the most re l e v a n t  
source of these cells. The importance of direct contact
144
between CD8+ T cells and tumour cells is also supported 
by the c o r r e l a t i o n  seen b e t ween the e x p r ession of HLA DR 
on these cells in the axillary nodes and the presence of 
nodal metastases.
Cytotoxicty assays are r e q uired to assess the functional 
capacity of these cells but a more sensitive and 
accurate m e t h o d  than the currently used chromium release 
assay is needed. Flow cytometry may also have an 
a pplication in this area.
The d i s t r i b u t i o n  of each phenotypic p o p u l a t i o n  is in 
keeping with our knowledge of their function. As both 
the B lymphocytes and CD4+ helper T lymphocytes have a 
primarily secretory function, the one producing 
immunoglobulin and the other lymphokines, they do not 
require to be situated with i n  the tumour but can perhaps 
function b e t t e r  within the regional lymph nodes where 
they can c ommunicate with other components of the immune 
system not p r e s e n t  in the tumour. The CD8 + 
s uppressor/cytotoxic T cells, however, function by 
r ecognizing antigenic structures on the surface of the 
tumour cell in conj u n c t i o n  with the class I MHC complex. 
This is followed by direct cell to cell killing. They 
must the r e f o r e  be based w i t h i n  the tumour to allow 
access to the antigenic tumour cells. These cells 
appear to be important in the initiation of an immune 
reaction as well as r e p r e s e n t i n g  the functional
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cytotoxic component of the cellular immune response. 
While some parameters of phenotypic p roportions and cell 
activation are r e f l e c t e d  among the circulating 
lymphocytes, this is generally to a lesser degree 
suggesting that the mai n  response is still loco-regional 
at the time of clinical presentation.
The components of this loco-regional immune response are 
therefore likely to be d e s t royed by conventional surgery 
or r a d i o t h e r a p y  and, if c hemotherapy is used, the entire 
immune system is depressed. While these m o d a lities may 
be indicated in many patients, those with evidence of a 
regionally b a sed response should perhaps be selected for 
c onservation of the axillary nodes and even 
immunotherapy such as regional a d m i n i s t r a t i o n  of IL-2. 
Analysis of the phenotypic proportions, and their 
surface a c t i v a t i o n  markers, with i n  peripheral blood 
samples may be useful as an indicator of the regional 
immune status and would allow the preop e r a t i v e  selection 
of patients to be considered for axillary lymph node 
conservation and immunotherapy.
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CHAPTER 4; H U M A N  M O N O C L O N A L  A NTIBODIES TO BREAST
CARCINOMA
INTRODUCTION
There are three major p o s s i bilities for i mmunotherapy by 
m a n i p u l a t i o n  of the immune response of breast cancer 
p a t i e n t s .
1) The pat i e n t ' s  own response may be enhanced in vivo 
using such lymphokines as interleukin 2 or by inducing 
tumour cell MHC complex exp r e s s i o n  with alpha or gamma 
i n t e r f e r o n .
2) The c e l lular immune response may be har v e s t e d  and 
augmented by in vitro culture and e x p ansion before being 
returned to the patient.
3) The humoral response may be isolated in the form of a 
human monoclonal antibody which could be used in 
patients who are not mo u n t i n g  a response.
While the first a p p roach has some potential, as 
discussed in chapter 3, the second is limited because of 
the logistical d i f f i culties of deve l o p i n g  a c o m p letely 
individualized therapy for each patient.
The advantages of monoclonal antibodies are that they
147
could be used in other patients and would also be useful 
in the r e s e a r c h  field to allow the isolation and 
cha r a c t e r i z a t i o n  of tumour a ssociated antigens.
The results p r e s e n t e d  in the previous chapters suggest 
that some patients are m o u nting a humoral immune 
response and, as the specificity of that response can 
only be studied w hen it has been isolated and 
immortalized in the form of a monoclonal antibody, we 
wished to look at the feasibility of such antibody 
p r o d u c t i o n .
148
HISTORICAL REVIEW
MURINE M O N O C L O N A L  ANTIBODIES
Since the first monoclonal antibodies were p r o duced by 
Kohler and M i l s t e i n  in 1975 2 3 5 , attempts have been made 
to apply the m  to the det e c t i o n  and treatment of cancer. 
Some ant i b o d i e s  of murine origin have been of use in the 
histological e x a m i n a t i o n  of tumours 1 5 2 , 2 1 5 , 3 0 6 , 3?t,
299 and for the in vitro  d e t e c t i o n  of bone m a r r o w 
metastases 81 > 1 5 8 , 4 0 5 ,  1 1 4 , 3 19 ,  9, 2 5 3 .  However,
while many localization studies have been carried out, 
attempting to diagnose 3 7 0 ,  75, 2 8 6 ,  u s ,  2 7 0 ,  237 o r
treat breast cancer 4 3 3 ,  2 1 s, 3 1 2 ,  i ^ 2 , their use in
vivo is severely limited.
HUMAN A N T I - M O U S E  RE S P O N S E
One of the m a j o r  problems of murine monoclonal 
antibodies is that the r e c ipient tends to raise an 
immune response against the foreign i m m u n o globulin w h ich 
can result in an adverse r e a c t i o n  to the ant i b o d y  if it 
is a d m i n i s t e r e d  more than once 4 5 3 ,  3 1 2 ,  1 <> 2 . At its
most severe this r e a c t i o n  can cause serum sickness,
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although this is rare, or a milder rea c t i o n  may simply 
result in the d e s t r u c t i o n  and excretion of the murine 
antibody before it is able to localize w i t h i n  the tumour 
ifcB. The a n t i b o d y  and its conjugate, which may be a 
radionuclide, cytotoxic drug or toxin, form immune 
complexes w ith the patient's anti-mouse antibody and are 
trapped in the r e t i c u l o - e n d o t h e 1ial system t h e reby 
greatly increasing the cytotoxic dose to the liver and 
spleen 2 1 8 . These immune complexes may also settle out 
in the k i d n e y  causing tubular damage (Fig. 64).
To avoid this p r o b l e m  several groups have tried to 
produce chimaeric antibodies which still have a murine 
variable r e g i o n  but a human constant r e g i o n  2 8 8 , 54,
4 0 8 , 216, 3 7 7 , 3 6 3 , 3 1 0 , 3 9 5 , 174, 254 (Fig. 64).
These a p pear to have had some success in increasing the 
circulation time 2 5 4 with only a few patients deve l o p i n g 
a detectable immune response to the mouse variable 
region. Some success was r e p orted when a chimaeric 
antibody, to a lymphocyte phenotypic marker, was used to 
eliminate all the lymphoid cells in two patients with 
non-Hodgkins lymphoma leaving the haemopoetic stem cells 
intact 1 74 but there have been no further reports of 
this approach.
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Fig. 64 Mouse monoclonal ant ibodies cannot be administered 
repeatedly because the rec ip ient  develops antibodies 
against the murine immunoglobulin  and the resu l tan t  
immune complexes cause damage to the kidneys and 
the re t icu lo -endo the l ia l  system. Humanising murine 
prolongs th e i r  c i rcu la t ion  t ime.
LACK OF SPECIFICITY
Unfor t u n a t e l y  the d e v e l opment of these chimaeric 
antibodies does not overcome the greatest p r o b l e m  of 
murine monoclonal a ntibodies which is poor a n t i - t u m o u r  
specificity. In vivo a d m i n i s t r a t i o n  of these antibodies 
leads to n o n - s pecific binding with normal tissues and 
poor tumo u r  localization 2 1 e, 2 3 7 .
As yet no clear tumour specific a n t igen has been 
isolated w h ich could be used to produce a murine 
monoclonal a n t i b o d y  against breast cancer.
Some groups suggest that breast cancer is caused by a 
viral agent, similar to the mouse m a mmary t u mour virus 
and that this could therefore be used as an a n t i g e n  to 
raise monoclonal antibodies in mice 3 Q ' 2 1 b ,  3 e i ,  5 but
the commonest breast cancer antigens, to w h i c h  murine 
antibodies react, are high m o l e c u l a r  weight 
glycoproteins < 2 1 , 2 t 7 ( many of which appear to be
components of the m ilk fat globule 4 1 3 - 6 2 > 1 9 0 , i69 ,
These antigens have not been well chara c t e r i z e d  and, as 
they were initially isolated using murine monoclonal 
antibodies, t h eir relevance to human breast tumours 
remains in doubt. If a patient raises an immune 
response ag a i n s t  her tumour, it is because her immune 
system r e c o g n i z e s  it as foreign and the r e s ponse is 
therefore likely to be di r e c t e d  against t u m o u r - s p e c i f i c
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antigen whereas if a mouse is inoculated with a human 
tumcur cell the overwhelming mouse a nti-human immune 
response will p redominate and make it almost impossible 
to detect any mouse anti-tumour reaction (Fig. 65).
This p r o b l e m  is p a r t i c u l a r l y  illustrated by the 
difficulty of m a king murine monoclonal antibodies to the 
Rhesus D blood group antigen. The response is dom i n a t e d 
by the r e a c t i o n  of the mice to the major ABO blood group 
antigens 56 > 84 ' 5 9 ' 4 1 9 , tt and it is this d i f f i c u l t y
which has g i ven much of the impetus to the search for 
human monoclonal antibodies.
HUMAN M O N O C L O N A L  ANTIBODIES
To address these problems, of r e p eated a d m i n i s t r a t i o n 
and tumour a n t i g e n  specificity, human monoclonal 
antibodies are required. These would be of importance 
not just clinically, for diagnosis or therapy, but also 
scientifically al l o w i n g  isolation and ident i f i c a t i o n  of 
tumour specific antigens. P r o d u c t i o n  of human 
monoclonal ant i b o d i e s  was first a t t e mpted by Steinitz et 
al in 1977 39 4 u s i n g  E p s tein Barr virus (EBV) to 
immortalize the stimulated lymphocytes r e m o v e d  from the 
patient. A l t h o u g h  some h u man a ntibodies have b een used 
to isolate b r east cancer antigens 1 1 2 ' 1 5 4 ,  3 5 2 ,  20 6,
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Mouse reacts s trong ly  to human 
ABO Ags but only weakly  to Rh Ag
Human red 
blood cell
Mouse reacts equally to tumour 
and other human Ags £  Tumour 
cell
T umour 
cellPat ient  reacts only 
to Tumour Ag on 
autologous tumour ce l ls
Eig_ 65 The humoral immune response of pat ients  to th e i r
autologous tumour ce l ls  is l i k e ly  to be more spec i f ic  
than that  raised in mice who mount a st rong response 
to al l human antigens on mal ignant and normal cel ls.
4oo, human monoclonal antibodies have, as yet, made 
little impact on the diagnosis or therapy of breast 
c a n c e r .
There are several reasons that may account for the 
failure to d e v e l o p  human monoclonal antibodies and, as 
no specific tumo u r  antigens have yet been identified, 
one p o s s i b i l i t y  is that there is no humoral immune 
response to immortalize. However, the results p r e s ented 
in the p r e vious chapters would suggest this is not the 
c a s e .
The gr e a t e s t  obstacle to the d evelopment and ass e s s m e n t 
of h u man monoclonal antibodies is the technical 
d ifficulty of pro d u c i n g  them and, because of this, their 
potential has not yet been fully explored.
The d i f f e r e n t  methods and their problems have been 
extensively r e v i e w e d  3 1 7 ,  2 1 1 ,  66, 67 and amount to
three m a jor difficulties.
Firstly, the source from which the B lymphocytes should 
be harvested.
How these lymphocytes can be immortalized and their 
production of useful immunoglobulin maintained.
Thirdly, how they should be selected to produce human 
monoclonal antibodies which will be specific for breast 
carcinoma.
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SOURCE OF B LYMP H O C Y T E S
Due to the ease of harvesting, some groups have used 
peripheral blood lymphocytes but the antibodies p r o duced 
from this source of B cells have tended to be of poor 
specificity wit h  w i d e s p r e a d  cross-r e a c t i v i t y  to other 
antigens 6 6 > 97 - 2 1 1 .  Olsson 3 17 suggested that the
lymphocytic infiltrate w i t h i n  tumours could also be used 
to produce monoclonal antibodies but as this appears to 
consist largely of T lymphocytes it is un l i k e l y  that 
sufficient B cells would be obtained.
Several groups have suggested that the regional lymph 
nodes are likely to contain the greatest number of 
relevant B lymphocytes i*>o, 7 9 ,  7 6 , 3 1 7 ,  s o  an(i these
have been used by most groups 3 8 5 , 3, 2 3 1 ,  4 0 9  while
Smordinsky et al 388 used lymphocytes h a r vested from a 
malignant pleural effusion. Unfortunately, lymph nodes 
are not always easily available and, in some centres, 
chemotherapy for breast cancer is given p r e o p e r a t i v e l y , 
making it d i f f icult to obtain lymph node lymphocytes 
which have not been damaged by cytotoxic therapy. From 
the results p r e s e n t e d  in the previous chapters it can be 
seen that the ax i l l a r y  lymph nodes of many patients with 
breast cancer contain a large p o p u l a t i o n  of B 
lymphocytes committed to the p r o d u c t i o n  of IgG. As this 
is suggestive of a mature humoral response, we u sed the
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nodes as our source of B lymphocytes and selected out 
the IgG b e a ring cells to be immortalized for monoclonal 
antibody production.
IMMORTALIZATION
The second p r o b l e m  of human monoclonal antibody 
production, and indeed the greatest, is the 
i m m o r t alization of antibody p r o ducing lymphocytes.
While the p r o d u c t i o n  of murine monoclonal antibodies has 
changed little since the initial success of Kohl e r  & 
Milstein 2 3 s ; the prod u c t i o n  of human antibodies has 
been t a c k l e d  in several different ways but as yet no 
s atisfactory m e t h o d  exists. Although new methods are 
currently being developed, the three most commonly 
available were c onsidered here to assess the feasibility 
of immor t a l i z i n g  the humoral response and thus a l low 
study of its specificity.
EBV t r a n s f o r m a t i o n
This m e t h o d  was used by Steinitz et al 394 to produce 
the first h u m a n  monoclonal antibody.
The h u m a n  B lymphocytes are tran s f o r m e d  by E p s t e i n - B a r r  
virus (EBV) w h ich is obtained from thz culture 
supernatant of the marmoset cell line B95-8 2 7 8 . EBV
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a herp e s - t y p e  DNA virus which pr e f e r e n t i a l l y  infects 
human B lymphocytes and can insert its DNA into the 
human genome causing the cell to become act i v a t e d  and, 
in some cases, immortalized. Although EBV can infect 
all B lymphocytes, only a small number are t r a n s f o r m e d 
and, as yet, c o n t roversy remains as to w h ich cells 
become immortalized. While it has been suggested by one 
group that EBV immortalizes small resting B lymphocytes 
which are IgG positive 6 , another group suggests that it 
is large, activated, IgM positive cells which are 
immortalized and that this is dependent on entry into 
the cell cycle 7 0 . It has also been suggested by one 
group that those cells which tra n s f o r m  are those which 
secrete i m m u n o g l o b u l i n  390 while others found the 
opposite 4 2 8. 85, i3. This latter group found that, of
B lymphocytes infected with EBV and carrying the EBV 
nuclear a n t i g e n  (EBNA), only those bearing the CD23 B 
cell a c t i v a t i o n  m a rker became immortalized. Whe n  the B 
lymphocytes were separated into CD23 positive and CD23 
negative cells the vast m a j ority of cells positive for 
cytoplasmic immuno g l o b u l i n  were in the CD23 negative 
group. A further problem of EBV t r a n s f o r m a t i o n  is the 
very poor cloning efficiency of lymphoblastoid lines 211 
and a l t h o u g h  most of the cells do not transform, many 
cells are sti m u l a t e d  to divide and make sel e c t i o n  of the 
transformed cells difficult. This explains the
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d i f f iculty in d e v e l o p i n g  longstanding antib o d y  p r o ducing 
cell lines from EBV tran s f o r m e d  B lymphocytes. Even 
when this can be achie v e d  the output of i m m u n o globulin 
from these cells is very low.
Our main aim, however, was not to produce monoclonal 
antibody lines but to set up short term cultures of IgG 
secreting B lymphocytes, harvested from the axi l l a r y  
lymph nodes, a nd assay the supernatants for autologous 
tumour binding. We therefore chose this meth o d  as our 
main app r o a c h  because of its simplicity.
Fus i on
Fusion w ith an immortal cell line, the m e t h o d  for 
producing muri n e  monoclonal antibodies, involves taking 
stimulated splenic B lymphocytes, from a mouse immunized 
with the a n t i g e n  of interest, and fusing them with cells 
from a n o n - s e c r e t i n g  mouse m y eloma cell line. The 
equivalent m e t h o d  in human monoclonal antibody  
p roduction w o u l d  be to harvest the B lymphocytes from a 
patient, w h i c h  have been naturally stimulated by her 
tumour, and fuse them with a non-se c r e t i n g  h u man m y e l o m a  
cell line. This was first attempted by O l s s o n  & K a p l a n  
315, who fused h u man B cells w ith a human m y e l o m a  line 
but, unfortunately, the myeloma they used sec r e t e d  IgE 
and was d i f f i c u l t  to handle.
Although a non-secreting human myeloma cell line does
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exist 202 most lines secrete their own i m munoglobulin 
and t h e refore produce a scrambled mixture of the m y e loma 
i m munoglobulin and the desired antibody.
While they are capable of a very high output of 
antibody, the human m y e loma cell lines that have been 
developed gro w  so poorly in culture and are so d i f ficult 
to clone that this largely precludes their use as fusion 
partners 4 2 3 ,  7 9 ,  b o ,  3 1 6 . The other type of human 
fusion pa r t n e r  available is the lymphoblastoid cell 
line. These cell lines are u s u ally produced from 
lymphocytes immortalized after infection with EBV. All 
of these cell lines secrete their own i m m u n o globulin 
despite the fact that they are generally poorly 
d eveloped for i m munoglobulin production, with sparse 
rough e ndoplasmic reticulum or golgi apparatus. They 
are, however, easier to grow than myelomas, al t h o u g h  
they clone poorly, and the m a j ority of human fusion 
partners for a n t i - t u m o u r  h u m a n - h u m a n  hybridomas have 
been lymphoblastoid cell lines 382 , 7 9 ,  1 6 0 ,  5 2 ,  s o ,  3 ,
2 3 1 ,  4 0 9 . p ue to the lack of adequate h u man fusion 
partners n o n - s e c r e t i n g  mouse myelomas have also been 
used in p r o d u c i n g  human antibodies 469 , 1 ,  i b i , 1 9 2 ,
38 5, 388, The resultant h uman-mouse hybrids secrete
only the h u m a n  antibody, and in g r e ater qua n t i t i e s  than 
the l y m p h o blastoid fusions, but u n f o r t u n a t e l y  they are 
unstable b e c ause of the two sets of genes w i t h i n  the
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cell. A f ter some time the human genes are 
p r e f e r e n t i a l l y  extruded 2 4 1 , 4 1 4 including chromosome 2, 
which codes for the light chain of the immunoglobulin, 
while c h r o mosome 14, which codes for the heavy chain, is 
retained 9 0 . This loss of the human genes leads to a 
loss of h u m a n  i m m u n oglobulin secretion and antibody 
production. To salvage secretion the h y b r i d o m a  must be 
recloned every few months and even this strategy does 
not p r e vent the loss of many useful monoclonal 
antibodies, a l t h o u g h  stability, with recloning, up to 36 
months has been re p o r t e d  19 2 .
In an a t t empt to overcome these difficulties 
h e t e r omyelomas have been d e v e loped but the a n t ibody 
secreting cell lines produced from them have also tended 
to be un s t a b l e  6 8 . As yet therefore, the search 
continues for an ideal fusion partner for human 
monoclonal a n t i b o d y  production.
Due to its b e t t e r  handling and cloning a n o n - s e c r e t i n g 
mouse myeloma, P3-x63 Ag8.653, was chosen as the fusion 
partner for this study.
EBV t r a n s f o r m a t i o n  and bac k f u s i o n
Kozbor et al 239 suggested combining both of the above 
techniques in an attempt to g ain the advantages of both 
methods while a v o iding some of the disadvantages. The 
biggest a d v a n t a g e  of EBV t r a n s f o r m a t i o n  followed by
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back f u s i o n  is that the fusion rate increases by a factor 
of five 2 4 0 , 196. This is due to the polyclonal
a c t i v a t i o n  of the B lymphocytes which causes the m  to 
pass t h r o u g h  the DNA cell cycle faster and therefore  
increases the chances of successful cell fusion.
When the three methods were compared using either lymph 
node lymphocytes or peripheral blood lymphocytes the 
greatest success was achieved using combined EBV 
infection and b a c k f u s i o n  with lymph node lymphocytes 
4 7 0 . This m e t h o d  does not however prevent the loss of 
the h u man genes from the mouse myeloma cell and with it 
the loss of an t i b o d y  secretion. These antibody 
producing cell lines are therefore no more stable than
those p r o d u c e d  by fusion alone.
ASSAY AND SEL E C T I O N
The c o m m onest assay used to identify antibody b i n ding is 
the enzyme linked immunosorbent assay (ELISA) which 
involves bi n d i n g  the antigen under study to a fixed 
surface, u s u a l l y  a multiwell plastic tray, a d ding the 
supernatant b e ing tested and staining for a positive
reaction using an enzyme linked to an a n t i ­
immunoglobulin antibody. This assay is q u i c k  and 
efficient w h e n  the antigen of interest is small and
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highly p u r i f i e d  but when whole tumour cells are used 
they very q u i ckly become damaged and this allows access 
of the antibody, or supernatant, under test to the 
intracellular and cytoskeletal proteins w h ich 
c ross-react w ith many antibodies 1 5 5 ,  6 6 , 9 7 ,  1 5 4
leading to false positive results (Fig. 66). This 
problem has led to the identification of many monoclonal 
a ntibodies w h i c h  appeared to react with tumour cells but 
were later found to cross-react with a wide range of 
antigens and normal tissues i s b ,  3 8 5 , 2 3 1 ,  « 0 9 , 
Antibodies were produced, from normal volunteers, which 
reacted w ith toxins such as ricin, which is lethal in 
nanogram amounts, to which the subject could not have 
had any pre v i o u s  exposure 9 7 . This p r o b l e m  of 
c r o s s - r e a c t i v i t y  or monoclonal m u l t i s p e c i f i c i t y  has only 
been a p p r e c i a t e d  in recent years and appears to be worst 
with IgM monoclonal antibodies which constitute the 
initial re s p o n s e  to an a n t igen and are p o l y v a l e n t  66 
while b i - v a l e n t  IgG antibodies, which de v e l o p  after 
isotype switching, represent a more mature secondary 
immune re s p o n s e  and have higher affinity, wit h  less 
m u l t i s p e c i f i c i t y  (Fig. 67). Cross- r e a c t i o n s  still 
occur even wit h  antibodies of the IgG class and care 
must still be t a ken in their assay.
Immunohistochemical assays, which allow direct vision of 
supernatant binding on frozen sections of tumour, are
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Antibodies bind 
inappropr ia te ly  to the 
DNA and cytoske le ta l  
proteins of damaged 
tumour ce l ls
. 6 6  While ELISA assays are fas t  and e f f i c ie n t  in the 
tes t ing  of ant ibodies to highly pu r i f ied  antigens, 
the lack of a defined tumour antigen and the 
access of antibodies to the DNA and cytoske le ta l  
prote ins of damaged tumour ce l ls ,  leads to the false 
id e n t i f i c a t io n  of ant ibodies as tumour specif ic .
IgM B ce o=
o
F i rs t  encounter w i th  
antigen leads to low 
a f f i n i t y  IgM binding 
and clonal expansion
IgM B ce l ls
o=
o
Second encounter w i th  
antigen leads to isotype 
sw i tch ing  and high 
a f f i n i t y  IgG binding
Fig. 67  While IgM is produced during the in i t i a l  humoral 
response to antigen, IgG is produced a f te r  isotype 
sw i tch ing  and maturat ion of that  response and binds 
the antigen w i th  greater  a f f i n i t y  and sp e c i f ic i ty .
more informative with regard to the degree and 
d i s t r i b u t i o n  of antibody binding w i t h i n  the tumour. 
Antibodies selected by this m e thod can be further 
assayed u s ing the live immunofluorescence a s s a y  in which 
live tumour cells are used to assay the antibody, or 
supernatant, w ith a f luorescein conjugated a n t i - h u m a n  
IgG second a n t i b o d y  showing any positive b i n d i n g  when 
v iewed by fluorescent microscopy. N on-specific binding 
to the intra c e l l u l a r  proteins in dead cells is a v oided 
by u s i n g  a H o e c h s t  p r e p a r a t i o n  w h ich stains the nuclei 
of dead cells blue, allowing their i d e n t ification and 
exclusion from the assay.
PRESENT STUDY
In an a t t empt to isolate and study the humoral immune 
response, s u g gested by the results presented in the 
previous chapters, the IgG p r o ducing B lymphocytes from 
the a x i l l a r y  lymph nodes of breast cancer patie n t s  were 
harvested, i mmortalized u s ing one of the three methods 
mentioned above and assayed on frozen sections of 
autologous tumour.
It was also hoped that by u s ing these p r e s e l e c t i o n  and 
assay methods, to isolate the humoral immune r e s ponse of 
breast cancer patients, it m i ght also be p o s sible to
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clone an IgG monoclonal antibody which would be specific 
for breast tumour and have little c r o s s - r e a c t i o n  with 
normal tissues.
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PATIENTS A ND METHODS
SELECTION OF B L YMPHOCYTES
Lymph nodes were obtained a s e p t ically from 35 patients 
undergoing def i n i t i v e  surgery for breast cancer which 
included ex c i s i o n  sampling of the axillary lymph nodes. 
Half of each node was sent for routine histological 
examination while lymphocytes were h a r v ested from the 
other half as des c r i b e d  in chapter 2. Briefly, u pon 
receipt of the lymph node sample, it was w a shed in RPMI 
1640 m e d i u m  and, after trans f e r  to a fresh petri dish, 
the cells were teased out using a needle and scalpel. 
This m e t h o d  left the connective tissue structure of the 
node behind, thus r e d ucing the c o n t a m i n a t i o n  by 
fibroblasts. The cells spilled from the node were 
pipetted up, w a s h e d  and r e s u s p e n d e d  in 10ml of RPMI 
medium. This cell suspension was layered over an equal 
volume of Ficoll Hypaque and the lymphocytes har v e s t e d  
by d e n sity gradi e n t  separation. These lymphocytes were 
again washed, r e s u s p e n d e d  in 10ml of RPMI m e d i u m  and 
counted in a h a e m o c y t o m e t e r . A process of negative 
selection was t hen used to isolate the IgG p r o d u c i n g  B 
cells, r e m o v i n g  first the T lymphocytes and the n  the IgM 
producing B cells (Fig. 68).
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at in te r face
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B ce l ls  at 
in te r face
T cell  
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at in te r face
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Fig. 68 A f te r  mechanical disaggregat ion of the lymph node (1), 
the lymphocytes were harvested by density gradient 
separation (2). The IgG bearing B ce l ls  were isolated, 
using negative select ion, by rose t t ing  out the T ce l ls  
and IgM B cells  (3-6).  These IgG B ce l ls  were then 
im m or ta l ized  by EBV t rans fo rm a t ion  or  cel l  fusion 
techniques.
The lymphocytes ha r v e s t e d  from the lymph node were 
centrifuged and r e s u s p e n d e d  in 2%
a m i n o e t h y l i s o t h i o u r o n i u m  bromide (AET) coated sheep red 
blood cells (SRBCs) to rosette out the T lymphocytes, 
lml of AET SRBCs was added for each 1 0 7 lymphocytes 
being treated, along with the same quantity of RPMI 
medium and foetal calf serum ( F C S ) . The test tube was 
c entrifuged at 100 G for five minutes and left on ice 
for 90 minutes.
After this time the tube was rocked gently to re s u s p e n d  
the rosettes, w h i c h  could be clearly seen u n der the 
microscope, and the ro s e t t e d  cells were r e moved by 
density g r a d i e n t  sep a r a t i o n  over Ficoll H y p a q u e . The 
unrosetted lymphocytes, w h ich consisted largely of B 
cells, were re m o v e d  from the interface, wash e d  and 
r e c o u n t e d .
The IgM be a r i n g  B lymphocytes were also removed by 
r osetting but this time the SRBCs were coated wit h  an 
antibody ag a i n s t  the u chain of IgM immunoglobulin.
The r e m a i n i n g  lymphocytes were r e t r ieved in the same way 
as before, u s ing d e n sity gr a d i e n t  separation. These 
remaining lymphocytes had a g r e a t l y  increased p r o p o r t i o n  
of IgG p r o d u c i n g  B lymphocytes which was c o n f irmed on 
several occasions by staining some of the susp e n s i o n 
with a FITC con j u g a t e d  a n t i - h u m a n  IgG an t i b o d y  and 
viewing u n der a fluorescent microscope. These IgG
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producing B lymphocytes were then immortalized.
P r e p a r a t i o n  of AET sheep red blood cells 
102mg of 2 - a m i n o - e t h y 1isothiouronium bromide (AET) was 
weighed out and dis s o l v e d  in 10ml of dis t i l l e d  water. 
This was a d j u s t e d  to pH 9 u s ing 5 molar (M) sodium 
hydroxide and the n  filter sterilized. The sheep red 
blood cells (SRBCs) were spun down out of fresh sheep 
blood and 1ml of the packed cell volume removed and 
washed twice in RPMI medium. 4ml of the AET solution 
was added to the w a shed SRBCs and incubated for 20 
minutes at 37°C. The SRBCs were then wash e d  five times 
in RPMI m e d i u m  and diluted with 9ml of RPMI m e d i u m  to 
give a 10% sus p e n s i o n  of AET coated SRBCs. This was 
stored at 4°C and used w i t h i n  one week. The suspension 
was d i l uted to 2% prior to its use in r o s e tting out the 
T cells from lymph node lymphocytes.
P r e p a ration of a n t i - u  chain coated sheep red blood cells 
2ml of SRBCs were washed three times in 0.15M sodium 
chloride and 0.5ml of the packed cells re m o v e d  and 
diluted w ith 4ml of 0.15M sodium chloride.
To this was added 0.5ml of a 1:200 d i l u t i o n  of rabbit 
anti-human IgM (u chain) a n t ibody (Dako), b r i n g i n g  the 
total volume to 5ml.
An aliquot of hyd r a t e d  chromic chloride was b r ought to
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pH 5 u s ing m o l a r  sodium hydroxide and diluted to 1:100 
by taking 0.1ml of chromium chloride and adding 9.9 ml 
of 0.15M sodium chloride. The solution was the n  filter 
sterilized and 5ml of this was added very slowly to the 
suspension of an t i b o d y  and SRBCs. This sus p e n s i o n  was 
then p l aced on a m i xing plate for 20 minutes.
After this peri o d  the SRBCs were washed three times in 
phosphate bu f f e r e d  saline (PBS) and r e s u spended in 4.5ml 
of PBS to give a 10% s u s p ension which was later diluted 
to 2% before being used to rosette out the IgM b e a ring B 
lymphocytes from the lymph node cell suspension.
I MMORTALIZATION
E PST E I N - B A R R  VIRUS TR A N S F O R M A T I O N
The s u s p e n s i o n  of IgG producing B lymphocytes, obtained 
by the s e l e c t i o n  meth o d  des c r i b e d  above, was spun down 
and the pell e t  r e s u s p e n d e d  in 1ml of EBV suspension.
The virus was obtained by u l t r a c e n t r i f u g a t i o n  of culture 
supernatant from the B95-8 m a r m o s e t  cell line. The 
suspension was incubated overnight at 3 7 °C and the 
following morning, RPMI m e d i u m  was added to the virus 
suspension and the cells cent r i f u g e d  to was h  out any 
viral particles. A f ter r e p e a t i n g  this last step, the
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IgG p r o d u c i n g  lymphocytes were r e s u spended in lymphocyte 
culture m e d i u m  and plated out on 96 well plates. IgG 
secreting B lymphocytes from 22 patients were t r e ated in 
this way.
CELL FUSI O N
Using this a p p r o a c h  the IgG b e aring B lymphocytes were 
fused w ith a n o n - s e c r e t i n g  mouse m y e l o m a  line P3-X63 
Ag8.653. The B lymphocytes had either been EBV 
transformed or were cultured for 5 days in a flask of 
lymphocyte m e d i u m  w h ich contained 3ng/ml phorbol 
myristate acetate (PMA), with added T cell c o n d i t i o n e d 
supernatant for the last three days. The B lymphocytes 
were h a r v e s t e d  and a p p r o x i m a t e l y  5 X 1 0 7 h u man and mouse 
cells were used.
A small control sample of each cell type was t a ken and 
plated out to assess how qu i c k l y  the selective culture 
medium k i l l e d  the u n f used cells. The two cell types 
were mixed, c e n t r i f u g e d  t o g ether at 600 G for 5 minutes 
and the supe r n a t a n t  d r a ined off to leave the cell 
pellet. This was loosened and then slowly r e s u s p e n d e d  
in 1ml of w a r m  p o l y e thylene glycol (PEG) while stirring 
gently for 3 minutes.
10ml of RPMI m e d i u m  was added very slowly over ten
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minutes with only l-2ml being added in the first 5 
minutes.
This cell suspension was incubated at 37° for 20 
minutes, the cells were then spun down and the 
supernatant decanted off thoroughly to remove all the 
PEG.
After washing, the cells were resuspended in medium 
containing 0.1M hypoxanthine, 0.016M thymidine and 0.4uM 
aminopterin so that only fused cells might survive. If 
EBV transformed cells were used in the fusion, 10-5M 
ouabain was also added to destroy unfused cells. The 
unfused parent cells should die out at 8-10 days as the 
fused clones begin to appear.
T cell conditioned supernatant
This is obtained by culturing the T cells which were 
removed from the lymph node lymphocyte suspension by AET 
SRBC rosetting. The T cells were released from the 
rosettes by lysing the SRBCs with distilled water and 
then harvested by density gradient separation over 
Ficoll Hypaque. The T cells were washed and resuspended 
in lymphocyte culture medium, at a density of 106/ml, 
containing PMA at a concentration of lOng/ml and 
phytohaemagglutinin (PHA) at a concentration of lOug/ml. 
After 48 hours of culture the cells were centrifuged and 
the supernatant collected for use in B cell cultures.
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Lymphocyte medium
This consisted of 80% RPMI medium and 20% FCS with both 
insulin and transferriin added at a concentration of 
5ug/ml. It was prepared in small volumes of 50ml to 
ensure that fresh medium was used at all times.
IMMUNOHISTOCHEMICAL ASSAY OF ANTIBODY SUPERNATANTS
This was performed on frozen sections of autologous 
tumour using one slide for each well to be assayed. The 
sections were cut on a microtome at 6u and dried for one 
hour in a box of silica crystals. The sections were 
fixed in acetone for fifteen minutes and placed in a 
humid box where all subsequent preparation was carried 
out. The sections were blocked for thirty minutes with 
bovine serum albumin (BSA) to reduce non-specific 
binding of the test supernatants and in particular to 
block the IgG present within the tumour.
50ul of test supernatant was placed on each slide, 
covering all of the tumour section, and incubated in the 
humid chamber for one hour (Fig. 69).
After this time the slides were rinsed with tris 
buffered saline (TBS) and 50ul of a 1:200 dilution of 
biotinylated anti-human IgG conjugate (Vector 
Laboratories, Peterborough) was added.
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Fig. 69 The supernatants f rom the im m or ta l ized  IgG B cells
were assayed on frozen sections of autologous tumour 
using a b io t in -av id in  l ink  between the murine 
ant i-human IgG antibody and the alkal ine phosphatase. 
A f t e r  developing, IgG binding could be seen as small 
red granules when viewed under a l ig h t  microscope.
This was incubated for one hour when, after rinsing the 
slides with TBS, 50ul of streptavidin bound alkaline 
phosphatase was added to each slide. The slides were 
again incubated for one hour in the humid chamber.
The slides were rinsed thoroughly with TBS and 
developed. The developer consisted of 4mg of napthol 
AS-MX phosphate, lOmg of fast red violet and 2.5mg of 
levamisole, the last of which inhibits intrinsic 
alkaline phosphatase in the tissue section. These were 
dissolved in 20ml of veronal acetate buffer and each 
slide was covered in an excess of developer and 
incubated until the remaining developer was seen to 
become opaque.
The slides were rinsed in tap water and left overnight 
in formal saline. The following morning, the slides 
were again rinsed in tap water and counterstained with 
haematoxylin and Scots tap water.
The sections were viewed under a standard light 
microscope and antibody binding was seen as crimson red 
granules.
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STOCK SOLUTIONS
Scots Tap Water
7g of sodium bicarbonate and 40g of magnesium sulphate 
were dissolved in 1000ml of distilled water. A few 
thymol crystals were added as a preservative.
Tris Buffered Saline (TBS) pH 7.4
6.055g of tris hydrochloride (50mM) and 11.68g of sodium 
chloride were added to 1000ml of distilled water and 
brought to pH 7.4 with 0.1M hydrochloric acid.
Veronal Acetate Buffer
9.78g of sodium barbitone and 6.7g of sodium acetate 
were dissolved in 1000ml of distilled water and brought 
to pH 9.2 using 0.1M hydrochloric acid.
Chromic Chloride
5g of hydrated chromic chloride and 4.383g of sodium 
chloride were added to 500ml of distilled water to 
produce a 1% w/v solution. This was aged at room 
temperature for two weeks and then aliquoted to avoid 
repeated pH adjustment.
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RESULTS
Lymph nodes from a total of 35 breast cancer patients 
were processed to remove the T cells and IgM producing B 
cells leaving the lymphocyte suspension enriched for IgG 
producing B cells. These lymphocytes were then 
immortalized by the three common methods discussed above 
and their supernatants assayed on frozen sections of 
autologous tumour using an anti-human IgG antibody to 
detect the binding of any IgG, present within the 
supernatant, to the tumour section.
EBV TRANSFORMATION
The IgG producing B lymphocytes from 22 patients were 
transformed using EBV. After the transformation, the 
growth period usually lasted between one to two weeks 
when expansion would slow and the cells would begin to 
deteriorate as the untransformed cells gradually died 
away. Lymphocyte cultures from six patients survived 
long enough to allow the supernatants to be assayed.
Four out of the six lymphocyte cultures had wells from 
which the supernatant showed some IgG binding to the 
tumour sections (Figs. 70-73 in which "a" is the 
control and "b" includes the supernatant under test). 
None of these cell cultures survived the subsequent 
efforts to clone out the positive antibody secreting B
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cells but died away when we attempted to establish 
monoclonal antibodies by seeding the cultures at a 
density of one cell per well. This problem was not 
overcome by the use of feeder layers such as mouse 
spleen cells.
FUSION
In four cases, the B cells were cultured with T cell 
conditioned supernatant and then fused with the 
non-secreting mouse myeloma P3-X63 Ag8.653.
Unfortunately none of these cultures even survived long 
enough to allow assay of the cell supernatants on 
autologous tumour. Two of the cultures became 
contaminated with mould in the incubators and the other 
two cultures died away without fused clones appearing.
EBV TRANSFORMATION AND BACKFUSION
The B cells from nine patients were processed by EBV 
transformation followed, one week later, by backfusion. 
Only two of these survived to be assayed on autologous 
tumour sections. One culture had a few wells with 
staining which included the nests of tumour cells (Fig. 
7 4 ; a = control, b = test) but antibody secretion was 
lost during the cloning stages, with later assays being 
negative. The other supernatant showed mild staining of 
the tumour stroma (Fig. 75; a = control, b = test).
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These cultures also, did not survive cloning due to cell 
death at low cell densities. Of the seven cultures 
w h ich did not survive long enough to be assayed, four 
failed to fuse and the other three became contaminated, 
two with yeasts and one with fibroblast overgrowth.
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DISCUSSION
EBV T R A N S F O R M A T I O N
This m e t h o d  alone has not been applied to the p r o d u c t i o n  
of h u man monoclonal antibodies from breast cancer 
patients. In our experience, although we could achieve 
good initial activation, and possibly transformation, it 
was d i f f i c u l t  to clone any of these cell lines. Six of 
the t r a n s f o r m e d  lines were a s s ayed and four of these 
showed some p o s itive staining on autologous tumour, 
which is in k e e p i n g  with the results p r e s e n t e d  in the 
previous chapters and suggests there is some a n t i - t u m o u r  
humoral r e s ponse present in these patients. As we were 
unable to est a b l i s h  stable a n t ibody clones, it was not 
possible to assess this response in more detail. It was 
p a r t i c u l a r l y  notable that the ma j o r i t y  of supernatants  
ap p e a r e d  to p r e f e r e n t i a l l y  stain the tumour stroma 
rather t h a n  the cell nests which is similar to the 
d i s t r i b u t i o n  found in studies of autologous IgG 
staining, u s i n g  immunohistochemical techniques 1 0 6 ,  2 0 8 ,
EBV t r a n s f o r m a t i o n  has been applied more often to the 
i solation of serum antibodies such as those a g ainst 
Rhesus factor 8 4 > 2 7 4 ,  14 6 , 1 6 3, 2 4 3 ,  2 4 4 ,  4 2 r. , 2 5 1  and
tetanus t o x o i d  ^ 3 e , where murine antibodies are
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inappropriate because the desired response is swamped by 
that to the major human antigens such as the ABO blood 
g r oup antigens. In this field also, the success has 
bee n  rath e r  limited.
FUSION
This is the most common method w h ich has b een a p p l i e d  to 
the p r o d u c t i o n  of human monoclonal antibodies from 
patients wit h  breast cancer. Like ourselves, most 
groups have use d  lymphocytes from the ax i l l a r y  nodes of 
breast cancer patients to fuse with an immortal cell 
line. While the early groups used n o n - s e c r e t i n g  mouse 
m y e lomas as their fusion partners 3 7 3 ,  4 6 9 , 4 1 5 ,  7 9 ,
2 0 5 , some more recent projects have used human fusion 
partners 3 8 2 , 7 9 ,  3 8 1, 3 9 9 ,  2 3 1 ,  3 8 8 , 3, 3 8 5 , 4 0 9 .
These groups had some initial success in pro d u c i n g  human 
monoclonal a ntibodies to breast carcinoma, three of 
w h i c h  were of the IgG class, eight were of the IgM 
class, while two produced both and in one r e port the 
imm u n o g l o b u l i n  class was not specified.
Many of these hybridomas, however, have not r e m a i n e d  
stable and while two are still being use d  in studies of 
tumo u r  a n t i g e n  2 0 5 - 3 9 9 ( none have, as yet, made any
clinical c o n t r i b u t i o n  to patient management.
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In this study we used only mouse m y eloma fusion partners 
because of their greater tolerance and easier h a n dling 
but none of the fusions were successful and so no assays 
were p e r f o r m e d  in this group.
EBV T R A N S F O R M A T I O N  AND BACK FUSION
This m e t h o d  has been applied by only one group w o rking 
with breast cancer patients since its intr o d u c t i o n  by 
K o zbor et al 2 3 9 . They used peripheral blood as the 
source of lymphocytes rather than axillary lymph nodes
6 5 ,
The mai n  advantage of this meth o d  is the h i gher fusion 
rate a c h i e v e d  because polyclonal a c t i v a t i o n  of the human 
B lymphocytes causes them to pass t h r o u g h  the cell cycle 
more qu i c k l y  and thus increases the fusion oppor t u n i t i e s 
1 9 6 . Nine patients were p r o cessed by this m e t h o d  and 
two of these were sufficiently successful to a l low assay 
of their supernatants. The cell line with the stronger 
staining survived the initial cloning but sec r e t i o n  was 
lost and r e c l o n i n g  at low density was not successful.
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FUTU R E  A P P R OACHES
From the results p r e s ented earlier in this w o r k  it would 
ap pear that some patients are mou n t i n g  a fairly strong 
humoral immune response and this may be a g a inst their 
tumours. This response can only be fully characterized, 
however, w h e n  the t echnology of monoclonal a n t ibody  
p r o d u c t i o n  has become sufficiently advanced to a l low the 
simple and d ependable immortalization of B cells from a 
large number of patients with breast cancer.
Conventional M e t h o d s
Easier imm o r t a l i z a t i o n  might be brought about by the 
d e v e l o p m e n t  of improved methods of cell fusion, such as 
e l e c t r o f u s i o n  4 7 3 ,  3 2 ,  i o 5 # and a human fusion partner
with similar attributes to those used in murine a n t ibody 
p r o d u c t i o n .
A good fusion partner should be well adapted for high 
output ant i b o d y  secretion, grow well in tissue culture 
and be easy to clone at low d e n sity to produce a 
monoclonal antibody.
It should produce no antibody of its own to avoid the 
p r o d u c t i o n  of a scrambled m i x ture of d e s ired a n t ibody 
with that of the fusion partner as this gr e a t l y  reduces 
the a f f i n i t y  of the antibody produced. As yet such an 
ideal fusion partner has not been identified.
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Gene Cloning Methods
Advances in h u man monoclonal antibody t e c h n o l o g y  are, 
perhaps, more likely to come from the d e v e l o p m e n t  of 
c o m p letely new approaches such as cloning h e avy and 
light chain genes within an e x p r ession vector. The 
immun o g l o b u l i n  chain genes of murine a ntibodies have 
b een e x p r essed in E scherichia coli *> * * 53 and yeast 4 6 6 . 
However, only antibody fragments can be p r o d u c e d  in E. 
coli and therefore, to obtain whole antibody, m a m m a l i a n  
cells such as m y e loma must be used 3 1 0 ,  2 1 6 , 3 7 7 ,  365 .
The plasmid, w h ich carries DNA into the exp r e s s i o n  
v e c t o r  may be t r a n s fected by several methods but the 
most e f f i cient of these is electroporation. By this 
m e thod an electrical impulse causes the cell me m b r a n e  to 
become t e m p o r a r i l y  permeable to the new DNA segment 1 0 .
The most recent hope for advance comes from the 
d e v e l o p m e n t  of the Polymerase C h ain R e a c t i o n  (PCR) 36 6. 
With this m e t h o d  it is possible to amplify small 
segments of DNA, less than 5 Kilo base pairs ( K b p ) , 
p r o v i d i n g  sequences of 18 to 28 base pairs at either end 
are k n o w n  4 5 7 .
There are still severe limitations of this new 
t e c h n o l o g y  in its appl i c a t i o n  to the p r o d u c t i o n  of human 
monoclonal antibodies .
The i n troductory segments must be sequenced by
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conventional techniques before PCR is possible and while 
this is possible with an e stablished hybridoma, because 
of the large number of identical cells a v a i lable for 
sequencing, it limits its use with u n i m m o r t a l i z e d  human 
B lymphocytes. One possible way round this w o uld be to 
use the consensus sequences, from the Kabat and Wu 
database, w h i c h  flank the variable regions as induction 
sequences 4 68. This is, however, likely to select for 
the poly s p e c i f i c  IgM repetoire rather than the 
hy p e r m u t a t e d  IgG antibodies and may therefore produce 
antibodies of rather poor affinity.
A further limitation, which may g r a dually be overcome as 
the t e c hnique develops, is the small size of DNA segment 
w h ich can be amplified. At present only 5 to 6Kbp can 
be a m p l i f i e d  whereas larger genomic DNA is r e q u i r e d  to 
produce whole antibody.
La stly there is a fairly high intrinsic error frequency 
when the heat stable Taq DNA polymerase is u s e d  and 
careful a s s a y i n g  will still be necessary. In the field 
of h u m a n  tumours, this will still pose logistical 
p r o b l e m s .
Thus there is some way to go before P CR makes a m a jor  
c o n t r i b u t i o n  to the d e v e lopment of human a n t i - t u m o u r  
monoclonal antibodies. Its m a i n  use at p r e s e n t  will be 
to a m plixy the variable r e gion DNA of e s t a b l i s h e d  but 
inherently u n s table hybridomas.
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C ONC L U S I O N S
It can be seen from our experience that imm o r t a l i z a t i o n  
of the humoral immune response, either for study or for 
the d e v e l o p m e n t  of a human monoclonal antibody, remains 
d i f f i c u l t  and requires great tissue culture expertise. 
Some of the d i fficulties we experienced were simply 
those inherent in long term tissue culture, such as cell 
death or the c o n t a mination of culture plates with 
micro-organisms, but even when these pitfalls were 
a v o i d e d  it was found to be very difficult to immortalize 
the cells and then to ma i n t a i n  i m m u n oglobulin secretion. 
The basic m e t h o d o l o g y  for the p r o d u c t i o n  of h u man 
monoclonal antibodies remains flawed with no 
s ati s f a c t o r y  technique, for the im m o r t a l i z a t i o n  of 
i m m u n o g l o b u l i n  secreting lymphocytes in humans, which  
w o uld be equivalent to murine hybridoma production.
If h u m a n  monoclonal antibody p r o d u c t i o n  is to m i rror the 
pr o d u c t i o n  of murine antibodies, we require a 
no n - s e c r e t i n g  h u man myeloma cell line which can be 
easily h a n dled in tissue culture and cloning and will 
r e m a i n  stable after fusion.
The other a l t e r native is the d e v e l o p m e n t  of c o m p letely 
new methods such as gene cloning w h ich are only now 
b e c o m i n g  available. These require much more r e f i n e m e n t  
before they will allow the reliable i m m o r t a l i z a t i o n  of
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the humoral immune response for both de t a i l e d  study and 
the p r o d u c t i o n  of human monoclonal antibodies.
The results p r e s e n t e d  earlier in this wor k  suggest that 
there is a mature humoral immune response in many 
patients with breast cancer. Reliable immort a l i z a t i o n  
t e c h niques w o u l d  allow the specificity of this response 
to be a n a l y s e d  and the tumour a n t igen to be identified 
and m i g h t  even t u a l l y  lead to the d e v e lopment of 
c l i n ically useful h u man monoclonal antibodies.
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C H A P T E R  5: C O N C LUSIONS
E V I D E N C E  OF AN IMMUNE RES P O N S E  IN BREAST C A N C E R  PATIENTS
F r o m  the results presented in chapter 2, there is 
evidence of act i v a t e d  T lymphocytes infiltrating the 
tumour, a t t r a c t e d  by tumour a n tigen in c o m b i n a t i o n  with 
class I MHC complexes. In most tumours, the CD8 + 
s u p p r e s s o r / c y t o t o x i c  T cells p r e d ominate a l t h o u g h  the 
CD4+ help e r  T cells were found in significant 
prop o r t i o n s  in those tumours with a heavy lymphocytic 
inf i 1t r a t e .
Both of these phenotypes express a c t i v a t i o n  markers, 
with more of the CD8+ T cells bearing HLA DR, suggestive 
of a n t i g e n  r e c o g n i t i o n  and p r e s e n t a t i o n  as well as 
activation, while more of the CD4+ T cells carry the 
r e c e ptors for IL-2 and t r a n s f e r r i n  w h ich suggest 
st i m u l a t i o n  by a n t igen and cell division.
The presence of H LA DR b e a r i n g  T cells was found to be 
g r e ater in poorly d i f f e r e n t i a t e d  tumours of high 
histological grade. This r e l a t i o n s h i p  was more m a rked  
in the CD8+ T cell subset.
All the p a r a meters of lymphocyte i n f i l tration and 
a c t i v a t i o n  correlate with the presence of the class I 
MHC c o m plex on the tumour cells.
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The degree of activation, although not the phenotypic 
proportions, also correlates with the tumour cell 
e x p r e s s i o n  of the class II MHC complex.
These findings suggest that some form of tumour a n t igen 
is p r e sent on breast carcinoma cells, p a r t i c u l a r l y  in 
p o orly d i f f e r e n t i a t e d  tumours, and that this a n t i g e n  is 
being p r e s e n t e d  for immune r e c o g n i t i o n  by the class I 
and class II MHC complexes, leading to a cellular immune 
response w i t h i n  the primary tumour.
The immune s t i m u l a t i o n  also includes the ax i l l a r y  lymph 
nodes where the pro p o r t i o n  of CD8+ T cells b e a r i n g  HLA 
DR correlates w ith tumour stage. The CD8+ T cells, 
w i t h i n  the nodes, would then have direct contact with 
the tumour cells present in nodal metastases.
Both HLA DR and the receptor for IL-2 are found on 
s i g n i f i c a n t l y  more T cells, of both phenotypes, in the 
lymph nodes of patients with breast cancer t han in those 
from normal controls.
In the ax i l l a r y  lymph nodes, the CD4+ T cell p o p u l a t i o n  
is g r e atly increased in many of the cancer patients with 
C D4 + / C D 8 +  ratios as high as 16:1.
A l t h o u g h  the p r o p o r t i o n  of B lymphocytes in the lymph 
nodes of breast cancer patients is similar to those of 
controls, the p r o p o r t i o n  of these cells b e a r i n g  m e m brane 
bound IgG is much greater in the cancer patients, in
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some cases accounting for up to 70% of the B cells.
These findings suggest antigenic stim u l a t i o n  of the 
regional immune system with the CD4+ helper T cell 
p o p u l a t i o n  g r e a t l y  increased in size and both T cell 
s ubgroups showing signs of a c t i v a t i o n  in patients with 
breast cancer.
The high p r o p o r t i o n  of IgG committed B lymphocytes, in 
many of the breast cancer patients, is suggestive of a 
mature humoral immune response.
HLA DR and the IL-2 receptor are also carried on more of 
the peripheral blood T cells from the cancer patients 
than from the controls and again a greater p r o p o r t i o n  of 
the B lymphocytes were positive for surface IgG.
The p h e n otypic c o n s t i t u t i o n  was found to be similar in 
the two groups a l t hough there was a g r e ater range of 
C D 4 + / C D 8 +  ratios and slightly fewer B lymphocytes in the 
blood of p a t ients with breast cancer.
A l t h o u g h  our results show evidence of immune stim u l a t i o n  
and re s p o n s e  to putative t u mour a n t i g e n  in many 
patients, further studies are re q u i r e d  to assess the 
functional c a p acity of this response, with c y t o t o x i c i t y  
assays of the CD8+ T cells, lymphokine sec r e t i o n  assays 
of the CD4+ T cells and ant i b o d y  binding studies of the 
IgG secre t e d  by the B lymphocytes.
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Of p a r t i c u l a r  interest are the CD4+ T cells as this 
p o p u l a t i o n  is g r eatly increased in many of the cancer 
patients. A m uch greater prop o r t i o n  of these cells than 
CD8+ T cells bear the IL-2 r e c eptor w h ich is in keeping  
w it h  the finding of several groups that, in IL-2 
s t i m ulated TIL culture, it is the CD4+ T cell subset 
w h i c h  expands. There are some reports of pro m i s i n g  
results u s i n g  TIL therapy for mal i g n a n t  m e l a n o m a  and it 
m ay be that these have been me d i a t e d  by CD4+ h e lper T 
cells r a ther t han the CD8+ suppre s s o r / c y t o t o x i c  T cells. 
The m e c h a n i s m  by w h ich this might have been m e d i a t e d  
requires clarification.
The impact of the immune response on disease free and 
overall survival would give some indication of its 
effect i v e n e s s  but the follow up of these patients is, as 
yet, too short to allow any effect to be seen or 
conclusions to be drawn.
THE ROL E  OF THE L Y MPH NODES IN THE IMMUNE R E S P O N S E
When the three lymphocyte sources are compared, the 
ax i l l a r y  lymph nodes are found to be the m a j o r  source of 
CD4+ h e lper T cells and IgG c o m m itted B cells.
A l t h o u g h  the lymph nodes are the major q u a n t i t a t i v e
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source of CD8+ T cells and a large p r o p o r t i o n  of them 
appear to be activated, the most relevant source of 
these cells is the primary tumour where they 
p r e d o m i n a t e .
The peripheral blood lymphocytes tend m e r e l y  to reflect, 
to a lesser degree, the status of the ax i l l a r y  lymph 
nodes, with regard to T cell subset p r o p o rtions and the 
IgG c o m m itment of B cells.
At the time of definitive surgery, the immune response 
d e t e c t e d  in some patients appears to be r e g i o n a l l y  based 
rather t h a n  centralized. This is therefore likely to be 
da m a g e d  by conventional t r e a tment of the breast and 
axilla, with surgery or radiotherapy, while the use of 
ad j uvant c h e m o t h e r a p y  causes gene r a l i z e d  
immunosuppress i o n .
It may be p o s sible to identify patients who are mou n t i n g  
a loco-regional immune response, cellular or humoral, by 
ana l y s i n g  the peripheral blood lymphocytes. This would 
allow these patients to be selected for lymph node 
conservation, if c l i n ically appropriate, and po s s i b l y  
even for immune e nhancement or immunotherapy.
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I M M O R T A L I Z A T I O N  OF THE H U M O R A L  RE S P O N S E
Despite the failure to produce a human monoclonal 
a n t i b o d y  from breast cancer patients, the problems yet 
to be overcome are largely technical and only w h e n  the 
humoral r e s ponse can be easily and re l i a b l y  immortalized 
will it be p o s sible to assess its effectiveness.
The presence, in some patients, of such a large 
p o p u l a t i o n  of IgG bearing B L y m p hocytes is e n c o uraging 
and the diagnostic, therapeutic and experimental 
potential of h u m a n  monoclonal antibodies makes the 
continued efforts to isolate them worthwhile.
This study the r e f o r e  provides evidence of a n t igen  
r e c o g n i t i o n  and a r e g i o n a l l y  based immune response in 
some patients wit h  breast carcinoma. This requires 
further functional analysis but should perhaps be taken  
into ac c o u n t  w h e n  planning the treatment of the 
pr i m a r y  t u m o u r  and may provide a basis for future 
i m m u n o t h e r a p y .
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